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It is well established that atherosclerosis, an inflammatory response to chronic injury 
in the blood vessel wall, plays a leading role in the development and progression of 
cardiovascular disease.  Mineralocorticoid receptor (MR) over-activation has been 
implicated in atherosclerosis.  In mineralocorticoid-target tissues, 11β-
Hydroxysteroid dehydrogenase type 2 (11β-HSD2) inactivates glucocorticoids, 
conferring aldosterone specificity upon the normally unselective MR.  Recent 
evidence suggests that 11β-HSD2 may also afford protection of MR in the cells of 
the vasculature, providing possible mechanisms by which MR activation may 





knockout (DKO) mice show accelerated atheroma development.  
 
The present thesis tested the hypothesis that inactivation of 11β-HSD2, allowing 
inappropriate activation of MR in cells of the vasculature, accelerates atherogenesis 
through promotion of a pro-inflammatory environment with increased endothelial 
cell expression of adhesion molecules and subsequent macrophage infiltration into 
plaques.   
 
DKO mice received either the MR antagonist eplerenone (200mg/kg/day) or vehicle 
in normal chow diet from 2 months of age for 12 weeks.  Eplerenone significantly 
decreased atherosclerotic burden in brachiocephalic arteries of DKO mice, an effect 
that was accompanied by alterations in the cellular composition of plaques such that 
a more stable collagen- and smooth muscle cell- rich plaque was formed.  
Eplerenone treatment was also associated with a reduction in vascular inflammation 
as demonstrated by a significant reduction in macrophage infiltration into DKO 
plaques.  The accelerated atherogenesis in DKO mice was clearly evident by 3 
months of age, a time point at which Apoe
-/-
 mice were completely lesion free.  By 6 
months, some Apoe
-/-
 mice had developed lesions whilst all DKO mice at this age 
showed much larger plaques.  Compared to Apoe
-/-
 mice, the cellular composition of 
DKO plaques was altered favouring vulnerability and inflammation, with increased 
macrophage and lipid content and decreased collagen content.   To investigate the 
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possible underlying mechanisms responsible for increased inflammatory cell content, 
the expression of vascular cell adhesion molecule 1 (VCAM-1) was compared in 
DKO and Apoe
-/-
 brachiocephalic arteries.  VCAM-1 immunostaining was 
significantly greater on the endothelial cells of DKO arteries at 3 months compared 
to age-matched Apoe
-/-
 mice.  At 6 months, DKO and Apoe
-/-
 mice had similar 
expression of VCAM-1.   
 
Finally, mouse aortic endothelial cells (MAECs) were used to investigate the 
mechanism of adhesion molecule up-regulation in the absence of 11β-HSD2.  Both 
aldosterone and TNF-α, included as a positive control, dramatically increased 
VCAM-1 expression in MAECs.  Spironolactone pre-treatment blocked the effect of 
aldosterone, suggesting an MR-mediated mechanism.  Corticosterone alone had no 
effect on VCAM-1 expression.  However, inhibition of 11β-HSD2 by pre-treatment 
with glycyrrhetinic acid allowed corticosterone to induce a significant increase in the 
number of VCAM-1-stained MAECs, demonstrating functional expression of 11β-
HSD2 in MAECs.  Consistent with 11β-HSD2 involvement, VCAM-1 up-regulation 
by corticosterone in the presence of glycyrrhetinic acid was reversed by blockade of 
MR with spironolactone.   
 
In conclusion, loss of 11β-HSD2 activity leading to inappropriate activation of MR 
in atherosclerotic mice promotes plaque vulnerability and increases vascular 
infiltration of macrophages which accelerates plaque growth, possibly through 
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Cardiovascular disease (CVD) is highly prevalent in the western world and is the 
leading cause of death and disability in the UK (responsible for a third of all deaths 
in 2006), with around 2.5 million people living with coronary heart disease.  It is 
well established that atherosclerosis, an inflammatory response to chronic injury in 
the blood vessel wall, is central to the pathogenesis of CVD.  Yet, the initiating 
events that lead to leukocyte accumulation and fat deposition within the arterial wall 
remain poorly defined, partly because atherogenesis in humans occurs silently over 
many years, making it particularly challenging to study.  Blockade of the 
mineralocorticoid receptor (MR) in patients has revealed an important role for 
adrenal steroids (mineralocorticoids and glucocorticoids) in the exacerbation of 
cardiovascular pathologies.  The demonstration that glucocorticoid access to the MR 
is regulated by pre-receptor metabolism in target tissues makes it increasingly 
important to clarify the roles of the metabolising enzyme, 11β-Hydroxysteroid 
Dehydrogenase 2 (11β-HSD2), in regulation of MR-mediated pathogenesis.  This 
will improve our understanding of both the role of inappropriate MR activation in 
regulation of atherosclerosis, and the therapeutic potential of manipulating steroid 




Around a half of all cardiovascular deaths in the UK are caused by coronary heart 
disease (CHD) and, due to the rapid increase in the incidence of cardiovascular risk 
factors such as obesity and diabetes, this trend may worsen.  CHD is caused by the 
formation of atherosclerotic lesions in the coronary circulation. In order to 
understand the vascular processes involved in atherogenesis, it is necessary to first 
consider the structure of the healthy arterial wall and the functions of its component 
layers. 
1.1.1 The normal arterial wall: Structure and function 
The healthy arterial wall consists of three distinct layers (Figure 1.1), each of which 





Figure 1.1 Structure of the arterial wall 
Transverse section of a wild type mouse brachiocephalic artery stained with United States 
trichrome (UST) histological stain (elastin, purple; collagen, blue/green; smooth muscle, 
pink).  The tunica adventitia (A) lies outside of the external elastic lamina (EEL, marked by 
white arrow heads), while the tunica media (M) lies between the EEL and internal elastic 
lamina (IEL, marked by black arrow heads). The tunica intima (I) consists of only a 


















1.1.1.1 Tunica intima 
This is the innermost layer of the arterial wall, which lines the vascular lumen, and it 
predominantly consists of a monolayer of endothelial cells sat upon on a basement 
membrane in mice.  In humans, proteoglycans and smooth muscle cells are also 
found in this layer (Stary, 1989).  The internal elastic lamina (IEL) separates the 
intima from the medial layer.  Thickening of the intima occurs during normal 
development and aging (Velican et al., 1976) and is a common feature of early 
atherosclerosis (Guyton et al., 1993).  The endothelial cells are vital to normal 
vascular function and it is believed that dysfunction of these cells is an initiating 
factor in atherogenesis (Moore et al., 1978).  Endothelial cells are crucial to the 
regulation of vascular tone, as they can release a variety of vasodilators (e.g. nitric 
oxide (N0) (Furchgott et al., 1980; Ignarro et al., 1987) and vasoconstrictors (e.g. 
endothelin-1) (Masaki, 1989).  In addition, the endothelium acts as a barrier between 
the blood and pro-thrombotic components of the vascular wall, and is an important 
modulator of inflammation and new blood vessel growth (Levick, 2003).   
1.1.1.2 Tunica media 
The middle layer of the vessel wall consists of vascular smooth muscle cells 
(VSMCs) along with extracellular matrix (ECM) proteins. Medial VSMCs are 
responsible for regulating luminal diameter, and hence blood flow and pressure.  
They do this by responding to stimulation by blood-borne signals, factors released by 
the endothelium and neurotransmitters released from nerve endings.  Healthy 
VSMCs display a contractile phenotype whilst differentiation towards a ‘synthetic’ 
phenotype is characteristic of vascular pathologies and remodelling (Rensen et al., 
2007).  The ECM consists of concentric sheets of elastin that enable the vessel to 
expand and recoil, in order to accommodate blood ejected from the heart (Levick 
2003). The ECM also contains collagen, which is important in the maintenance of 
vessel shape and integrity, and prevents over-expansion of the artery wall (Levick 
2003). 
1.1.1.3 Tunica adventitia 
The outermost layer of the vessel wall is separated from the media by the external 
elastic lamina (EEL).  It consists of connective tissue, VSMCs, fibroblasts and 
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macrophages.  The adventitia can also contain nerve cells and small blood vessels 
(vasa vasorum), which supply the vessel wall with nutrients (Levick 2003).  The 
adventitia gives the blood vessel stability and strength, and physically connects it to 
surrounding tissues.  In addition to this, the adventitia can also regulate vascular 
structure and function, e.g. NO can be released from the adventitia via the action of 
inducible nitric oxide synthase (iNOS) (Muller et al., 2000) and neuronal nitric oxide 
synthase (nNOS) (Pluta, 2006).  The adventitia may also influence vascular 
remodelling, as it has been proposed that proliferation and migration of adventitial 
fibroblasts contributes to the development of atherosclerotic lesions (Xu et al. 2007). 
1.1.2 Pathogenesis of atherosclerosis  
Atherosclerosis is the thickening of an artery wall due to the presence of an 
atheromatous plaque and it is primarily a disease of the large and medium-sized 
arteries.  Atherosclerosis is characterised by the accumulation of lipids and fibrous 
material within the arterial wall.  Development of atherosclerotic plaques usually 
occurs silently, with their presence only being noticed upon display of clinical 
symptoms associated with interruption of the blood supply.   For example, arterial 
occlusion in the coronary circulation results in loss of blood supply to the 
myocardium, which can produce angina or myocardial infarction, the hallmarks of 
CHD.  Whilst luminal narrowing is clearly a detrimental feature of atherosclerosis, 
the current opinion is that rupture of unstable plaques, leading to acute thrombosis, is 
the most clinically significant consequence of atherosclerosis (Davies et al., 1984; 
Falk, 1983; Horie et al., 1978).   
Atherosclerotic plaques are classically described on the basis of pathological studies 
(Badimon et al., 1993; Stary, 1989; Wissler, 1992) and are usually divided into three 
main types of lesion (Ross et al., 1976a; Ross et al., 1976b): the fatty streak, the 
fibrous plaque and the complicated lesion, representing initial, progressive and final 
complicated stages of atherosclerosis.    
1.1.2.1 Initiation of atherosclerosis 
Due to their complexity, the initiating events of atherosclerosis are not fully 
understood, although it is widely accepted that lesion development begins as an 
excessive wound-healing response to injury in the blood vessel wall (Ross, 1999; 
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Ross, 1986; Ross, 1993).  This hypothesis proposes that atherogenesis occurs in 
response to injury induced by local formation of vasculotoxic factors after exposure 
to risk factors for atherosclerosis, including cigarette smoking, diabetes mellitus, 
hyperlipidemia and hypertension.  Initially, damage to the endothelium stimulates an 
inflammatory response, partially a reaction to the incorporation of cholesterol into 
the vascular wall, leading to fatty streak formation. 
 The incorporated cholesterol is bound by the low density lipoprotein (LDL) complex 
and is subject to oxidation in the vessel wall, a process that confers pro-inflammatory 
and pro-atherogenic properties upon the modified complex (Glass et al., 2001).  In 
response to these inflammatory stimuli the overlying endothelial cells express a 
variety of adhesion molecules that aid the recruitment and uptake of leukocytes into 
the vessel wall.  P-selectin mediates the rolling of leukocytes (Carlos et al., 1994) 
whilst the tethering of these inflammatory cells to the vessel wall is mediated by 
vascular cell adhesion molecule 1 (VCAM-1) (Carlos et al., 1994; Cybulsky et al., 
2001).  Subsequently, chemoattractant molecules, such as monocyte chemoattractant 
protein 1 (MCP-1), stimulate the entry of these bound leukocytes into the intimal 
space via platelet-endothelial cell adhesion molecule 1 (PECAM-1) (Carlos et al., 
1994).  The incorporated leukocytes, along with oxidised LDL, can induce further 
endothelial expression of MCP-1, which acts in a self-propagating fashion to 
stimulate the further uptake of more inflammatory cells (Gu et al., 1998).  Within the 
intima, macrophage colony stimulating factor (M-CSF) instigates the differentiation 
of migrating monocytes into macrophages (Smith et al., 1995) and these cells 
express the scavenger receptors via which oxLDL is taken up (Yamada et al., 1998).  
Macrophage accumulation of cholesterol in this way gives rise to lipid-laden foam 
cells that are characteristic of fatty streaks (Brown et al., 1983).  Activated plaque 
macrophages and T cells express a variety of cytokines, such as interferon γ (IFNγ), 
tumour necrosis factor α and β (TNFα/ β), and interleukin-1 (IL-1), that recruit and 
activate further leukocytes, and stimulate endothelial cells and VSMCs to produce 
additional inflammatory mediators (Libby, 2008b).  These processes lead to the 
reversible formation of a fatty streak, containing lipid and leukocytes. However, with 
continued exposure to risk factors for atherosclerosis, this inflammatory response 
will continue and atherogenesis progresses indefinitely. 
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1.1.2.2 Progression to fibrous plaque 
Immigration of medial smooth muscle cells into the intimal space symbolises the 
progression from the relatively innocuous fatty streak to the fibrous plaque. 
Continued injury and inflammation produces a cascade of proliferative and 
chemotactic factors that promote activation of VSMCs, and their migration to, and 
proliferation in, the intima.  This results in the development of a fibrous plaque with 
a smooth muscle cell-rich cap.  VSMCs within the developing plaque change 
phenotype from a ‘contractile’ state into a ‘synthetic’ state and secrete ECM 
components, which contribute to cap formation (Chamley-Campbell et al., 1981).  It 
is thought that SMCs are the major cellular source of collagen in plaques (Rekhter, 
1999) and that collagen deposition is required for SMC migration (Rocnik et al., 
1998), illustrating the inter-dependent and self-propagating nature of atherogenesis.  
Intimal SMCs also take up modified lipoproteins, thereby contributing to foam cell 
formation (Glass et al., 2001).   
1.1.2.3 The complicated lesion  
Further expansion and development of the fibrous plaque results in the formation of a 
complicated lesion with characteristic necrosis, calcification, thinning of the fibrous 
cap and protrusion into the lumen (Wissler 1992).  Continuation of the inflammatory 
response increases the numbers of macrophages and T lymphocytes in the lesion, 
augmenting the release of degradative enzymes, cytokines, and growth factors (Ross 
1999).   In turn, these inflammatory cytokines, such as IFNγ, can induce macrophage 
apoptosis, contributing to the development of the necrotic core (Inagaki et al., 2002).  
The lesion continues to increase in size and becomes structurally modified, with the 
fibrous cap covering a core of lipid and necrotic tissue. 
These advanced lesions may be subject to silent, non-occlusive episodes of plaque 
rupture and thrombosis (Weissberg 2000), resulting in platelet adhesion and 
activation, platelet derived growth factor (PDGF) release and thrombin formation. 
Further VSMC recruitment, proliferation and ECM synthesis ensues (Libby, 2008a) , 
and thus the formation of a new fibrous cap over the thrombus occurs.  In this way, 
atherosclerotic plaques can grow periodically due to repeated episodes of rupture and 
repair (Weissberg 2000).   
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As mentioned above, many clinical consequences of atherosclerosis are the result of 
plaque rupture and occlusive thrombosis (Libby et al., 1995).  Thrombosis occurs 
when the contents of an atherosclerotic plaque come into direct contact with 
circulating clotting factors.  Tissue factor, the main mediator of thrombosis in 
atheroma, is produced by macrophages in response to stimulation by T cell-derived 
CD40 (Mach et al. 1997), and also by endothelial cells (Bevilacqua et al. 1984) and 
VSMCs (Schecter et al. 1997) exposed to inflammatory cytokines.  This reinforces 
the proposed link between inflammation and thrombosis in atherosclerosis (Libby & 
Simon 2001).  Thrombotic clots can produce sudden occlusion of the vascular lumen, 
resulting in the clinical sequalae associated with atherosclerotic disease, i.e. 
myocardial infarction or stroke. 
1.1.3 Plaque stability 
It is now widely accepted that plaque rupture is the main mechanism that precipitates 
the thrombotic events prerequisite to clinical symptoms in atherosclerosis (Weissberg 
2000) . In this model, plaque stability is not determined by size or degree of luminal 
obstruction, but by its composition.  The homogeneity of plaque development 
throughout the vasculature, and indeed across species, might mask the fact that 
plaques are not all uniform in their characteristics.   Two major morphological 
classifications exist; stenotic and non-stenotic.  A smaller lipid core and thick fibrous 
cap, indicating stability, are typical of stenotic plaques (Libby et al., 2005).  Due to 
lack of compensatory vascular enlargement these plaques encroach on the lumen, 
eventually resulting in ischaemic damage.  Non-stenotic lesions are so-called because 
positive vascular remodelling maintains luminal diameter.  These plaques are often 
characterised by large necrotic cores and thin fibrous caps, rendering them 
vulnerable to rupture (Libby et al., 2005).    
Plaque ruptures associated with acute myocardial infarction generally occur at the 
shoulder regions of the plaque and are more likely to occur in lesions with thin 
fibrous caps, a high concentration of lipid-filled macrophages, and large necrotic 
cores (Davies et al., 1993; Lee et al., 1997).  Collagen provides much of the 
biomechanical strength of the fibrous cap, and plaques with a thick cap are more able 
to resist local mechanical stresses created by blood flow (Libby 2000).  Thus, a low 
plaque collagen content is associated with reduced strength and therefore a less 
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stable plaque.  It is also thought that a lack of VSMCs, particularly at the shoulder 
regions of a plaque, can contribute to instability (Lendon et al. 1991; van der Wal et 
al. 1994).  The susceptibility of plaque shoulder regions to rupture is increased when 
inflammatory cell content is high in these areas (Davies 1996).  Macrophages are 
generally the most populous inflammatory cell type found in atherosclerotic plaques 
and the formation of macrophage-derived foam cells, via uptake of plaque lipids, is 
associated with necrosis and plaque vulnerability.  A large lipid core is a key feature 
of unstable plaques (Glass et al., 2001) as it consists of soft gruel like material that 
lacks mechanical strength, increasing the stress exerted on the fibrous cap (Lee et al., 
1997).  It has been suggested that the presence of buried fibrous caps in a plaque 
indicate instability as they are thought to represent previous plaque ruptures 
(Williams et al., 2002).  Overall, a vulnerable plaque might be described as having a 
low collagen and smooth muscle cell content and a high content of macrophages and 
lipids.      
Plaque stability can be reduced in several ways.  Inflammatory cytokines have wide 
ranging effects including increasing the expression of matrix metalloproteinase 
(MMP) enzymes in macrophages and VSMCs, which degrade collagen in the cap 
(Galis et al. 1994a) and inducing apoptosis in VSMCs (Geng et al. 1996).  Activated 
macrophages can induce VSMC apoptosis by direct cell-cell contact (Boyle et al., 
2001a).  In addition to enzymic decomposition there is evidence for inhibition of 
ECM protein synthesis by intraplaque cytokines liberated from activated T-cells 
(Amento et al., 1991), such as IFN-γ.  This mechanism is thought to have particular 
impact on lesion stability as T-cells accumulate at the rupture-prone shoulder regions 
of the plaque (van der Wal et al., 1994).  In this way inflammation clearly plays an 
active role in mediating plaque stability. 
1.1.4 Animal models of atherosclerosis 
The slow and silent development of atherosclerosis makes investigation of lesion 
development in humans extremely difficult.  Indeed, information on lesion pathology 
obtained from post-mortem and atherectomy specimens provides only a ‘snapshot’ in 
the life of a plaque.  Vascular imaging techniques (e.g. angiography, intra-vascular 
ultrasound, and magnetic resonance imaging (MRI)) can provide information on 
luminal narrowing and lesion size, but give little or no information on the molecular, 
10 
 
biochemical and cellular events involved in lesion formation.  These obstacles to 
clinical investigations into the pathogenesis of atherosclerosis have resulted in much 
of our knowledge of these processes being gained from animal models. 
1.1.4.1 Common models of atherosclerosis 
There is no ideal animal model that completely replicates the stages of human 
atherosclerosis, but cholesterol feeding and mechanical endothelial injury are two 
common features shared by most animal models of atherosclerosis.  Species used in 
experimental models of lesion formation can be broadly divided into large animals, 
such as the pig, dog and non-human primate, and small animals, including the rabbit, 
rat and mouse (Mehta et al., 1996; Narayanaswamy et al., 2000).  Small animals are 
increasingly favoured as they are readily available, cost relatively little, are easy to 
handle and their small size reduces the amount of drug needed for intervention 
studies.  Also, the rapid growth of lesions in small animals allows a quick assessment 
of atherogenesis, and it is possible to include large numbers in each group for more 
powerful statistical analysis.   
The cholesterol-fed rabbit, first described by Anichkov in 1913 (Finking et al., 1997) 
is a widely used model as it develops severe hypercholesterolemia and accumulates 
lipid and macrophages in the intima of the aortic arch and thoracic aorta (Dhanya et 
al., 2008).  Also, Watanabe heritable hyperlipidemic rabbits, which are massively 
hyperlipidemic due to a single genetic defect, develop spontaneous atherosclerotic 
lesions without the need for cholesterol feeding (Watanabe, 1980).  However, the 
lesions that form in rabbits rarely advance beyond the fatty streak stage (Prior et al., 
1961), and so only replicate the early stages of atherosclerosis.   In addition, rats and 
mice do not even develop these early lesions of atherosclerosis when fed a high-fat 
diet (Wissler et al., 1968), as a result of differences in lipid handling compared with 
humans (Paigen et al., 1994).  Despite this, murine models of atherosclerosis have 
provided valuable information about the processes that lead to lesion formation and 
progression (Smith et al., 1997).   This stems from the generation of mice harbouring 
disruptions in genes involved in lipoprotein metabolism/cholesterol transport.  
Transgenic techniques have been used to generate mice that are prone to the 
development of atherosclerosis, such as the low density lipoprotein (LDL) receptor 
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and Apolipoprotein E (ApoE) knockout mice (Breslow, 1993).  Furthermore, these 
techniques make it possible to assess lesion development in animals with transgenic 
deletion of key factors involved in atherogenesis, allowing the molecular 
mechanisms involved in lesion formation to be investigated at a genetic level. 
1.1.4.2 The Apoe-/- mouse model of atherosclerosis 
Apolipoprotein E (ApoE) is a glycoprotein synthesized mainly in
 
the liver and brain, 
and it is a constituent of all lipoprotein complexes except
 
low-density lipoproteins 
(LDL).  It serves as a ligand for receptor-mediated removal of chylomicrons and very 
low density lipoproteins (VLDL) from the blood.  Consequently, mice lacking ApoE 
(Apoe
-/-
) develop hypercholesterolemia and atherosclerotic lesions (Plump et al., 
1992; Zhang et al., 1992) which are morphologically similar to human lesions and 
occur at similar sites in the vasculature (Nakashima et al., 1994; Reddick et al., 
1994; VanderLaan et al., 2004).  Indeed, advanced lesions in the brachiocephalic 
artery characteristic of vulnerable plaques found in humans have been reported 
(Rosenfeld et al., 2000), indicating the clinical significance of this model.  However, 
there is controversy as to whether or not plaque rupture, the cause of clinical 
symptoms in humans, occurs in Apoe
-/-
 mice.  One study reported that plaque rupture 
in atherosclerosis prone mice is rare, restricted to older animals, and is not 
augmented by a high fat diet (Calara et al., 2001) whereas a more recent study 
demonstrated signs of rupture; including buried fibrous caps, intraplaque 
haemorrhage, and breaks in the fibrous cap; in brachiocephalic plaques from fat-fed 
Apoe
-/-
 mice (Johnson et al., 2005).  Nonetheless, despite the controversy over the 
clinical relevance of the atherosclerosis in Apoe
-/-
 mice, this mouse remains the most 
widely used model for investigations of atherosclerotic disease.   
1.1.4.3 Double knockout models on the Apoe-/- background 
The generation of double knockout (DKO) mouse models has allowed investigations 
of the effects of other genes on atherosclerosis.  The majority of available models 
have studied genes that are thought to be pro-atherogenic and so the atherosclerotic 
burden is reduced in the DKO mice.  For example it was reported that knockout of 
ICAM-1 (Bourdillon et al., 2000), iNOS (Ponnuswamy et al., 2009), PECAM-1 
(Stevens et al., 2008), angiotensin II type 1 receptor (AT1) (Eto et al., 2008), the 
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receptor for advanced glycation end products (RAGE) (Soro-Paavonen et al., 2008), 
and cyclooxygenase 1 (COX 1) (McClelland et al., 2009) on the Apoe
-/-
 background 
all decreased atherogenesis compared to single Apoe
-/-
 mice.  These studies are 
important as they reveal possible targets in the treatment of atherosclerosis and 
confirm the roles of inflammatory and oxidative pathways in atherogenesis.  On the 
other hand, there are fewer investigations into possible ‘athero-protective’ genes, 
which could be important in determining individual susceptibility to atherosclerotic 
disease.  It was found that knockout of apelin (Kojima et al., 2008) and the urotensin 
II receptor (Bousette et al., 2009) on the Apoe
-/-
 background resulted in exacerbation 
of atherosclerosis.  These studies suggest that novel therapeutic strategies to enhance 
the availability of certain factors may be worth investigating.  Overall, DKO mice 
not only aid the study of the roles of specific gene products in atherosclerosis but 
they also demonstrate the contributions of distinct phenotypes (e.g. 
hypercholesterolemia and hypertension or oxidative stress) to atherogenesis.         
 
 
1.2 Adrenal steroids 
Glucocorticoids (cortisol in man and corticosterone in rodents) and 
mineralocorticoids (aldosterone) are steroid hormones synthesised from cholesterol 
in the adrenal cortex, and released from the adrenal gland into the systemic 
circulation.  These steroids share the initial part of their biosynthetic pathway with 
the last step mediated by either aldosterone synthase (for aldosterone) or 11β-
hydroxylase (for corticosterone).  These enzymes are differentially expressed within 
the adrenal cortex with aldosterone synthase present in the zona glomerulosa 
(Williams et al., 2003) and 11β-hydroxylase found in the zona reticularis (Borkowski 
et al., 1972).   
1.2.1 Physiological actions of steroid hormones  
1.2.1.1 Glucocorticoids 
Glucocorticoids exert a host of wide-ranging effects throughout the central and 
systemic body systems, and regulate a number of important metabolic and 
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homeostatic processes.  One of the most important physiological roles of 
glucocorticoids is thought to be during the stress response (Munck et al., 1984), 
during which increased levels act to alter metabolism to increase blood glucose 
levels, preparing the body for the ‘fight or flight’ response.  Glucocorticoids play a 
major role in metabolism, particularly in organs such as the liver, adipose tissue, and 
muscle, where they enhance the conversion of stored energy (in glycogen, 
triglycerides and protein) into fuel (glucose, free fatty acids and amino acids) 
(Dallman et al., 1993).  The anti-inflammatory properties of glucocorticoids are well 
characterised and endogenous glucocorticoids can regulate both the adaptive and 
innate immune systems (Franchimont et al., 2002).  Glucocorticoids are known to 
modulate the physiology of blood vessels, inflammatory cells and mediators of 
inflammatory responses (Barnes et al., 1993) such that their anti-inflammatory 
properties are pleiotropic in nature.  They ultimately alter the recruitment of immune 
cells, such as neutrophils and monocytes, to the site of inflammation and also 
decrease the activation and proliferation of leukocytes (Barnes et al., 1993).  
Glucocorticoids also display diverse effects on the cardiovascular system, with 
cardiac, renal and vascular actions documented.  Glucocorticoids can regulate the 
contractility of the heart such that cardiac output is altered (Ishikawa et al., 1984; 
Krosch et al., 1977) and they also regulate fluid and electrolyte balance by increasing 
renal sodium retention and plasma volume expansion by the kidney (Montrella-
Waybill et al., 1991).  Glucocorticoids also have direct effects on vascular tone 
through modulation of the sensitivity of the vessel wall to vasoconstrictors and 
vasodilators (Ullian, 1999).  
1.2.1.2 Mineralocorticoids 
Much of our knowledge of the physiological actions of aldosterone has come from 
investigations of pathologies arising from dysfunction of aldosterone synthesis and 
activity.  The finding that hyperaldosteronism resulting from an adrenal tumor in 
Conn’s syndrome presented with hypertension and hypokalaemia (Conn, 1955) 
defined a clear role for aldosterone in regulation of electrolyte balance and blood 
pressure homeostasis.  The classical actions of aldosterone are on the kidney where it 
acts on the principal cells of the distal tubule and the collecting duct to increase the 
permeability of the apical membrane such that potassium is secreted into the urine 
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whilst sodium is reabsorbed into the blood stream (Williams et al., 2003).  
Aldosterone increases sodium transport through its stimulatory actions on the 
synthesis of the epithelial sodium channel (ENaC) (Rossier, 1997).  Water is 
reabsorbed along with sodium due to changes in fluid osmolarity thereby increasing 
blood volume and hence blood pressure.  Aldosterone also plays a role in acid/base 
balance through stimulation of H
+
 secretion by intercalated cells of the renal 
collecting duct, regulating plasma bicarbonate levels (Wagner et al., 2009).  In 
addition to this, aldosterone acts on the posterior pituitary gland in the central 
nervous system to stimulate the release of anti-diuretic hormone which, in turn, 
promotes conservation of water by direct actions on tubular reabsorption.  In addition 
to these classical mineralocorticoid effects, it is now widely recognised that 
aldosterone has important actions in non-epithelial tissues.  It has been shown that 
aldosterone in combination with excess sodium can regulate inflammation and 
fibrosis in the cardiovascular system (Brilla et al., 1992; Rocha et al., 1998; Rocha et 
al., 2002a).  These pathological consequences of aldosterone action are introduced 
later in section 1.3.        
1.2.2 Regulation of steroid action 
Due to their varied and vital physiological functions throughout the body, the actions 
of steroid hormones are subject to regulation on several levels.   
1.2.2.1 Aldosterone 
Aldosterone is stimulated by several factors, which generally alter the activity of one 
or both of the two major steps involved in its biosynthetic pathway (Aguilera et al., 
1982; Albano et al., 1974; Balla et al., 1985; Boyd et al., 1971).  The renin-
angiotensin system (RAS) is a major regulator of aldosterone secretion.  When blood 
volume is low, the kidney secretes renin which stimulates the conversion of 
angiotensinogen to angiotensin I, which in turn is converted into the main bioactive 
effector of the RAS, angiotensin II (Ang II) by angiotensin converting enzyme 
(ACE) (Paul et al., 2006).  Within the adrenal cortex, Ang II acts upon the membrane 
bound angiotensin 1 (AT1) receptor (Ouali et al., 1993) to activate protein kinase C 
(PKC) and raise intracellular calcium levels (Capponi et al., 1984), thereby 
stimulating the enzymes involved in aldosterone synthesis.  Potassium plays a key 
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role in regulating aldosterone production (Quinn et al., 1988), with increased plasma 
levels stimulating adrenal glomerulosa cells to secrete aldosterone.  Potassium 
depolarises the plasma membrane leading to activation of voltage-dependent calcium 
channels (Quinn et al., 1987) and, reminiscent of Ang II action, the resultant 
increased intracellular calcium levels activates aldosterone synthetic enzymes 
(Kojima et al., 1985a).  This activation of aldosterone secretion by increased 
potassium is a very important mechanism as aldosterone then acts to return 
potassium to physiological levels.  It is thought that Ang II and potassium act 
synergistically to stimulate aldosterone secretion as it has been shown that the 
potassium feedback is inoperative in the absence of Ang II (Pratt, 1982).  Whilst not 
as potent a regulator as potassium, sodium also has a role in aldosterone production 
(Quinn et al., 1988).  Reduced plasma sodium levels, as detected by osmotic pressure 
sensors (Schneider et al., 1985), stimulate aldosterone secretion with the aim of 
increasing reabsorption of sodium in the kidney.  A further level of regulation is 
exerted by factors secreted from the pituitary gland in the central nervous system; 
including adrenocorticotrophic hormone (ACTH), melanocyte stimulating hormone 
(MSH), and β-endorphins (Quinn et al., 1988).  Of these factors, ACTH is the most 
potent aldosterone secretagogue but it only plays a minor role in the overall 
regulation of aldosterone secretion (Quinn et al., 1988).  Membrane bound G-protein 
coupled receptors on adrenal cells allow ACTH to activate intracellular pathways 
that ultimately result in increased calcium levels and stimulation of aldosterone 
production (Fujita et al., 1979; Kojima et al., 1985b).  Finally, sympathetic nervous 
system drive to the adrenals is known to regulate aldosterone secretion via β-
adrenergic receptors (Cugini et al., 1980).  Indeed, long term treatment with β 
receptor blocking drugs associates with decreased plasma Ang II and aldosterone 
levels, a partial mechanism through which these drugs may reduce blood pressure 
(Karlberg, 1983).           
1.2.2.2 Glucocorticoids   
The hypothalamic-pituitary-adrenal (HPA) axis controls the release of 
glucocorticoids from the adrenal glands.  Basal release of glucocorticoids shows a 
normal diurnal variation, with peak concentrations at the beginning of the active 
period (Lommer et al., 1976).  Glucocorticoid release can also be stimulated by 
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physiological stimuli such as stress, injury, or infection, which increase the secretion 
of corticotrophin-releasing hormone (CRH).  CRH is released  from the 
hypothalamus (Vale et al., 1981) and acts to stimulate CRH receptors in the anterior 
pituitary, resulting in the secretion of ACTH into the systemic circulation (Horrocks 
et al., 1990).  As mentioned in the previous section, ACTH stimulates adrenal cells 
to synthesise steroids, a reaction catalysed by members of the cytochrome P450 
oxidative enzyme family, finally resulting in glucocorticoid secretion.  
Glucocorticoids exert a negative feedback effect on the HPA axis, at the level of both 
the hypothalamus and the pituitary, thereby regulating their own release in order to 
maintain physiological plasma levels (De Kloet, 1991).  The bioavailability of 
plasma glucocorticoids for uptake across cell membranes is regulated by 
glucocorticoid binding proteins.  In the circulation, glucocorticoids are 
predominantly bound to corticosteroid-binding globulin (CBG) and albumin, and in 
this way only a small fraction of glucocorticoids are free in the plasma to enter cells 
(Breuner et al., 2002; Westphal, 1971).  Inside the cell, glucocorticoids can bind to 
and activate both the glucocorticoid receptor (GR) and the mineralocorticoid receptor 
(MR), which are discussed in detail in the next section (1.2.3).  Glucocorticoids exert 
most of their physiological effects through GR, which are ubiquitously expressed.  
However, it has been demonstrated that expression levels vary between and within 
tissues (Reul et al., 1985; Reul et al., 1989), providing a means of tissue-specific 
sensitivity to glucocorticoids.  
1.2.3 Steroid hormone receptors   
Steroid hormone receptors are members of the nuclear hormone receptor super 
family of ligand-activated transcription factors which reside in the cell cytoplasm 
(Parker, 1993).  Aldosterone solely activates the MR whilst glucocorticoids can 
activate both the GR and the MR (Arriza et al., 1987), however, glucocorticoids 
predominantly activate the GR due to enzyme-mediated protection of MR from 
glucocorticoid access in aldosterone target tissues (discussed in detail in the next 
section, 1.2.4).  Whilst GR are ubiquitously expressed throughout the body, receptor 
density varies considerably between tissues with particularly high expression found 
in metabolic organs such as the liver, adipose tissue and skeletal muscle (Seckl et al., 
2004).  In contrast, the expressional pattern of MR is largely restricted to aldosterone 
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target tissues, including the kidney, gut, and sweat glands, and to some areas of the 
central nervous system (CNS) and cardiovascular system (Funder, 2005a).  Within 
the cytosol, both MR and GR are complexed with heat shock proteins which 
maintain the receptors in an inactive state with high affinity for ligands (Funder, 
1997).  Upon ligand binding, the hormone-receptor complexes dissociate from these 
chaperone proteins, exposing nuclear localisation signals in the receptors.  They are 
then thought to form homodimers and translocate to the nucleus where the receptors 
bind specific deoxyribonucleic acid (DNA) sequences through interaction with their 
DNA binding domains (Funder, 1997).  MR and GR DNA binding sequences are 
called mineralocorticoid-responsive elements (MRE) and glucocorticoid-responsive 
elements (GRE) respectively.  Upon binding of receptors to response elements, 
transcription or repression of target genes is initiated and the overall effect on gene 
transcription is dependent upon interaction of the receptor-hormone complex with 
specific sets of co-activator and co-repressor proteins as well as with other 
transcription factors (Funder, 1997).    
1.2.4 Tissue specific metabolism 
The peripheral metabolism of glucocorticoids, resulting in conversion of active 
steroid into inactive metabolites, provides a means of clearing these hormones from 
the circulation and, hence, adds another level of control to glucocorticoid activity. 
Metabolism of glucocorticoids (Figure 1.2) occurs mainly in the liver and the 
resultant metabolites are then excreted by the kidney.  Inter-conversion of 
corticosterone with its inactive 11-keto metabolite 11-dehydrocorticosterone is 
catalyzed by the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD1 
and 2).     
1.2.4.1 The 11β-hydroxysteroid dehydrogenase enzymes  
The 11β-HSDs are microsomal enzymes of the short-chain alcohol dehydrogenase 
super family (Stewart et al., 1999).  The inter-conversion of active glucocorticoids 
with their inert 11-keto forms by 11β-HSD was first described over fifty years ago 
(Amelung et al., 1953), but its significance has only become apparent more recently. 
Subsequent studies have identified two isozymes of 11-HSD with different tissue 




Figure 1.2 Metabolism of Glucocorticoids 
This pathway involves the inter-conversion of active (corticosterone) and inactive (11-
dehydrocorticosterone) hormone by the isozymes of 11β-hydroxysteroid dehydrogenase 
(11β-HSD).  Local glucocorticoid action is amplified in target tissues by re-generation of 
active glucocorticoid by 11β-HSD1.  In mineralocorticoid target tissues, conversion of 
cortisone into inactive glucocorticoid by 11β-HSD2 confers aldosterone specificity upon the 
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(Agarwal et al., 1989) and purified from liver homogenates had a Km in the μM 
range for corticosterone (Lakshmi et al., 1988) and was shown to exhibit NADP(H)-
dependent reductase activity in vivo.  The second isozyme (11β-HSD2) of 11-HSD, 
with NAD-dependent dehydrogenase activity and a Km for corticosterone in the nM 
range, was later identified in the aldosterone target cells of the kidney (Mercer et al., 
1992; Naray-Fejes-Toth et al., 1991; Stewart et al., 1994a).  The functional role of 
11β-HSD1 is to provide the GR with corticosterone, in a tissue-specific manner, by 
locally re-generating active glucocorticoids from inert metabolites (Stewart et al., 
1994b).  11β-HSD1 has a wide expression pattern, being found in a variety of 
glucocorticoid target tissues including the liver, lung, adipose tissue, brain, vascular 
smooth muscle, skeletal muscle, anterior pituitary, and adrenal cortex (Stewart et al., 
1999; Tomlinson et al., 2004).  Glucocorticoids are also potent activators of the MR 
(Arriza et al., 1987), however, despite a several fold molar excess of circulating 
glucocorticoids compared to mineralocorticoids, MR remains selective for its 
physiological ligand aldosterone in target cells (Sheppard et al., 1987).  This tight 
control is a consequence of the pre-receptor metabolism of corticosterone, to inactive 
11-ketoglucocorticoids, by 11β-HSD2 in mineralocorticoid target tissues such as the 
kidney.  Due to the fact that its 11-OH cyclises with the aldehyde group on C18, 
aldosterone is not a substrate for this enzyme.  This mechanism serves to protect the 
MR from illicit activation by glucocorticoids, thus conferring aldosterone specificity 
upon MR.  The functional significance of this pre-receptor metabolism of 
glucocorticoids has subsequently been explored in greater detail, particularly since 
the generation of mice with selective transgenic disruption of each isozyme 
(Kotelevtsev et al., 1999; Kotelevtsev et al., 1997). 
1.2.4.2 11β-HSD1 
In tissues with few MR but abundant GR, 11β-HSD1 reactivates glucocorticoids 
suggesting that the physiological role of 11β-HSD1 is to amplify local glucocorticoid 
concentrations in glucocorticoid target tissues (Seckl et al., 2001).  It was initially 
suggested that 11β-HSD1 might be bi-directional, with both dehydrogenase and 
reductase activities observed in vitro (Monder et al., 1989).  However, it is now 
accepted that any dehydrogenase activity of 11HSD1 is attributable to release of 
enzyme from damaged cells in culture, and dissociation from hexose-6-phosphate 
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dehydrogenase, which maintains the NADP concentrations necessary for reductase 
activity (Bujalska et al., 2005; Hewitt et al., 2005).  In intact cells in liver (Jamieson 
et al., 1995), adipose tissue (Bujalska et al., 1997), neurones (Rajan et al., 1996) and 
vascular smooth muscle (Brem et al., 1995), 11β-HSD1 predominantly acts in the 
reductase direction.  These results are supported by studies in 11β-HSD1 deficient 
mice, which cannot convert 11-dehydrocorticosterone to corticosterone in vivo 
(Kotelevtsev et al., 1997).   
1.2.4.3 11β-HSD2 
The importance of 11-HSD2 activity is most convincingly displayed in the 11β-
HSD2 knockout mouse, which models the human ‘syndrome of apparent 
mineralocorticoid excess’ (SAME) with characteristic hypertension associated with 
sodium retention, low plasma renin and hypokalemia (Kotelevtsev et al., 1999).  
Deficiency of 11β-HSD2 in humans and mice results in impaired inactivation of 
cortisol/corticosterone to cortisone/11-dehydrocorticosterone (Monder et al., 1986; 
Shackleton CH, 1985; Ulick et al., 1979) and consequent inappropriate binding of 
glucocorticoids to MR in the kidney.  This phenotype can also be recapitulated by 
ingestion of licorice derivatives, such as glycyrrhetinic acid, which inhibit 11β-HSD2 
at the messenger RNA level and therefore allow illicit activation of MR (Whorwood 
et al., 1993).  As well as protecting the MR by reducing the local glucocorticoid 
concentrations, 11β-HSD2 may also provide an additional level of protection through 
the generation of inactive 11-dehydrocorticosterone.  It has been shown that 11-
dehydrocorticosterone can inhibit the binding of aldosterone to the MR (Morris et 
al., 2009) and the subsequent aldosterone-induced anti-natriuresis (Brem et al., 
1993).  Perhaps, this inert metabolite can also limit binding of active glucocorticoid 
to MR.   
It is clear that rather than merely representing a clearance mechanism, pre-receptor 
metabolism by 11β-HSD enzymes in target tissues is an essential component in 
regulating tissue-specific responses to glucocorticoids (Seckl et al., 2001). 
Consequently, in addition to its role in rare conditions such as SAME, tissue-specific 
pre-receptor metabolism of glucocorticoids is now thought to contribute to the 
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pathogenesis of common conditions such as obesity, insulin resistance, essential 
hypertension and cardiovascular disease. 
1.3 Adrenal steroids and cardiovascular pathologies 
It has been known for some time that aldosterone, acting via the MR, in combination 
with salt is pro-inflammatory and pro-fibrotic in the cardiovascular system with 
detrimental effects on the heart, blood vessels and the kidney.  Despite their potent 
anti-inflammatory properties, there is emerging evidence to suggest that 
glucocorticoids may exacerbate inflammatory diseases such as atherosclerosis.  This 
is likely through activation of MR and may help to explain why MR antagonists are 
beneficial in patients with low aldosterone levels.   
1.3.1 Increased glucocorticoids and cardiovascular risk 
Given their anti-inflammatory actions, glucocorticoids have been extensively used in 
the clinic to treat a variety of allergic, inflammatory and autoimmune disorders, 
including arthritis and asthma.  However, it was recently demonstrated in a large 
case-control study that patients receiving oral glucocorticoids had a 25% higher risk 
of cardiovascular disease than those receiving non-oral glucocorticoid treatment 
(Souverein et al., 2004).  This study also found that associations between oral 
glucocorticoids and cardiovascular disease were independent of confounding factors 
such as smoking and BMI.  This suggests that excess circulating glucocorticoids are 
directly associated with adverse cardiovascular outcomes.  Indeed, patients with 
rheumatoid arthritis have an increased risk of developing cardiovascular disease 
(White et al., 2006), a connection thought to be associated with the exogenous 
glucocorticoid treatment employed in this condition (Davis et al., 2005; Morand et 
al., 2006).  In addition to exogenous glucocorticoid pharmacotherapy, there is a well 
established link between increased levels of endogenous glucocorticoids and 
cardiovascular disease.  The most significant causes of morbidity and mortality in 
patients with Cushing’s syndrome,  who have increased systemic glucocorticoid 
concentrations, are cardiovascular diseases (Ross et al., 1982).  Cushing’s patients 
often demonstrate intimal thickening, increased arterial stiffness and a higher 
incidence of atherosclerotic plaques in the carotid artery (Faggiano et al., 2003).  
Enhanced activation of the HPA axis, with consequent increases in glucocorticoid 
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secretion, can also be observed in non-Cushing’s patients.  This could be caused by 
programming events during early life (Seckl 2004), leading to cardiovascular and 
metabolic disorders in adulthood.  This form of hypercortisolemia has also been 
associated with hypertension, hyperglycemia and dyslipidemia in several studies 
(Walker, 2006b).   
There is evidence to suggest that increased tissue sensitivity to glucocorticoids is 
associated with cardiovascular risk factors (Walker, 2006a; Walker et al., 1998). 
Individuals vary in their sensitivity to glucocorticoids and sensitivity between tissues 
within an individual can also vary.  Since tissue-specific metabolism is a major 
regulator of local glucocorticoid activity, it might be proposed that variations in 
11β-HSD enzyme activity are involved in altered sensitivity to glucocorticoids.  In 
line with this, central obesity in humans is associated with dysregulation of 
11β-HSD1 activity in adipose tissue (Rask et al., 2001) and transgenic mice 
over-expressing 11β-HSD1 selectively in adipose tissue (Masuzaki et al., 2001) or 
liver (Paterson et al., 2004) display features of the metabolic syndrome.   
Animal and cell culture experiments also support a role for glucocorticoids in 
atherosclerosis.  A study utilising pharmacological inhibition of 11β-HSD1, reported 
that atherosclerotic plaque formation in Apoe
-/-
 mice was significantly decreased by 
inhibition of intracellular corticosterone activation (Hermanowski-Vosatka et al., 
2005).  In addition to this, it was found that treatment of human umbilical vein 
endothelial cells (HUVECs) with the synthetic glucocorticoid dexamethasone 
resulted in an increase in free radical production and a decrease in nitric oxide (NO) 
production (Iuchi et al., 2003), implicating a direct pro-atherogenic action of 
glucocorticoids on cells on the vascular wall.   
1.3.2 Vascular steroid action 
Systemic effects of glucocorticoids such as obesity, hypertension and dyslipidemia 
are clearly very important in cardiovascular pathologies, however, there is also 
evidence that adrenal steroids can act directly upon the vascular wall to alter 
structure and function (Hadoke et al., 2006).   
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1.3.2.1 Vascular steroid receptors and metabolism 
The ability of steroid hormones to interact with the vascular wall indicates the 
presence of receptors in cells of the vasculature.  Indeed, both GR and MR have been 
found in freshly isolated vessels (Christy et al., 2003; Kornel et al., 1982) and in 
cultured VSMCs (Scott et al., 1987) and endothelial cells (Caprio et al., 2008; 
Golestaneh et al., 2001; Inoue et al., 1999).  The finding that blockade of GR with 
RU38486 inhibited induction of ACE activity in rat aortic endothelial cells 
(Sugiyama et al., 2005) shows functional activity of vascular GR.  Similarly, the 
functional ability of vascular MR was demonstrated by the finding that antagonism 
of MR inhibits Ang-II-induced hypertrophy of VSMCs (Hatakeyama et al., 1994) 
and aldosterone-induced swelling of endothelial cells (Oberleithner et al., 2003). 
In addition to receptors, the expression of both 11β-HSD1 and 11β-HSD2 in the 
vasculature suggests that pre-receptor metabolism of glucocorticoids may influence 
steroid action within the vessel wall.  There is some controversy over the precise 
cellular localisation of these enzymes.   In the mouse aorta 11β-HSD1 is localised to 
VSMC whilst 11β-HSD2 resides in endothelial cells (Christy et al. 2003), however 
in cultured human and rat cells both isoforms exist in VSMCs (Cai et al., 2001; 
Hatakeyama et al., 1999) and endothelial cells (Brem et al., 1998; Caprio et al., 
2008). Therefore, the cellular distribution of these enzymes may vary between 
species, and with the anatomical location of the vessel (Hadoke et al. 2006).  
1.3.2.2 Actions of adrenal steroids on the vascular wall 
Whilst many of the cardiovascular actions of aldosterone are attributed to activation 
of renal MR with consequent changes in electrolyte and blood volume balance, 
increasing evidence suggests that aldosterone may directly alter the function of the 
vascular wall through activation of extra-renal MR.  A very early study in dogs and 
rats showed that administration of the mineralocorticoid Deoxycorticosterone acetate 
(DOCA) induced hypertension, despite the fact that these animals had been 
bilaterally nephrectomised (Langford et al., 1959).  Later studies suggest that this 
may be due to direct effects of mineralocorticoids on the VSMC MR (Kornel, 1993; 
Kornel et al., 1993).  As well as this,  enhancement of vascular contractility by 
glucocorticoids has been implicated in the development of hypertension (Brem, 
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2001).   Evidence for a direct effect of glucocorticoids on the vascular wall in this 
comes from the finding that selective GR agonists, such as dexamethasone, increase 
blood pressure in the absence of an increase in sodium retention or plasma volume 
(Whitworth, 1992).  Possible mechanisms may be associated with the observations 
that glucocorticoids can reduce the release of vasodilators (e.g. prostaglandins, NO) 
(Rosenbaum et al., 1986; Whitworth et al., 2002), whilst increasing the release of 
vasoconstrictors (e.g. angiotensin II, endothelin-1) (Mendelsohn et al., 1982; Morin 
et al., 1998), from endothelial cells.   
Various effects of aldosterone on the endothelium have also been documented 
(Schiffrin, 2006a).   Studies using HUVECs have defined a role for aldosterone in 
processes associated with endothelial dysfunction such as endothelial cell swelling 
(Oberleithner et al., 2004), stiffening and vulnerability to shear stress (Oberleithner 
et al., 2006), and  decreased NO production (Oberleithner et al., 2007).  A role for 
aldosterone in vascular oxidative stress has been repeatedly shown (Brown, 2008) 
and involves activation of NADPH oxidase in endothelial and VSMCs (Callera et al., 
2005).  Aldosterone has also been shown to enhance VSMC hypertrophy (Duprez et 
al., 2000) and aortic fibrosis (Benetos et al., 1997), consistent with the known pro-
fibrotic actions of aldosterone.  In contrast to this, glucocorticoids are known to 
inhibit smooth muscle cell migration and proliferation as well as inflammation in the 
vasculature (Hadoke et al., 2009).  Glucocorticoids also inhibit angiogenesis via a 
GR-dependent mechanism (Small et al., 2005).  Overall, these studies suggest a 
negative effect of glucocorticoids and a positive effect of mineralocorticoids on 
vascular remodelling.   
However, caution must be employed when determining the overall effects of 
glucocorticoids on vascular function.  Activation of GR might be expected to protect 
against the pathogenesis of vascular dysfunction whilst activation of MR by 
glucocorticoids might mimic the effects of aldosterone, resulting in disease.  Whilst 
the presence of 11β-HSD2 in cells of the vasculature will normally protect MR from 
illicit activation by glucocorticoids, perhaps under conditions of disease this 
protective mechanism is overcome.       
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1.3.3 Activation of MR in cardiovascular pathology      
Recently there has been a surge in research aiming to investigate the pathological 
consequences of MR activation in non-epithelial tissues, such as the heart and 
vasculature.  This has been stimulated by the fact that MR antagonists, administered 
at doses that do not significantly lower blood pressure, improve survival in patients 
with heart failure and acute myocardial infarction (Pitt et al., 2001; Pitt et al., 1999), 
suggesting cardiovascular effects independent of renal control of blood pressure.  
Much of the knowledge of the detrimental effects of MR activation in CVD stems 
from studies employing the MR antagonists spironolactone and eplerenone.  The 
beneficial effects of these drugs are undeniable yet the mechanisms by which they 
produce these effects are largely unknown.   
Spironolactone, a competitive aldosterone antagonist, has long been the MR blocking 
drug of choice for treating patients with heart failure.  It is a member of the class of 
drugs called the potassium sparing diuretics and it competes with aldosterone for 
occupation of MR in renal distal tubules.  However, spironolactone also has affinity 
for androgen and progesterone receptors and so produces off-target effects with pro-
longed treatment.  Selective aldosterone receptor antagonists (SARA) have been 
developed which are similar in structure to spironolactone, but are much more 
selective for the MR (Delyani, 2000).  Eplerenone is one of these selective MR 
blockers and is being preferentially used over spironolactone in an increasing number 
of studies.   
Several studies in humans and rodents have reported detrimental effects of MR 
activation in cardiovascular pathologies.  Mineralocorticoid over-production causes 
pathophysiological changes in the arterial wall (Wexler et al., 1978) possibly by 
stimulating production of vasoactive peptides such as angiotensin II (Ang II) or 
endothelin 1 (ET-1) (Letizia et al., 1996; Rossi et al., 2001), or reducing NO activity 
(Ikeda et al., 1995; Rajagopalan et al., 2001).  Also,  another study reported that 
eplerenone improved endothelial cell function and reduced superoxide production in 
cholesterol fed rabbits (Rajagopalan et al., 2002).  Pro-inflammatory changes in 
endothelial cells underlie the pathogenesis of atherosclerosis and it has been 
consistently shown that activation of MR produces an endothelial inflammatory 
26 
 
phenotype.  Indeed, a study in human vascular endothelial cells found that 
aldosterone mediated activation of MR lead to up-regulation of ICAM-1 mRNA and 
protein (Caprio et al., 2008).  Also, MR antagonism in mice with heart failure 
resulted in reduced expression of ICAM-1 (Kuster et al., 2005).  Furthermore, it was 
recently reported that aldosterone significantly increased VCAM-1 mRNA in 
HUVECs (Hashikabe et al., 2006) and that MR blockade in aldosterone-treated rats 
reduced aortic expression of VCAM-1 mRNA (Hirono et al., 2007).  These 
mechanisms could be important in the promotion of CVD since endothelial 
dysfunction is known to be a crucial initiating event.  A recent study demonstrated 
that administration of aldosterone to Apoe
-/-
 mice for 1 month led to accelerated 
atherogenesis; a mechanism mediated, at least in part, by MR and AT1 receptors 
(Keidar et al., 2004).  Furthermore, eplerenone significantly reduced atherosclerosis 
in mice (Suzuki et al., 2006a) and in non-human primates (Takai et al., 2005) fed a 
high cholesterol diet without affecting blood pressure.  The authors suggest that the 
plaque reduction may have been due to effects of eplerenone on decreasing levels of 
oxidized LDL and improving endothelial cell function (Takai et al., 2005).  Pro-
inflammatory effects of MR activation have been reported in several studies.  Rats 
treated with aldosterone/salt for 5 weeks developed a pro-inflammatory and 
fibrogenic heart phenotype which was attenuated by MR blockade with 
spironolactone (Sun et al., 2002).  Also, a role for MR in stimulating MCP-1 
expression has been shown in the rat heart, where treatment with aldosterone and salt 
resulted in increased MCP-1 mRNA, an effect that was reversed by MR blockade 
with spironolactone (Sun et al., 2002).  Perhaps, this effect of MR activation on 
MCP-1 might partially explain the finding that blockade of MR in mice reduced 
monocyte infiltration into the failing heart (Kuster et al., 2005).  In addition to this, a 
role for MR in macrophage biology has been demonstrated in other studies where 
MR activation was found to be involved in macrophage oxidative stress in mice 
(Keidar et al., 2003) and in macrophage adherence to endothelial cells in vitro 
(Caprio et al., 2008).  Given the important role of the macrophage in atherogenesis, it 
is likely that MR-mediated effects on these cells are involved in the pro-atherogenic 
properties of MR agonists.   
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The implication of these studies is that aldosterone-mediated activation of MR has 
wide ranging effects on the cardiovascular system.  However, as mentioned 
previously, MR is not only activated by mineralocorticoid, but is also a high affinity 
glucocorticoid receptor (Arriza et al., 1987).  Given the fact that glucocorticoids 
acting via the GR are generally anti-inflammatory, it is tempting to postulate that the 
increased cardiovascular risk asociated with excess glucocorticoids is due to 
inappropriate activation of the MR.  Support for a role for glucocorticoid-mediated 
activation of MR in cardiovascular pathologies is found in studies using MR 
antagonists.  The patients in the RALES and EPHESUS trials who benefited from 
MR blockade had pre-treatment plasma aldosterone levels that were in the low 
normal range (Funder, 2006).  Also, a sub-hypotensive dose of eplerenone attenuated 
coronary vascular inflammation and heart failure in hypertensive Dahl salt-sensitive 
rats, despite the fact that these animals had low aldosterone levels (Nagata et al., 
2006).  The finding that MR blockade was beneficial in the setting of low to normal 
mineralocorticoid levels in these studies implicates activation of MR by 
glucocorticoids as an important mechanism in cardiovascular disease promotion.  In 
agreement with this, it was reported that 11β-HSD blockade with carbenoxolone
 
in 
uninephrectomised rats produces a coronary perivascular
 
inflammatory response 
similar to that observed with mineralocorticoid treatment in rats (Young et al., 
2003b).  This effect
 
was completely blocked by coadministration of
 
eplerenone, 
providing evidence for a detrimental effect of endogenous glucocorticoids via MR 
activation.  Also, evidence for a direct effect of glucocorticoids on vascular cell MR 
comes from a study in cultured human VSMCs which demonstrated cortisol-
mediated activation of mineralocorticoid response elements only when 11β-HSD2 
was inhibited (Jaffe et al., 2005).  Taken together, these studies suggest an important 
pathophysiological role for glucocorticoid-mediated activation of MR under 





1.4 The Apoe-/-/11β-HSD2-/- double knockout mouse 
Despite this wealth of evidence linking activation of MR with the pathogenesis of 
cardiovascular diseases, the mechanisms by which MR activity exacerbate 
atherosclerosis have yet to be fully established.  In order to dissect out the 
importance and contribution of inappropriate activation of MR, along with the 





double knockout mouse (DKO) was generated.  A null mutation of the Hsd11b2 gene 
was originally generated by replacing the genomic fragment encompassing exons 2–
5 with a neomycin resistance cassette through homologous recombination in mouse 




DKO mouse, the Hsd11b2 null allele was transferred onto a C57B1/6J genetic 
background and crossed with Apoe
-/-
 mice (Zhang et al., 1992) on a C57B1/6 
background and double homozygotes (DKO) were identified by PCR.  This model 
promises several potential advantages over existing models of atherogenesis: (i) both 
mutations are on a pure C57Bl/6 background, minimizing variations associated with 
modifier loci, (ii) rapid atherogenesis develops on a normal chow diet, (iii) this 
occurs in young adults (6 months) rather than in senescence and (iv) the mice are 
fully viable beyond puberty, enabling successful breeding and the generation of 
sustainable colonies. 
The schematic in Figure 1.3 illustrates the suitability of the DKO mouse for 
investigations concerning MR activation in atherosclerosis.  It shows that the DKO 
mouse combines the atherosclerosis prone nature of the Apoe
-/-
 mouse with the 
moderate hypertension and increased MR activity of the 11β-HSD2
-/-
 mouse.  Whilst 
a human presenting with defects in both Apoe
 
and 11β-HSD2 genes would be an 
extremely rare find, the clinical relevance of this model stems from the fact that a 
large proportion of western populations do suffer from hypercholesterolemia and 
hypertension.  Also, the cardioprotective effects of MR blockade in patients indicates 
that people with underlying cardiovascular pathologies may indeed have increased 











 DKO mouse combines the hypercholesterolemia and atherosclerotic 
nature of the Apoe
-/-
 mouse with the hypertension and MR activation of the 11β-HSD2
-/-
 
mouse.  The DKO also has an electrolyte imbalance due to activation of renal MR.  The 
combined phenotype of the DKO mouse is reminiscent of humans suffering from 
cardiovascular pathologies.    























Initial investigations revealed that in contrast to Apoe
-/-
 mice, DKO mice fed on a 
normal chow diet showed a high incidence of sudden death, with around 50% of 
animals dying by 6-7 months of age.  The original studies in 11β-HSD2 single KO 
mice found an increased incidence of sudden death (Kotelevtsev et al., 1999), 
particularly at the neonatal stage, suggesting that this phenotype in DKO mice is due 
to loss of 11β-HSD2-mediated protection of MR.  The cause of sudden death in 
DKO mice is unknown but may be associated with the massive cardiac enlargement 
observed upon post-mortem examination (Deuchar et al., 2009).  Whilst some of the 
older DKO mice had near occlusive atheroma in the origins of the coronary arteries, 
histopathological analysis showed no evidence of myocardial infarction, plaque 
ruptures, or thrombosis (Deuchar et al., 2009).  Thus, it appears as though the DKO 
mice do not die of their atherosclerotic disease.  However, coronary atherosclerosis 
may have exacerbated the heart disease by inducing cardiac ischaemia.  DKO mice 
also show fibrosis of the heart and kidney, which could be a result of local MR 
activation leading to collagen deposition (Pellman et al., 2009) or of haemodynamic 
changes associated with activation of renal MR.          
Compared to Apoe
-/-
 mice, DKO mice also demonstrate much larger more occlusive 
atherosclerotic lesions in the aortic arch, thoracic aorta and the major branches, with 
the brachiocephalic artery being particularly affected.  Quantification revealed 
accelerated atherogenesis in DKO mice compared to age-matched Apoe
-/-
 mice.  In 
addition to this, the plaques from DKO mice had a greater number of submerged 
fibrous caps than those from Apoe
-/-
 mice.  Since these caps are thought to be an 
indication of plaque rupture (Johnson et al., 2005), it could be suggested that DKO 
mice have vulnerable plaques.      
This initial characterisation of the DKO mouse did not dissect out the mechanisms 
responsible for the severe phenotype observed.  The important role of 11β-HSD2 in 
protection of renal MR against inappropriate activation by glucocorticoids is 
highlighted in the 11β-HSD2 knockout mouse and in patients with SAME.  The 
question now arises as to whether or not the 11β-HSD2 present in cells of the 
vasculature has this same protective role over vascular MR.  That this is likely is 
suggested by the fact that 11β-HSD2 knockout mice have endothelial cell 
dysfunction (Hadoke et al., 2001) and that blockade of MR, without blood pressure 
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reduction, is beneficial in vascular disease.  Therefore, with the aim of determining 
the contributions of renal and extra-renal MR activation to the DKO atherosclerotic 
phenotype, a drug study was performed.  The effects of a sub-hypotensive dose of 
the MR antagonist eplerenone were compared with those of the blood pressure 
reducing drug amiloride.  In this way, the role of renal hypertension in 
atherosclerosis in the DKO mouse could be investigated.  The results demonstrated a 
significant reduction in both global and brachiocephalic atherosclerotic burden in 
eplerenone treated animals without a reduction in blood pressure (Deuchar et al, 
2009).  Conversely, treatment of DKO mice with the epithelial sodium channel 
(ENaC) blocker amiloride did significantly reduce blood pressure but had no impact 
upon atherogenesis (Deuchar et al., 2009).  Amiloride may also inhibit uPA (Vassalli 
et al., 1987) and, given the role of uPA in thrombolysis, this in itself could affect 
atherosclerotic processes.  Together these results suggest that activation of extra-
renal MR, and not hypertension brought about by activation of renal MR, is 














1.5 Hypothesis and aims 
1.5.1 Hypothesis 
Activation of MR has been implicated in the pathogenesis of atherosclerosis and 
Apoe
-/-
 mice deficient in 11β-HSD2 activity have accelerated atherogenesis.  
Pharmacological inhibition of MR in animals and humans has been shown to reduce 
atherosclerosis yet the mechanisms remain unclear.  Therefore, it was hypothesised 
that loss of 11β-HSD2-mediated protection in the vasculature allows glucocorticoids 
to illicitly activate the MR resulting in a pro-inflammatory vascular phenotype and 
accelerated atherogenesis.  It was proposed that activation of vascular cell MR would 
directly alter plaque composition rendering DKO plaques more vulnerable to rupture.  
Lastly, it was anticipated that activation of endothelial cell MR would be key in 
mediating the enhanced pro-inflammatory environment associated with 
atherosclerosis in DKO mice.   
1.5.2 Aims 
In order to address this hypothesis, the aims of this thesis were: 
(i) To determine the role of MR activation in the DKO atherosclerotic 
phenotype.  
(ii) To determine the cellular and molecular mechanisms by which 11β-HSD2 
protects against atherogenesis and the formation of unstable plaques. 
(iii) To investigate the effects of 11β-HSD2 deficiency on vascular, and in 
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2.1.1 Buffers and Solutions 
2.1.1.1 Electrophoresis 
50x Tris acetate EDTA (TAE) buffer: 242g of Tris base and 57.1mL of glacial 
acetic acid were mixed with 100mL of 0.5M EDTA (pH 8).  The volume was made 
up to 1L with water.   
5x Tris Borate EDTA (TBE) buffer: 54g of tris base and 27.5g of boric acid were 
mixed in 980mL of water and 20mL of 0.5M EDTA (pH 8) was added to make the 
final volume up to 1L.  
10% Ammonium Persulfate (APS): 100mg of APS was dissolved in 1mL 0.5x 
TBE buffer. 
2.1.1.2 Histology and Immunohistochemistry 
PBS-Tween (PBST): 250µL of Tween20 was added to 100mL of commercially 
available PBS solution. 
Tris EDTA (TE) buffer: 5mL of 1M Tris-Cl (pH 7.5) was mixed with 1mL 0.5M 
EDTA (pH 7.8) and made up to 500mL with water.  
Proteinase K antigen retrieval solution (20µg/mL): 200µL of 10mg/mL proteinase 
K stock solution was dissolved in 100mL TE buffer.  Fresh solution was made up 
immediately prior to each experiment. 
3% Hydrogen peroxide (H2O2): 10 mL of commercially available 30% H2O2 
solution was diluted in 100mL PBS.  This solution was kept for up to 2 weeks at 4
0
C. 
1% Bovine serum albumin (BSA): 1g of BSA was dissolved in 100mL PBS.  Fresh 
solution was made up immediately prior to each experiment. 
2.5% Non-fat milk (NFM): 2.5g of NFM was dissolved in 100mL PBS.  Fresh 
solution was made up immediately prior to each experiment. 
Gomori’s aldehyde fuchsin: 5 g of pararosaniline base was dissolved in 500 mL of 
60% ethanol. To this 1 mL of hydrochloric acid (HCl) and 2 mL of fresh paraldehyde 
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were added, and the mixture was allowed to blue at room temperature for at least two 
days. Before use the solution was filtered.  
Gomori’s trichrome: 3 g of phosphotungstic acid was dissolved in 500 mL of 
distilled water. To this 3 g of chromotrope 2R and 1.5 g of fast green FCF were 
added and mixed until dissolved, then 5 mL of acetic acid were added. The solution 
was filtered before use. 
Weigert’s iron haematoxylin: Equal volumes of Weigert’s iron haematoxylin 
solution A and solution B were mixed and filtered before use. 
0.3% Potassium permanganate in 0.3% aqueous sulphuric acid: Prepared from 
stock solutions of 1% potassium permanganate (5 g dissolved in 500 mL distilled 
water) and 3% sulphuric acid (15 mL concentrated sulphuric acid made up to 500 
mL with distilled water), made up to the appropriate volume with distilled water.  
2% Oxalic acid: 10 mL of a commercially available solution was diluted in 490 mL 
of distilled water. 
5% Phosphotungstic acid: 250 mL of a commercially available solution was diluted 
in 250 mL of distilled water. 
0.2% Aqueous acetic acid:  1mL of glacial acetic acid was dissolved in 499mL 
distilled water. 
2.1.1.3 Nuclear Protein Extractions 
Buffer A: 100µL Hepes-KOH (made by adding concentrated KOH solution to 1M 
Hepes buffer until pH 7.9 was reached); 100µL 1M KCl (made by dissolving 7.45g 
KCL in 100mL water); 15µL 1M MgCl2 (made by dissolving 9.52g MgCl2 in 100mL 
water); 100µL 50mM DTT (made by dissolving 77.1mg DTT in 10mL water); 
100µL 50mM PMSF (made by dissolving 87.1mg in 10mL isopropanol) made up to 
final volume of 10mL with water.  This gives final solution: 10mM Hepes-KOH (pH 
7.9), 10mM KCl, 1.5mM MgCl2, 0.5mM DTT, and 0.5mM PMSF.  
 
Buffer C: 4.2mL 1M NaCl (made by dissolving 5.84g NaCl in 100mL water); 
100µL Hepes-KOH (pH 7.9); 15µL 1M MgCl2; 20µL 0.5M EDTA (made by 
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dissolving 14.61g EDTA in 100mL water); 2.5mL 100% glycerol; 100µL 50mM 
DTT; 100µL 50mM PMSF made up to final volume of 10mL with water.  This gives 
final solution: 420mM NaCl, 10mM Hepes-KOH (pH 7.9), 1.5mM MgCl2, 0.2mM 
EDTA, 25% glycerol, 0.5mM DTT, and 0.5mM PMSF. 
Buffer D: 2mL Hepes-KOH (pH 7.9); 7.5mL 1M NaCl; 20µL 0.5M EDTA; 20mL 
100% glycerol; 1mL 50mM PMSF made up to final volume of 100mL with water.  
This gives final solution of 20mM Hepes-KOH (pH 7.9), 75mM NaCl, 0.1mM 
EDTA, 20% glycerol, and 0.5mM PMSF.  
 
2.1.2 Drugs 
2.1.2.1 Cell Culture Drugs 
Tumour necrosis factor α (TNF-α): Recombinant mouse TNF-α protein 
(0.1mg/mL) was diluted 1:100 in serum free cell culture medium (SFM) to obtain a 
1µg/mL solution.  
Aldosterone: 3.6mg of aldosterone was dissolved in 1mL ethanol to obtain a 10
-2
M 





M).   
Corticosterone: 3.5mg of corticosterone was dissolved in 1mL ethanol to obtain a 
10
-2
M solution.  Serial dilutions of this were made in 1mL SFM to produce a range 




M).   
Spironolactone: 4.2mg of spironolactone was dissolved in 1mL ethanol to obtain a 
10
-2
M solution.  Serial dilutions of this were made in 1mL SFM to produce a range 




M).   
Glycyrrhetinic acid: 4.7mg of glycyrrhetinic acid was dissolved in 1mL ethanol to 
obtain a 10
-2
M solution.  Serial dilutions of this were made in 1mL SFM to produce a 







2.1.2.2 Drug Study 
Eplerenone: Based on the average mouse weighing 30g and eating 10g of food per 
day; in order to achieve a dosage of 200mg/kg of body weight/day for each mouse, 
every 1kg of diet contained 600mg of eplerenone.  The diet was made up as follows: 
40g of gelatine was dissolved in 300ml boiling water and 600mg eplerenone was 
dissolved in 300ml cold water (eplerenone was omitted from the water in vehicle 
diet).  Following cooling of the gelatine, the two solutions were added together and 
360g of powdered chow diet was mixed in to form a paste.  The paste was packed 
tightly into 50ml tubes and frozen until needed.   
 
 
2.2 DKO and Apoe-/- Mice 
 
2.2.1 Generation of DKO Mice 
A null mutation of the Hsd11b2 gene was originally generated by replacing the 
genomic fragment encompassing exons 2–5 with a neomycin resistance cassette 
through homologous recombination in mouse 129 ES cells (Kotelevtsev et al., 1999).  




 double knockout mouse, the Hsd11b2 
null allele was transferred onto a C57B1/6J genetic background and crossed with 
Apoe
-/-
 mice (Zhang et al., 1992) on a C57B1/6 background and double homozygotes 
(DKO) were identified by PCR.  DKO and Apoe
-/-
 mice were maintained under 
controlled conditions of light (lights on 0800h-2000h) and temperature (21-22
o
C), 
and allowed free access to standard chow (Special Diet Services, U.K.) with water ad 
libitum. Animal experiments were carried out under the auspices of the UK Home 
Office Animals (Scientific Procedures) Act, 1986.  Mice were killed by Schedule 1 




2.2.2 DNA Extraction 
DNA was extracted from mouse ear notches for use in genotyping PCR.  Ear notches 
were immersed in 100µL of DirectPCR buffer containing 0.3mg/mL proteinase K 
and were placed in a rotating hybridising oven (Techne, hybridiser HB-1D) at 55
0
C 
for 16 hours overnight.  The crude lysates were then incubated at 85
0
C for 45 
minutes and allowed to cool before storing at -20
0
C until use.   
2.2.3 Genotyping 
DNA extracted from ear notches at weaning was used in PCR reactions to genotype 
the mice.  This DNA (2µL) was subjected to 32 cycles of PCR amplification with 
primers specific to the wild type 11β-HSD2 allele (forward: 5’-
AGGCTGATGATAGATTCACGAGAC-3’; reverse: 5’-
CGAATGTGTCCATAAGCAGTGC-3’) and the neomycin resistance cassette 
present only in the mutant allele (forward: 5’-
AGGCTGATGATAGATTCACGAGAC-3’; reverse: 5’-
GCGAATGGGCTGACCGCTTCCTCG-3’).   
 
The final PCR mix (DNA, 1 X Taq buffer, 2.5mM MgCl2, 200µM dNTPs, 10µM 
primers, 1 unit Taq polymerase, and dH2O to a final volume of 20µL) was amplified 
in a PTC-200 lightcycler (MJ Research) under the following conditions: initial 
denaturation at 94
0
C for 3 minutes, 72
0
C for 2 minutes, followed by amplification for 
32 cycles of denaturation at 94
0
C for 30 seconds, annealing at 55
0
C for 1 minute, and 
extension at 72
0
C for 2 minutes.  To finish, a final extension period of 5 minutes at 
72
0
C was used.   
 
To prepare a 2% gel, 2 g of agarose were melted in 100 mL 1x TAE buffer. 
Following the addition of 10µL of ethidium bromide (10µg/mL), the gel was allowed 
to set at room temperature before being placed in a tank containing 1x TAE running 
buffer.  8µL of each reaction was analysed by electrophoresis with a 100bp DNA 
ladder used to verify product size.  Products were visualised under UV light (Uvitec, 
BXT-20-M), the wild-type allele gave a band of 981bp whilst the knockout allele 
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gave a 562bp product.  Heterozygous animals had both the wild-type and the 
knockout band.     
2.2.4 Drug Administration 
2.2.4.1 Eplerenone 
Spironolactone, a competitive aldosterone antagonist, has long been the drug of 
choice for treating patients with heart failure.  It is a member of the class of drugs 
called the potassium sparing diuretics and it competes with aldosterone for 
occupation of MR in renal distal tubules.  However, spironolactone also has affinity 
for androgen and progesterone receptors and so produces off-target effects with pro-
longed treatment.  Selective aldosterone receptor antagonists (SARA) have been 
developed which are similar in structure to spironolactone, but are much more 
selective for the mineralocorticoid receptor (Delyani, 2000).  Eplerenone is one of 
these selective MR blockers and has been shown to provide benefits independent of 
blood pressure lowering effects in patients and mouse models of cardiovascular 
disease (Pitt et al., 2001; Wang et al., 2004).   
 
2.2.4.2 Eplerenone Administration in Mouse Diet  
Eplerenone is commonly administered in mouse chow diet and so food containing 
either eplerenone or vehicle was made.  It was previously established that the mice 
eat around 10g of food per day (observation by Graeme Deuchar) and so the food 
was made up to ensure that each mouse received the correct daily dose of eplerenone 
(200mg/kg of body weight/day).  To make up 1kg of food the mixture contained 
360g of powdered diet, 600mL H2O, 40g gelatin, and 600mg eplerenone.  Briefly, 
the gelatin was dissolved in boiling water and the eplerenone was dissolved, and 
formed a suspension, in cold water.  The powdered diet was added slowly to the 
mixture of gelatin (once sufficiently cooled) and eplerenone (or water in the 
vehicles) and mixed to form a paste with the drug as evenly distributed as possible 
throughout.  The diet was tightly packed into tubes and frozen until given to the 




2.2.4.3 Drug Study Mice 
To study the effect of MR blockade on the inflammatory component of 
atherosclerosis in DKO mice, at 2 months of age male DKO mice received diet 
containing 200mg/kg of body weight/day eplerenone (n=5) or vehicle (n=4).  The 
mice were fed their respective diets for 12 weeks until they reached 5 months of age.  
This time course of treatment was chosen as a previous drug study in DKO mice 
(Deuchar et al., 2009) demonstrated that eplerenone caused a significant reduction in 
atherogenesis that was independent of blood pressure lowering.   
 
2.3 Characterisation of Atherosclerotic Phenotype 
2.3.1 Organ harvest and preparation 
2.3.1.1 Culling and Blood Sampling 
DKO and Apoe
-/-
 mice at 3 or 6 months of age, or at 5 months of age in the drug 
study, were killed by asphyxiation with CO2.  Terminal blood samples were taken 
from the left ventricle of the heart by cardiac puncture with a 19.5G needle (0.5 inch) 
fitted to a 1ml syringe, collected into heparin/lithium coated tubes to prevent blood 
clotting, and centrifuged (Sorvall, Biofuge fresca) at 894 x g for 10 minutes at 4
0
C to 
separate the plasma fraction (upper layer) from the whole blood.  Plasma samples 
were stored at -80
0
C until use.      
 
2.3.1.2 Collection and Fixation of Organs 
The heart was exposed and the vasculature perfused via the left ventricle with 10mL 
phosphate buffered saline (PBS) followed by 10mL 10% neutral buffered formalin 
(for paraffin embedded samples) in order to flush out blood cells and maintain the 
structure of the blood vessels.  However, perfusion under constant physiological 
pressure would have been more appropriate for measurements of vessel dimensions.  
The chest cavity was then cleaned of fat and connective tissue so that the aortic arch 
and its’ major branches could be located.  Due to its’ predisposition to developing 
atherosclerotic plaques, the brachiocephalic artery was of interest and therefore 
preferentially used in these studies.  The arch with attached brachiocephalic artery 
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(excised from the arch to the bifurcation of the right subclavian and carotid arteries) 
and the thoracic aorta were taken out, remaining fat was removed under the 
dissecting microscope (Nikon, SMZ-2B), and either fixed in 10% neutral buffered 
formalin for 24 hours or rapidly frozen in Optimum Cutting Temperature (OCT) 
compound.  Formalin fixation, by cross-linking proteins, preserves tissues from 
degradation and helps to maintain the structure of cells and sub-cellular components.  
However, this process can mask some antigens, so some vessels were frozen in OCT 
compound which removes the need for formalin fixation and thus preserves antigenic 
sites.    
 
2.3.1.3 Processing and Sectioning of Vessels 
Tissues contain a high water content and since paraffin embedding medium is 
immiscible with water, the vessels were processed through increasing concentrations 
of alcohols and xylene to dehydration then infused with paraffin wax using an 
automatic tissue processing machine (Shandon, U.K.).  They were then placed 
vertically in embedding moulds with molten paraffin wax which was allowed to cool 
and set into a solid block.  A microtome (Leitz Wetzlar, 1512) was used to cut 4µm 
thick transverse sections which were floated on a water bath at 37
0
C to remove folds 
and wrinkles.  In the case of the frozen organs, 8µm thick sections were cut on a 
cryostat (Leica, CM1900) and stored at -20
0
C until use.  A cutting strategy was 
employed to maximise the number of useful sections gained from a vessel, which 
involved cutting in from the proximal end of the vessel, taking the first sections at 
the beginning of a lesion.  Four serial sections were taken every 50µm until the 
plaque disappeared.  Sections were collected onto positively charged superfrost plus 
microscope slides and dried in an oven for 16 hours at 37
0
C (fixed tissues) or stored 
at -20
0
C (frozen tissues).   
 
2.3.2 Histology and Immunohistochemistry 
2.3.2.1 Slide Preparation 
Prior to staining, paraffin embedded sections require to be dewaxed and rehydrated, 
this was carried out by immersion in sequential baths of: xylene (x2) for 5 minutes 
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each, 100% ethanol for 1 minute, 74 O.P. (x2) (A solution of 99.5% ethanol and 
0.5% methanol)  for 1 minute each, and finally tap water for 5 minutes.   
 
2.3.2.2 United States Trichrome 
The United States Trichrome (UST) stain is a histological procedure which combines 
Gomori's aldehyde fuchsin stain for elastin with Gomori's one-step trichome stain 
(Hadoke et al., 1995).  It colours cell cytoplasms pink-red, nuclei blue-black, elastic 
fibres deep purple, and collagen blue-green.  The staining procedure was carried out 
in an automated staining machine (Varistain Gemini; Thermo Shandon, U.K.). 
Sections were dewaxed and rehydrated, 0.3% potassium permanganate in 0.3% 
aqueous sulphuric acid was applied and, after rinsing in water, sections were 
decolourised in 2% aqueous oxalic acid.  Sections were rinsed in water and 70% 
ethanol and then immersed in Gomori aldehyde fuchsin.  After differentiating in 70% 
ethanol and washing in water, Weigert’s iron haematoxylin was applied.  The slides 
were then left to blue in running tap water, before 5% aqueous phosphotungstic acid 
was applied, which prepares the tissue for the trichrome stain.  After washing in 
water, sections were immersed in Gomori trichrome stain for 20 minutes before 
rinsing in 0.2% aqueous acetic acid, dehydrating and clearing in xylene.  Given its 
ability to differentially stain numerous plaque components, the UST stain is 
particularly useful in the evaluation of plaque composition and stability.  UST was 
employed for the purposes of assessing general plaque composition and for making 
measurements of lipid content (Johnson et al., 2005).   
 
2.3.2.3 Picrosirius Red Stain  
In order to assess plaque collagen content, the Picrosirius red histological stain was 
employed (Puchtler et al., 1973).  This stain was carried out by Susan Harvey and 
Bob Morris (histology technicians) in an automated staining machine (Varistain 
Gemini; Thermo Shandon, U.K.) and involved dewaxing and rehydrating sections 
before immersion in a solution of Sirius red and saturated aqueous picric acid for 1 
hour in order to stain collagen fibres red.   
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2.3.2.4 Principles of Immunohistochemistry 
Immunohistochemistry is the process of localizing specific proteins in the cells of a 
tissue section and it exploits the principle of antibodies binding specifically to 
antigens.  This technique is widely used in the diagnosis of abnormal cells, e.g. in 
tumours, but it is also very useful in basic research to understand the distribution and 
localization of specific biomarkers.  The two types of antibody employed in 
immunohistochemistry are called primary and secondary antibodies.  Primary 
antibodies are raised against an antigen of interest and can be either monoclonal or 
polyclonal.  Polyclonal antibodies are made by injecting an animal, e.g. a rat, with 
the antigen of interest from another species, e.g. mouse.  This induces the rats B-cells 
to produce IgG immunoglobulins specific for the mouse antigen and these antibodies 
can be collected and purified from the serum.  Most antigens induce multiple B-cell 
clones and so polyclonal antibodies are therefore a heterogeneous mix of antibodies 
that recognise several epitopes on an antigen.  On the other hand, monoclonal 
antibodies are produced by one type of B-cell which are all clones of a single parent 
cell, selected for its ability to produce the most specific and stable antibodies, and are 
thus considered to be more specific.  Secondary antibodies are raised against primary 
antibodies and recognise immunoglobulins, or immunoglobulin fragments, of a 
particular species.   
 
There are two methods of immunohistochemistry, direct or indirect, and they are 
summarised in Figure 2.1.  The direct method involves a one-step staining protocol 
with a labelled primary antibody and whilst it is simple and rapid, it suffers from 
problems with sensitivity.  The most commonly used method is the indirect one 
which uses a two-step protocol with an unlabelled primary and labelled secondary 
antibody.  This method has greater sensitivity due to the signal amplification 
conferred by the ability of one primary antibody to bind numerous secondary 
antibodies.   
 
Formalin fixation causes protein cross-linking in tissues and although this helps to 
maintain cell morphology it can also mask some antigens.  The demonstration of 
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Figure 2.1 Comparison of direct and indirect immunohistochemistry 
Direct immunohistochemistry (A) employs a labelled primary antibody and suffers from 
insensitivity due to lack of signal amplification.  Indirect immunohistochemistry (B) is a two-
step method which exploits the ability of one unlabelled primary antibody to bind numerous 



























treatment with an antigen retrieval reagent.  The two major methods of antigen 
retrieval are Heat Induced Epitope Retrieval (HIER) and Proteolytic Induced Epitope 
Retrieval (PIER).  HIER utilises a source of heat, e.g. microwave or pressure cooker, 
in combination with a citrate or TRIS-EDTA buffer to unmask antigenic sites.  PIER 
uses proteolytic enzymes such as proteinase K or trypsin to digest the protein cross-
links and reveal the antigen.   
 
Prior to incubating sections with antibodies, various blocking steps need to be 
performed to prevent non-specific binding of the primary antibody to proteins.  The 
main cause of non-specific background staining is non-immunological binding of the 
specific immune sera by hydrophobic and electrostatic forces to certain sites within 
tissue sections.  When using the Horse Radish Peroxidase (HRP) method of detection 
(discussed below) it is important to quench endogenous peroxidase activity in a 
tissue, this is most commonly done by pre-treating the section with 3% hydrogen 
peroxide (H2O2).  In order to reduce non-specific staining by antibodies, sections are 
incubated with non-immune serum from the species that the secondary antibody is 
raised in.  Bovine Serum Albumin (BSA) and Non-Fat Milk (NFM) are also 
commonly used to block non-specific protein and lipid sites and can be used as a 
diluent for the primary antibody.  The general immunohistochemistry procedure 
employs the avidin-biotin complex (ABC) method outlined in Figure 2.2.  Briefly, 
the specific primary antibody binds to the antigen of interest and the biotinylated 
secondary antibody binds the primary antibody.  A complex of streptavidin linked to 
HRP is added and the biotin molecules on the secondary antibody can each bind 
three streptavidin-HRP molecules.  The HRP substrate Diaminobenzidine (DAB) is 





Figure 2.2 ABC method of immunohistochemistry 
Immunohistochemical method employed in this thesis based on the indirect procedure 
described in figure 2.1.  Antigen of interest is recognised by primary antibody which, in turn, 
is bound by species-specific biotinylated secondary antibodies.  Following addition of the 
ABC complex, the biotin binds three molecules of streptavidin-linked HRP, further amplifying 
the primary signal.  Reaction of HRP with its substrate DAB produces an insoluble brown 















2.3.2.5 Immunohistochemistry in Brachiocephalic Artery Sections 
Immunohistochemistry using primary antibodies against smooth muscle cell α-actin 
(SMA), macrophage specific galectin-3 (MAC2) (Ho et al., 1982), and intracellular 
adhesion molecule 1 (ICAM-1) was performed on paraffin-embedded  
brachiocephalic artery sections, and vascular cell adhesion molecule 1 (VCAM-1) on 
frozen sections, from DKO and Apoe
-/- 
mice.  Immunohistochemistry was performed 
in sequenza racks using microplate holders (Shandon, UK) which minimises the 
volume of reagents required (150µL/slide).  The specific conditions associated with 
each primary antibody are detailed in Table 2.1.  Generally, following quenching of 
endogenous peroxidase activity for 15 minutes with 3% Hydrogen Peroxide (H2O2), 
sections were washed 3 x 150µL with PBS then blocked with 20% non-immune 
serum from the species that the secondary antibody was raised in for 20 minutes to 1 
hour.  Sections were then exposed to primary antibodies at pre-determined dilutions 
in 150µL PBS or 1% BSA at 4 
0
C overnight or room temperature (RT) for 30 
minutes.  Controls included substitution of the primary antibody with an equal 
concentration of IgG from the species that the primary antibody was raised in.  
Following washing with 3 x 150µL PBS, biotinylated secondary antibodies were 
incubated at pre-determined dilutions in 150µL PBS with the sections at RT for 30 
minutes or 1 hour.  Subsequently, bound secondary antibodies were detected with 
ABC reagent (streptavidin-biotin peroxidase ABC kit) at RT for 30 minutes.  The 
sections were then stained with the HRP substrate DAB, for a time determined 
specifically for each batch of staining, then washed in tap water for 5 minutes.  
Counterstaining with haematoxylin was carried out for 1 minute prior to dehydration 
through graded alcohols and clearing in xylene in preparation for coverslipping with 
DPX mountant.  Examples of specific staining are shown by comparison with a 



























20% GS Goat anti-Rat 
IgG 
1:200 
1h at RT 
Mouse anti-
Mouse SMA  
1:400 (1% 
BSA) 
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Table 2.1 Immunohistochemical Staining Conditions 
The conditions detailed in this table were used during immunohistochemistry on paraffin-
embedded sections, with the exception of VCAM-1 staining which was performed on frozen 
sections.  MAC2 = macrophage-specific galectin-3; SMA = smooth muscle actin; ICAM-1 = 
intracellular adhesion molecule 1; VCAM-1 = vascular cell adhesion molecule 1; BSA = 
bovine serum albumin; GS = goat serum; RS = rabbit serum; NFM = non-fat milk; RT = room 











Figure 2.3 Specificity of primary antibodies 
Sections of brachiocephalic arteries from DKO mice were stained with antibodies against 
SMA, Mac-2, ICAM-1 and VCAM-1 (right-hand panel).  The specificity of each antibody was 
demonstrated by absence of specific staining in negative control images (left-hand panel), in 
which the primary antibody was substituted with IgG.  Captured at x10 magnification, scale 






   
   
   
   




   
   
   
   
   




   
   
   
   






2.3.3 Image Analysis 
2.3.3.1 Light Microscopy 
Images of stained sections were digitised using a light microscope (Zeiss Axioskop) 
coupled to a Photometrics CoolSnap camera (Tucson, U.S.A.) via a microcolour 
liquid crystal turnable RGB filter (Cambridge Research and Instrumentation Inc., 
Woburn, U.S.A.). Microcomputer Imaging Device software (MCID; Imaging 
Research Inc., St. Catharines, Canada) was used to integrate the microscope and 
camera and images were taken at x10 and x40 magnifications.   
2.3.3.2 Morphometric Analysis 
Photoshop CS3 Extended software was used to perform measurements on images of 
stained brachiocephalic artery sections.  The measurement scale was calibrated such 
that pixels were converted into microns for quantifying images taken on the Zeiss 
Axioskop microscope at x10 magnification.  Total plaque area was measured and by 
instructing the software to measure the area of positive staining within plaques, it 
was possible to express the area of stained cells as a percentage of plaque size.  For 
each separate staining experiment a colour template, which tells the software which 
colour to measure, is created for one image and applied to all other images in the 
same set.  Measurements were performed blinded to genotype and age.  
 
2.3.4 Serum Cholesterol Measurements 
Total serum cholesterol levels were measured in Apoe
-/-
 and DKO mice using a 
cholesterol/cholesteryl ester quantification kit (Calbiochem), following the 
manufacturer’s instructions.  Briefly, samples and cholesterol standards (0-10µg) 
were prepared in cholesterol reaction buffer and 50µL of each was added to 
appropriate wells in triplicate in a 96-well plate.  To each of these, 50µL of reaction 
mix (cholesterol reaction buffer, cholesterol probe, enzyme mix, supplied with the 
kit) was added and the plate was incubated at 37
0
C in the dark for 1 hour.  The 
absorbance at 590nm was read in a plate reader (Dynatech labs, MRX) and the 
cholesterol concentration in each sample was calculated from the cholesterol 




2.4 Cell Culture 
2.4.1 Cells and General Principles 
2.4.1.1 Mouse Aortic Endothelial Cells (MAECs) 
Mouse Aortic Endothelial Cells (MAECs) were obtained from the lab of Dr Saito at 
Tsurumi University in Japan (Nishiyama et al., 2007).  These immortalised cells 
were isolated from the aortas of p53-deficient mice and the group initially cultured 
the MAECs for over 100 passages to ensure they retained endothelial cell (EC) 
properties, such as cobblestone morphology, active uptake of acetylated low-density 
lipoprotein, and expression of EC markers (Nishiyama et al., 2007).  As well as this, 
tumour necrosis factor α (TNF-α) treatment promoted lymphocyte adhesion to 
MAECs (Nishiyama et al., 2007), lending these cells to the study of inflammatory 
responses and atherosclerosis.   
2.4.1.2 Culture Conditions 
MAECs were preserved by freezing aliquots (10
6
 cells) in FCS with 10% Dimethyl 
Sulphoxide (DMSO) and storing in liquid nitrogen freezers.  MAECs were cultured 
in Endothelial Basal Medium 2 (EBM-2) supplemented with 10% fetal calf serum 
(FCS) and penicillin/streptomycin (250U/250U) mix under standard culture 
conditions (5% CO2 at 37
0
C).  Cells were grown to confluence in T75 culture flasks 
and passaged every 3-4 days, with around 10
6
 cells used for continuing culture and 
the remaining cells (around 5 x 10
6
) plated out for experimental use as required.  
Sterile cell culture techniques were employed at all times in order to minimise risk of 
infection.     
2.4.1.3 Passaging 
Once confluent, MAECs were washed twice with 10mL PBS to remove any traces of 
FCS (this inhibits trypsin) and then incubated at 37
0
C with 3ml trypsin-versene 
EDTA mixture (1X) for 3 to 5 minutes to dissociate the cells, checked 
microscopically.   Following this, trypsin was inactivated by the addition of 9mL 
complete growth medium and the cell suspension was centrifuged (Heraeus, labofuge 
400R) at 112 x g for 5 minutes.  The cell pellet was resuspended in 10mL EBM-2 
and 2ml (1:5 split) was added to a T75 flask to continue culture whilst the remaining 
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cells were plated out at densities specific to individual experiments, see below for 
details.     
 
2.4.2 Drug Treatments 
2.4.2.1 Justification of treatments  
TNF-α was chosen as a positive control treatment in all studies as it is a potent pro-
inflammatory stimulus well known to up-regulate a wide variety of inflammatory 
responses in endothelial cells (Wajant et al., 2003).  Aldosterone and corticosterone 
were the main focus of the treatments as they both act on MR and are expected to be 
dysregulated in DKO mice.  Spironolactone is a competitive antagonist of the MR 
and thus prevents the actions of aldosterone and corticosterone at this receptor.  The 
glycyrrhetinic acid metabolite, 3-Beta-D-(monoglucuronyl)18-beta-glycyrrhetinic 
acid, inhibits 11β-HSD2 activity (Bujalska et al., 1997) and was used in these studies 
to determine whether or not 11β-HSD2 actively protects MR from illicit activation 
by glucocorticoids in endothelial cells.   
 
2.4.2.2 Drug specifics and treatment conditions 
MAECs were treated with various hormones at near physiological concentrations 
such that in vitro conditions mirrored in vivo conditions as closely as possible.  The 
following hormones and drugs were employed at the indicated concentrations: TNF-
α (10ng/mL, 0.5µM), Aldosterone (1nM), Corticosterone (1nM), Spironolactone 
(1µM), and glycyrrhetinic acid (1µM).  MAECs were seeded into either 6-well (500 
000 cells), 12-well (250 000 cells), 96-well (10 000 cells), or 10cm (10
6
 cells) plates 
and grown to 80-100% confluency before complete growth medium was substituted 
with serum free medium (SFM).  In all studies, MAECs were first pre-treated with 
the inhibitor drugs (spironolactone or glycyrrhetinic acid) for 2 hours prior to the 






2.4.3.1 Preparation and Treatment of Cells 
MAECs were seeded onto circular glass coverslips (sterilised in ethanol and 
thoroughly washed in PBS) in 12-well plates (250 000 cells) for Vascular Cell 
Adhesion Molecule 1 (VCAM-1) staining or directly onto the plastic in 96-well 
plates (10 000 cells) for Intercellular Cell Adhesion Molecule 1 (ICAM-1) staining.  
Cells were grown in complete medium to around 80% confluency before substitution 
with SFM and treatment with the aforementioned drugs for 24 hours.        
 
2.4.3.2 MAEC staining conditions 
Treated MAECs were fixed in methanol containing 5% Dimethyl Sulphoxide 
(DMSO) and, following 3 x 5 minute washes with 250 µL PBS containing 0.05% 
Tween (PBST), endogenous peroxidase was quenched with a 0.3% solution of H2O2 
in methanol (250µL).  Following further PBST washing and blocking with 3% non-
fat milk/10% normal serum (250µL), cells were exposed to either a 1:50 dilution of 
rat anti-mouse VCAM-1 primary antibody (12-well plates with coverslips) or a 
1:1000 dilution of goat anti-mouse ICAM-1 primary antibody (96-well plates) at 4
0
C 
overnight.  Substitution of the primary antibody with rat IgG or goat IgG was 
employed as a negative control.  Dilutions of primary and control antibodies were 
made in 250 µL blocking solution.  Primary antibody was removed by 3 x 5 minute 
washes with PBST and then goat anti-rat (VCAM-1) or rabbit anti-goat (ICAM-1) 
biotinylated secondary antibodies were applied at 1:200 or 1:600 dilutions in 250µL 
PBS respectively at room temperature for 1 hour.  Cells were washed with PBST and 
bound secondary antibodies were detected with a streptavidin-biotin peroxidase ABC 
kit (see section 2.3.2.4 for details).  For VCAM-1 detection the cells were then 
stained with 250µL of the HRP substrate DAB for 1 to 2 minutes.  For ICAM-1 
detection, the DAB was replaced with the soluble HRP substrate o-
Phenylenediamine dihydrochloride (OPD) which forms a yellow product upon 
reaction with peroxidase.  After 1 minute, the reaction was stopped by the addition of 
2M sulphuric acid which turns the product orange.  The intensity of staining, which 
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correlates with the amount of ICAM-1 protein present, was measured 
colorimetrically at a wavelength of 490nm in a plate reader (Dynatech labs, MRX).   
 
2.4.3.3 Image Analysis 
Following DAB staining of MAECs to detect VCAM-1 expression, the glass 
coverslips, with adherent cells, were removed from the wells and dehydrated through 
alcohols and xylene.  The coverslips were then mounted cell-surface down onto 
microscope slides with DPX non-aqueous mounting media.  Slides were 
subsequently viewed under a light microscope (Zeiss Axioskop) coupled to a 
Photometrics CoolSnap camera (Tucson, U.S.A.) via a microcolour liquid crystal 
turnable RGB filter (Cambridge Research and Instrumentation Inc., Woburn, 
U.S.A.). Microcomputer Imaging Device software (MCID; Imaging Research Inc., 
St. Catharines, Canada) was used to integrate the microscope and camera and images 
were taken at x10 and x40 magnifications.  The number of positively stained cells 
per field (x40) were counted in four randomly selected fields per slide for each 
treatment and this procedure was repeated in five individual cell culture experiments. 
 
2.4.4 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
2.4.4.1 Principles of ELISA 
The ELISA was developed as a safer alternative to the radioimmunoassay for 
assessing the expression level of specific antigens in biological samples (Van 
Weemen et al, 1971).  It utilises enzyme-linked (e.g. HRP) antibodies in place of 
radioactively-labelled antibodies and exploits the colorimetric reactions catalysed by 
these enzymes as a means of measuring antigenic expression.  A variant of this 
technique called the solid phase sandwich ELISA is a commonly used method of 
measuring the amount of specific antigen between two layers of antibodies (capture 
and detection antibodies). Figure 2.4 depicts the general principles of the sandwich 
ELISA in which a capture antibody, immobilised on the surface of a 96-well plate, 
binds the specific antigen in a sample and this in turn is bound by a biotinylated 
detection antibody specific to that same antigen.  Streptavidin-labelled HRP enzyme 





Figure 2.4 Sandwich ELISA 
Sandwich ELISA method of measuring antigen levels in serum or cell culture media.  The 
antigen of interest is captured by a specific primary antibody, coated onto the surface of a 
well in a 96-well plate, and detected by the addition of a biotinylated antigen-specific 
antibody, which binds to the captured antigen.  The addition of streptavidin-linked HRP 
followed by reaction with an HRP substrate allows chromogenic detection of the antigen 
where the colour intensity is directly related to the levels of antigen present in the original 





















production of a chromogenic substrate, allowing antigenic expression levels to be 
determined by measurement of colour intensity.         
2.4.4.2 MCP-1 and sVCAM-1 sandwich ELISA 
Around 500 000 MAECs were seeded onto 6-wells plates in complete growth 
medium and incubated until 100% confluency was reached.  Cells were then treated 
with the aforementioned hormones/drugs in SFM for 16h and the culture media were 
collected for analysis of MCP-1 or sVCAM-1 secretion by ELISA.  A mouse MCP-1 
(Invitrogen) or sVCAM-1 (R&D Systems) sandwich ELISA kit was used according 
to the manufacturer’s instructions.  Briefly, standards (0-2500pg/mL and 0-20ng/mL, 
supplied with kits) and samples (100µL) were added to appropriate wells in a 96-
well plate containing the immobilised capture monoclonal antibody specific to 
mouse MCP-1 or sVCAM-1, and incubated at room temperature for 2 or 3 hours, 
respectively.  Following removal of unbound components by washing with a mild 
detergent (supplied with the kit), a biotinylated anti-mouse MCP-1 or sVCAM-1 
detection antibody (supplied with the kit) was applied to the wells for 45 minutes or 
1 hour respectively at room temperature.  Wells were washed to remove unbound 
antibody and a solution of streptavidin-HRP (supplied with the kit) was added for a 
further 45 minutes and, subsequently, excess was removed by washing.  Stabilised 
chromogen (supplied with the kit) was then applied and a yellow product was 
formed, the intensity of which was dependent upon the amount of antigen present in 
the cell culture media.  The chromogen was incubated for 15 (MCP-1) or 30 
(sVCAM-1) minutes before a stop solution (supplied with the kit) was added, turning 
the colour from yellow to blue.  The colour intensity was measured at a wavelength 
of 450nm in a plate reader (Dynatech labs, MRX) and the concentration of MCP-1 or 
sVCAM-1 in the samples was inferred from the standard curve produced by plotting 





2.4.5 Electrophoretic Mobility Shift Assay (EMSA) 
2.4.5.1 Principles of EMSA    
The electrophoretic mobility shift assay (EMSA) is widely used to study the 
interaction of proteins with DNA and it relies on the principle that a DNA-protein 
complex will have a retarded mobility during electrophoresis compared to non-bound 
DNA (Garner et al., 1981).  The shifts can be visualised on a native acrylamide gel 
using labelled DNA to form the DNA-protein binding complex.  The majority of 
protocols to date use DNA labelled with radioisotopes, digoxygenin, or biotin.  
However, it is now possible to perform an EMSA using specific oligonucleotides 
labelled with an infrared dye, removing the need for hazardous radioisotopes, gel 
transfer, and lengthy film exposure.  The Odyssey
®
 infrared imaging system is used 
in combination with IRDye
®
 700 EMSA oligonucleotides in standard EMSA 
protocols to detect DNA-protein interactions.   
2.4.5.2 Bradford Protein Assay 
Protein concentration measurements were performed using Bradford’s reagent 
(Bradford, 1976).  To prepare the standard curve, a 2mg/mL solution of BSA was 
made up and serial dilutions gave standards with the range 0 – 2mg/mL.  In a 96-well 
plate, 2µL of standard or sample was mixed with 98µL of Bradford’s reagent and 
incubated at RT for 5 minutes.  Absorbance at 595nm was measured in a plate reader 
(Dynatech labs, MRX) and the standard curve was used to determine the protein 
concentration of nuclear protein extracts. 
2.4.5.3 MAEC Nuclear Protein Extractions 
MAECs (10
6
 cells) were grown in complete medium to confluency in 10cm dishes 
prior to treatment with the aforementioned hormones/drugs in SFM for 2 hours, ten 
10cm dishes were used for each treatment.  Following treatment, nuclear proteins 
were extracted using a modified version of the protocol described by Dignam et al 
(Dignam JD, 1983).  MAECs were washed in ice cold PBS w/o calcium and 
magnesium, scraped in 2mL ice cold PBS, and collected into 15mL falcon tubes for 
counting.  The ten dishes per treatment typically yielded around 50 million cells.  
The MAECs were then collected by centrifugation at 112 x g (Heraeus, labofuge 
400R) for 10 minutes, resuspended in 5 packed cell volume (PCV) of buffer A 
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(10mM Hepes-KOH pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT, and 0.5M 
PMSF), and allowed to swell on ice for 10 minutes.  Following this, cells were again 
collected by centrifugation at 112 x g (Heraeus, labofuge 400R) for 10 minutes and 
resuspended in 2.5 PCV buffer A with 0.1% NP40.  Cells were then lysed with 12 
strokes in a pre-chilled glass homogeniser with tight-fitting pestle then centrifuged at 
447 x g (Heraeus, labofuge 400R) for 10 minutes to collect the nuclei, which were 
subsequently washed in 2mL buffer A without NP40.  This solution was centrifuged 
at 18000 x g (Beckman, Optima MAX-E ultracentrifuge) for 15 minutes to pellet the 
nuclei which were then resuspended in 2.5 nuclei pellet volume buffer C (420mM 
NaCl, 10mM Hepes-KOH pH 7.9, 1.5mM MgCl2, 0.2mM EDTA, 25% glycerol, 
0.5mM DTT, and 0.5mM PMSF) and homogenised with 10 strokes with a tight 
fitting pestle as before.  The lysed nuclei were then stirred slowly for 30 minutes at 
4
0
C followed by centrifugation for 30 minutes at 25000 x g (Beckman, Optima 
MAX-E ultracentrifuge).  The supernatant, containing the nuclear proteins, was 
dialysed against 50 volumes of buffer D (20mM Hepes-KOH pH 7.9, 75mM NaCl, 
0.1mM EDTA, 20% glycerol, and 0.5mM PMSF) at 4
0
C for 3 hours in order to 
remove the salt from the protein extracts.  Bradford’s protein assay (see section 
2.4.5.2) was employed to determine the concentration of nuclear proteins in the 
extracts, which were aliquoted and stored at -80
0
C until use.   
2.4.5.4 5% Polyacrylamide Gels 
Native polyacrylamide gels (6%) were made with TBE buffer for electrophoresis of 
EMSA reactions.  Glass plates and spacers are assembled such that the resulting gel 
is 1mm thick, and a 2% agarose solution is used to seal the edges of the glass plates 
to prevent leaking.  The gel is made by mixing 3g of acrylamide/bisacrylamide 
(19:1) with 50mL of 0.5x TBE buffer (diluted 1:10 from 5x TBE stock) and adding 
300µL of 10% ammonium persulfate (APS).  Immediately prior to pouring, 40µL of 
TEMED is added to the gel mixture to aid polymerisation, which normally occurred 
within 10 to 20 minutes of carefully pouring the gel between the glass plates and 
inserting the comb.  Before loading, the gel was pre-run at 20mA for 30 minutes in 




2.4.5.5 NF-κB EMSA 
The activity of NF-κB in nuclear protein extracts was determined by EMSA.  NF-κB 
IRDye 700-labelled DNA oligonucleotides were obtained from LI-COR.  Crude 
nuclear extract (10µg/reaction) was incubated for 20 min on ice in binding buffer 
(EMSA buffer kit, LI-COR UK) containing 25mM DTT/2.5% Tween20, 1µg/mL 
Poly (dI-dC), and with or without 1µg NF-κB antibody (Abcam).  Following this, 
1µL of the IR-labelled oligonucleotides encoding the consensus NF-κB site 5’- 
AGTTGAGGGGACTTTCCCAGGC-3’ was added to each reaction (total volume 
20µL) and incubated for 30 minutes on ice.  Orange loading dye (1µL) was added 
and samples were separated by electrophoresis at 20mA in pre-run 6% 
polyacrylamide gels for around 2 hours.  The glass plates were then removed from 
the electrophoresis apparatus and placed directly onto the Odyssey infrared imaging 
system flatbed (LI-COR).  The gel was scanned using the parameters detailed in 




All data are expressed as mean  standard error of the mean (sem). Values quoted for 
n refer to the number of different mice used in each experiment.  GraphPad Prism 5 
software was used to create graphs and perform statistical analyses. Data were 
analysed by unpaired t test, One or Two Way Analysis of Variance (ANOVA) 
followed by post hoc tests, or the non-parametric Kruskal wallis test, as appropriate. 












Scanning Channel Scan Intensity Focus Offset Resolution 
700 8.0 3mm 169µm 
 
Table 2.2 Odyssey Scan Parameters 
The parameters detailed in this table were used to scan EMSA gels using the LI-COR 
odyssey infrared imaging system.  The scanning channel refers to the dye that is linked to 
the oligo of interest and the intensity is that recommended in the manufacturer’s instructions.  
The focus offset is the glass plate thickness (2.5mm) + ½ the gel thickness (0.5mm) and the 


























3 Chapter 3: Effect of Mineralocorticoid Receptor 







Effect of Mineralocorticoid Receptor Blockade on the 














The major aim of the work described in this thesis was to determine the cellular and 
molecular mechanisms underlying the accelerated development of atherosclerosis in 
the Apoe/11β-HSD2 DKO mouse.  In order to do this, it was first necessary to assess 
the role of MR activation in atherogenesis in the DKO mouse.  Given the loss of 
11β-HSD2-mediated protection of MR in DKO mice it is likely that illicit MR 
activation is implicitly involved in this phenotype.   
Several studies in humans and rodents have reported detrimental effects of MR 
activation in cardiovascular pathologies (see section 1.3).  Loss of 11β-HSD2-
mediated protection of MR in DKO vessels may produce the vascular dysfunction 
necessary to drive the progression of atherosclerosis.  In support of this proposal, a 
recent study demonstrated that administration of aldosterone to Apoe
-/-
 mice for 1 
month led to accelerated atherogenesis; a mechanism mediated, at least in part, by 
MR and AT1 receptors (Keidar et al., 2004).  Recently there has been a surge in 
research aiming to investigate the pathological consequences of MR activation in 
non-epithelial tissues, such as the heart and vasculature.  This has been stimulated by 
the fact that MR antagonists, administered at doses that do not significantly lower 
blood pressure, improve survival in patients with heart failure (Pitt et al., 2001; Pitt 
et al., 1999), suggesting cardiovascular effects independent of renal control of blood 
pressure.   
The mechanisms by which the selective MR antagonist eplerenone exerts its 
cardioprotective effects are largely unknown, highlighting the necessity for 
continued research in this area.  Given that the DKO mouse combines the 
atherosclerosis-prone nature of the Apoe
-/-
 with the inappropriate MR activation of 
the 11β-HSD2
-/-
, it is an ideal model for investigating the effects of MR activation on 
atherogenesis and may, thereby, aid in dissecting out the mechanisms of eplerenone 
action.  A previous drug study in the DKO mice demonstrated a significant reduction 
in both global and brachiocephalic atherosclerotic burden in eplerenone treated 
animals without a reduction in blood pressure (Deuchar et al, 2009).  Conversely, 
treatment of DKO mice with the epithelial sodium channel (ENaC) blocker amiloride 
did significantly reduce blood pressure but had no impact upon atherogenesis.  
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Together these results suggest that activation of extra-renal MR, and not 
hypertension brought about by activation of renal MR, is important in the 
atherosclerotic phenotype and so based on this, it was hypothesised that blockade of 
MR would alter the cellular components of the DKO atherosclerotic plaque, 
favouring stability by reducing vascular inflammation.  The specific aims of this 
chapter were: 
(i) To assess the effects of a sub-hypotensive dose of eplerenone on the 
cellular composition and stability of plaques from DKO mice. 
(ii) To determine whether or not the reduction in plaque size with MR 

























 DKO mice received either vehicle (n=4) or 200mg/kg of 
body weight/day eplerenone (n=4) in standard chow diet from 2 months of age (for 
diet preparation, see section 2.2.4).  Treatment was for 12 weeks and at 5 months of 
age mice were culled by asphyxiation with CO2.  This particular treatment regime 
was based on the previous drug study in DKO mice which demonstrated an effect of 
eplerenone on lesion size without significantly altering blood pressure (Deuchar et 
al., 2009).  
3.2.2 Assessment of atherosclerosis 
For detailed methods on the characterisation of atherosclerosis see section 2.3.  The 
brachiocephalic artery (anatomical location depicted in Figure 3.1) was preferentially 
used in these studies due to its propensity to develop advanced lesions.  Histological 
and immunohistochemical techniques were performed according to the methods 
detailed in section 2.3.2.  Total plaque area was measured in transverse sections by 
drawing around the lesion and by instructing the software to measure the area of 
positive staining within plaques, it was possible to express the area of stained cells as 
a percentage of plaque size (see Figure 3.2a).  For each separate staining experiment 
a colour template, which tells the software which colour to measure, is created for 
one image and applied to all other images in the same set.  Measurements were 
performed blind to genotype and age.  Additional parameters measured were: buried 
fibrous caps (% of animals with buried caps), mean area (µm
2
) inside the external 
elastic lamina (EEL), internal elaαstic lamina (IEL) and lumen (see Figure 3.2b). 
These measurements could then be uαsed to calculate the area of the media (area 
inside EEL – area inside IEL). Three evenly spaced sections were chosen to 
represent each artery when calculating the mean parameters in a group.        
3.2.3 Statistical analysis 
Data are mean ± sem and were analysed by students’ unpaired t-test. 






Figure 3.1 Anatomical location of brachiocephalic artery 
Schematic diagram of the aortic arch with its’ major branches, of which the brachiocephalic 
artery (B) is studied in this thesis.  The brachiocephalic artery (also called the innominate 
artery) is the first branch off the aortic arch and it supplies blood to the right arm, the head, 
and the neck.  Soon after it emerges, the brachiocephalic artery divides into the right 
αcommon carotid artery (RC) and the right subclavian artery (RS).  The second and third 
major branches off the aortic arch are the left common carotid artery (LC) and the left 



















Figure 3.2 Morphometric and quantitative analysis of brachiocephalic 
sections 
Photoshop CS3 Extended software was used to quantify: (A) immunohistochemical staining 
in brachiocephalic artery sections.  A line was drawn around the plaque and the brown 
staining, macrophages in this example, within the area of interest was then selected and 
highlighted (red in the right-hand image) and, by dividing the area of the highlighted regions 
by the total plaque area the percentage contribution of the stained cell type to the plaque can 
be calculated.  (B) Vascular remodelling was quantified by measuring the mean area (µm
2
) 
inside the external elastic lamina (EEL), and by subtracting the mean area inside the internal 
elastic lamina (IEL), the medial area (M) could be calculated (left panel).  Luminal patency 
was determined by subtracting the plaque area (P) from the area inside the IEL in order to 













3.3.1 Influence of MR blockade on vascular remodelling and 
atherogenesis in DKO brachiocephalic arteries 
To determine whether or not inappropriate MR activation played a causative role in 
the DKO atherosclerotic phenotype, DKO mice received either the selective MR 
antagonist eplerenone (n=5) (at a dose that does not alter blood pressure) or vehicle 
(n=4) administered for 12 weeks in their diet from 2 months of age.  In order to 
confirm the findings of the previous drug study in DKO mice (Deuchar et al., 2009), 
plaque size was compared in brachiocephalic arteries from vehicle and eplerenone 
treated DKO mice.  Haematoxylin stained sections revealed smaller plaques in 
eplerenone (EPL) treated animals compared to vehicle (VEH) treated animals ( 
Figure 3.3a).  Quantitative analysis of three evenly spaced sections per vessel, using 
Photoshop CS3 Extended software, confirmed that antagonism of MR significantly 
reduced plaque size in DKO brachiocephalic arteries compared to vehicle treatment 
(Figure 3.3b).   
The formation of atherosclerotic lesions is often associated with remodelling of the 
blood vessel such that a compensatory enlargement of the vessel occurs to 
accommodate
 
the plaque and maintain the lumen (Glagov et al., 1987).   Vascular 
remodelling was investigated in vehicle and eplerenone treated DKO brachiocephalic 
arterial sections to determine whether or not the reduction in plaque size with MR 
blockade was associated with alterations in other vascular parameters.  The results 
are shown in Table 3.1 and indicate that eplerenone treatment significantly reduced 
both the area inside the EEL and the area inside the IEL, thereby maintaining the 
medial area.   Despite a reduction in plaque area, the luminal area was not altered by 
eplerenone, an effect that may be explained by the reduction in the area inside the 
IEL in eplerenone treated animals.  The percentage of animals containing buried 
fibrous caps was significantly decreased by eplerenone, and since this feature is 







Figure 3.3 Eplerenone reduced plaque size in DKO brachiocephalic arteries 
Sections of brachiocephalic arteries from DKO mice treated with 200mg/kg/day eplerenone 
or vehicle for 12 weeks were stained with haematoxylin (A).  Atherosclerotic plaques 
developed in both groups but appeared smaller in size with eplerenone compared to vehicle 
treatment.  Representative images from two vehicle and two eplerenone treated animals, 
captured at x10 magnification.   Scale bar = 250 µm.  The area of atherosclerotic plaque was 
quantified using Photoshop CS3 Extended software (B).  Compared to vehicle, eplerenone 
administration caused a decrease in plaque area after 12 weeks of treatment. Data are 
mean ± sem, n= 4-5. Analysed by Student’s unpaired t test: * p<0.05. 

































 Vehicle Eplerenone 
Area inside EEL (µm2) 283600 ± 17630 245400 ± 3995 * 
Area inside IEL (µm2) 182500 ± 12240 144700 ± 5592 ** 
Medial area (µm2) 101100 ± 6198 100700 ± 4142 
Plaque area (µm2) 85610 ± 11470 57060 ± 7369 * 
Lumen area (µm2) 108800 ± 6904 94620 ± 6235 
Buried fibrous caps (% 
mice with caps) 
75% 20% 
 
Table 3.1 Compensatory remodelling maintains luminal area of 
brachiocephalic arteries 
Sections of brachiocephalic arteries from vehicle and eplerenone treated DKO mice were 
subjected to morphometric analysis using Photoshop CS3 Extended software. The 
measurements show that MR blockade reduced the area inside the external elastic lamina 
(EEL) and internal elastic lamina (IEL) with no change in the medial area.  Whilst plaque size 
was reduced with eplerenone treatment, the luminal area remained comparable with that in 
vehicle treated mice.  Eplerenone also showed a trend to reduce the % of plaques that 
contained buried fibrous caps.  Data are mean ± sem, n = 4-5.  Data were analysed by 










3.3.2 Effect of MR blockade on the cellular composition of 
brachiocephalic plaques in DKO mice 
Given the beneficial effect of eplerenone on atherogenesis in DKO brachiocephalic 
arteries, it was decided to investigate whether or not the cellular composition of 
plaques was also altered by MR blockade.  Thus, brachiocephalic sections from 
vehicle and eplerenone treated animals were subjected to histological staining and 
immunohistochemistry using cell-specific antibodies.   
3.3.2.1 Smooth Muscle Cells 
Immigration of medial smooth muscle cells into the growing plaque signifies the 
progression from the fatty streak to the more complex lesion.   Smooth muscle cells 
synthesise the extracellular matrix (ECM) proteins that contribute to the development 
of the fibrous cap, and are generally considered to be a stabilising factor in plaques.  
Immunohistochemical staining with anti-smooth muscle α-actin antibody revealed a 
higher density of SMCs in the plaques of eplerenone treated mice compared to 
vehicle treated mice (Figure 3.4).  Quantitative analysis of 2-3 sections per vessel 
established that plaques from mice in the eplerenone group contained a significantly 
greater proportion of SMCs than did those from mice in the vehicle group (Figure 
3.5).   
3.3.2.2 Collagen 
Collagen fibres are major components of the ECM that exists to provide stability to 
both healthy cells and tissues and to atherosclerotic plaques.  Collagen content was 
assessed by staining DKO brachiocephalic sections with Picrosirius red and it was 
found that plaques from eplerenone treated animals appeared to show more abundant 
collagen staining when compared to plaques from animals in the vehicle group 
(Figure 3.4).  Quantification of collagen staining in 2-3 sections per vessel confirmed 
that collagen content was significantly increased in plaques from DKO mice treated 








Figure 3.4 Altered composition of atherosclerotic plaques in DKO mice 
treated with eplerenone 
Atherosclerotic plaques from mice treated with 200mg/kg/day eplerenone differed in 
composition from vehicle-treated controls.  Plaques in eplerenone treated animals 
demonstrated increased staining for SMCs and collagen with no apparent difference in lipid 
content, compared to those in vehicle treated DKO mice.  Representative images from 
vehicle (n=4) and eplerenone (n=5) treated animals, captured at x10 magnification.   Scale 
bar = 250 µm.  
 
 








































Figure 3.5 Eplerenone increased plaque SMC content in DKO mice 
The area of smooth muscle actin staining in animals treated with 200mg/kg/day eplerenone 
or vehicle was quantified using Photoshop CS3 Extended software and expressed as a % of 
total plaque area. Eplerenone administration increased plaque SMC content compared to 












































Figure 3.6 Eplerenone increased plaque collagen content in DKO mice 
The area of collagen staining in animals treated with 200mg/kg/day eplerenone or vehicle 
was quantified and expressed as a % of total plaque area. Eplerenone administration 
increased plaque collagen content compared to vehicle treatment.  Data are mean ± sem, n= 














































With atherosclerotic progression, lipids
 
accumulate within the plaque at the expense 
of ECM and
 
smooth muscle cells, aiding the formation of a destabilising necrotic 
lipid core.  Thus, as a measure of plaque instability, lipid content was investigated by 
measuring the lipid holes left behind during histological processing in UST stained 
brachiocephalic sections.  It appeared from observation of plaques from eplerenone 
and vehicle treated mice that lipid content was comparable between the two groups 
(Figure 3.4).  Indeed, a lack of effect of eplerenone on the area of lipid holes was 
verified by quantitative analysis (Figure 3.7).   
 
3.3.3 Effect of MR blockade on brachiocephalic plaque inflammation in 
DKO mice 
Infiltration of monocytes into plaques and their subsequent differentiation into 
macrophage-derived foam cells is an important step in the development and 
progression of atherosclerosis.  To investigate possible mechanisms behind the 
eplerenone-mediated retardation of atherogenesis in DKO mice, inflammatory cell 
infiltration was assessed in brachiocephalic plaques from vehicle and eplerenone 
treated animals.  Macrophage content was determined using immunohistochemistry 
with specific antibodies and, upon microscopic examination, eplerenone treatment 
appeared to reduce the area of Mac-2 positive staining compared to vehicle treatment 
(Figure 3.8a).  Quantitative image analysis revealed that eplerenone did indeed 
significantly reduce the macrophage content of plaques in DKO mice compared to 





Figure 3.7 Eplerenone had no effect on plaque lipid content in DKO mice 
The area of lipid holes in animals treated with 200mg/kg/day eplerenone or vehicle was 
quantified and expressed as a % of total plaque area. Eplerenone administration had no 
effect on the lipid content of DKO plaques with levels being comparable to those in vehicle 




































Figure 3.8 Eplerenone reduced plaque macrophage content in DKO mice 
Sections of brachiocephalic arteries from animals treated with 200mg/kg/day eplerenone or 
vehicle for 12 weeks were stained with antibodies against Mac-2 (A).  Plaque macrophage 
abundance appeared reduced with eplerenone compared to vehicle treatment.  
Representative images from two vehicle and two eplerenone treated animals, captured at 
x10 magnification.   Scale bar = 250 µm.  The area of Mac-2 staining was quantified and 
expressed as a % of total plaque area (B).  Eplerenone administration led to a reduction in 
macrophage content of plaques from DKO mice compared to vehicle control mice.  Data are 
mean ± sem, n= 4-5. Analysed by Student’s unpaired t test: * p<0.05. 

































3.3.4 Influence of MR blockade on overall plaque stability in DKO mice 
The fate of an advanced dynamic plaque depends on the balance of stabilising 
(SMCs and collagen) and degrading (lipids and macrophages) forces, the ratio of 
which is often used as an indication of overall plaque stability (Davies, 1996; Shiomi 
et al., 2008).  Creating a stacked-bar graph, where each stack represents either 
stabilising or destabilising components, allows a simple comparison of overall plaque 
composition between vehicle and eplerenone treated mice (Figure 3.9).  The graph 
suggests that eplerenone treatment alters the composition of plaques, favouring a 
more stable phenotype.  Plaques from eplerenone treated mice were made up of 56% 
stabilising components, largely collagen, and only 30% destabilising components, 
almost equal lipids and macrophages.  In contrast, plaques from vehicle mice 
consisted of only 33% stabilising components, largely collagen, and 41% 
destabilising components, mostly macrophages.  These four components, however, 
do not add up to 100% of lesion area and so there must also be other cell types within 
the plaque that aren’t detected by any of the stains employed in this study.  Other 
candidates could include ECM proteins other than collagen (e.g. elastin and 
fibronectin), minerals such as calcium, or other leukocytes (e.g. T-cells and mast 
cells).   














Figure 3.9 Eplerenone improved plaque stability in DKO mice 
The contribution that stabilising and destabilising components make to the overall plaque 
gives an indication of plaque stability.  Eplerenone treatment promotes plaque stability by 
altering plaque composition such that the ratio of stabilising (SMC and collagen) to 
































These studies demonstrated that treatment with eplerenone for 12 weeks slowed the 
progression of atherosclerosis and vascular remodelling in DKO mice.  Plaque 
composition was altered such that mice receiving eplerenone developed more stable 
smooth muscle cell- and collagen-rich plaques whilst vulnerable lipid- and 
macrophage-rich plaques developed in vehicle treated mice.  Vascular inflammation 
in DKO mice was reduced by eplerenone treatment as shown by a decrease in 
macrophage infiltration.       
 
Effects of eplerenone on atherogenesis and vascular remodelling 
Eplerenone was administered in standard chow diet at a dose of 200mg/kg of body 
weight/day, which was chosen as it reduced brachiocephalic lesion size without 
altering blood pressure in a previous study in DKO mice (Deuchar et al., 2009).  In 
the current study, eplerenone significantly decreased both plaque size and expansive 
vascular remodelling, without affecting medial or luminal area in DKO 
brachiocephalic arteries.  This suggests that whilst inappropriate activation of MR 
accelerates atherogenesis in DKO mice, the lumen is maintained by compensatory 
expansion of the vascular wall.  It is well established that atherosclerosis promotes 
this type of remodelling (Glagov et al., 1987) and, since a reduction in plaque size 
with eplerenone was associated with a reduction in vascular remodelling, it is clear 
that the outward remodelling in DKO mice is a direct consequence of plaque growth, 
and not due to other effects of MR activation such as hypertension, which was not 
normalised in eplerenone treated mice (Deuchar et al., 2009).  Moreover, 
remodelling in hypertensive disorders is generally ‘inward’ and is characterised by 
medial thickening, decreased luminal patency, and an increased extracellular matrix 
(Roman et al., 1992; Safar et al., 1998), features that were not observed in 
brachiocephalic arteries of vehicle or eplerenone treated DKO mice.  In addition to 
this, although MR activation by aldosterone is associated with vascular injury and 
remodelling in stroke-prone hypertensive rats (Rocha et al., 1998) and in 
hypertensive humans (Schiffrin et al., 2004), it is the inward type of remodelling and 
not the expansive type that is found with atherosclerosis.  This lends further support 
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to the notion that the vascular remodelling associated with MR activation in DKO 
mice is a result of increased plaque size.   
The fact that eplerenone significantly reduced plaque size in DKO mice demonstrates 
that inappropriate MR activation is causal in the accelerated atherogenesis in this 
model.  DKO mice are hypertensive, due to loss of 11β-HSD2-mediated protection 
of renal MR, and the link between hypertension and atherosclerosis is well 
established.  Indeed, atherosclerosis has been shown to be 3 times more common in 
patients with hypertension (Doyle, 1990) and Apoe
-/-
 mice that are hypertensive due 
to inactivation of the eNOS gene developed larger lesions than single Apoe
-/-
 controls 
(Knowles et al., 2000).  However, the plaque reducing effects of eplerenone in DKO 
mice occurred at a dose that did not reduce blood pressure, suggesting an important 
role for MR activation in extra-renal cells in this phenotype.  In line with this, 
reduction of the renal consequences of MR activation by inhibition of ENaC with 
amiloride did significantly reduce blood pressure but had no effect on the 
atherosclerotic burden in DKO mice (Deuchar et al., 2009).  This is in agreement 
with the RALES (Pitt et al., 1999) and EPHESUS (Pitt et al., 2001) trials where 
treatment with sub-hypotensive doses of spironolactone and eplerenone had 
significant cardio-protective benefits in patients with heart failure.   
 
Cells of the vasculature are prime candidates for a role in MR-mediated 
atherogenesis; not only are they implicitly involved in all stages of atherosclerosis 
(Libby et al., 2002) but they also express the necessary components (Takeda, 1993) 
to be mineralocorticoid/glucocorticoid responsive.  The major initiating event in 
atherosclerosis is endothelial cell dysfunction and, given that 11β-HSD2
-/-
 mice 
display features of this (Hadoke et al., 2001), it is likely that endothelial dysfunction 
is an important contributor to the accelerated atherogenesis in DKO mice.  An 
elegant set of studies using HUVECs has defined a role for aldosterone-mediated 
MR activation in processes associated with dysfunction such as endothelial cell 
swelling (Oberleithner et al., 2004), stiffening and vulnerability to shear stress 
(Oberleithner et al., 2006), and  decreased nitric oxide (NO) production 
(Oberleithner et al., 2007).  Whilst aldosterone has been shown to have a wide range 
of detrimental effects on the vasculature (Schiffrin, 2006b), which may be important 
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in the DKO phenotype, the loss of glucocorticoid inactivation by 11β-HSD2 in DKO 
mice points towards inappropriate activation of MR by glucocorticoids as a 
significant mechanism in the accelerated atherogenesis.  A recent study in rat 
vascular smooth muscle cells reported stimulation of MR-dependent signalling 
pathways by physiological concentrations of corticosterone in the absence of 11β-
HSD2 activity (Molnar et al., 2008).  This same study also reported that 
corticosterone acts on intact endothelial cells to enhance the phenylephrine-induced 
contraction of aortic rings; reduction of this effect by spironolactone showed that this 
action of corticosterone was at least partially MR-mediated.  Thus, glucocorticoids 
are able to regulate vascular function through MR but the specific role of 11β-HSD2 
in mediating these actions remains to be defined.       
  
Mechanisms of eplerenone action 
The reduction in plaque size with MR blockade in DKO mice may represent one of 
the potential mechanisms by which eplerenone exerts its beneficial effects on 
cardiovascular morbidity and mortality.  The question now arises as to how MR 
blockade results in reduced plaque size.  In DKO mice, MR is likely to be 
continually occupied by glucocorticoids, causing a level of illicit activation that 
would not commonly be reached in most animals.  Thus, it could be that blockade of 
MR in the DKO would produce effects in this model that wouldn’t necessarily be 
beneficial, or relevant, in other animals.  However, evidence from studies using 
eplerenone in other models, where 11β-HSD2 was not manipulated, suggests that 
MR blockade does reduce atherosclerotic burden in the absence of 11β-HSD2 
inactivation.  In support of this, eplerenone significantly reduced atherosclerosis in 
non-human primates fed a high cholesterol diet without affecting blood pressure 
(Takai et al., 2005).  The authors suggest that the plaque reduction may have been 
due to effects of eplerenone on decreasing levels of oxidized LDL and improving EC 
function (Takai et al., 2005).  Another study reported that eplerenone improved EC 
function and reduced superoxide production in cholesterol fed rabbits (Rajagopalan 
et al., 2002).  Taken together, these studies in combination with the present DKO 
data suggest a detrimental role for endothelial cell MR activation and subsequent 
dysfunction in promoting atherosclerosis.  It is also evident that eplerenone is 
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efficacious in cardiovascular pathologies even when 11β-HSD2 is present to protect 
MR, suggesting that either increased mineralocorticoid/glucocorticoid levels or 
decreased vascular 11β-HSD2 activity may be features of certain diseases.  In 
agreement with this, it was recently reported that tumour necrosis factor α (TNF-α) 
dose-dependently inhibited 11β-HSD2 activity and mRNA expression in a human 
bronchial epithelial cell line (Suzuki et al., 2005).  Further, an in vivo study 
demonstrated that transgenic over-expression of TNF-α in mice led to reduced 11β-
HSD2 activity and mRNA in the kidney (Kostadinova et al., 2005).  Thus, it is 
plausible that in pro-inflammatory states, where TNF-α, and perhaps other cytokines 
are up-regulated, 11β-HSD2 activity may be compromised.  Indeed, TNF-α is known 
to be expressed in macrophages, smooth muscle cells, and endothelial cells in human 
blood vessels affected by atheroma, but not in unaffected vessels (Barath et al., 
1990).  Taken together, these studies support the idea that the normal protection of 
MR afforded by 11β-HSD2 may be reduced or even lost during atherosclerosis.  
When the findings from the DKO model are also considered, it could be suggested 
that pro-inflammatory processes lead to down-regulation of 11β-HSD2 activity 
thereby promoting illicit activation of MR and accelerating atherogenesis.  This may 
also explain why MR blockade with eplerenone is cardioprotective.  However, 
decreased 11β-HSD2 activity may not be the only mechanism involved in pro-
inflammatory regulation of MR activation.  It has also been shown that transgenic 
mice over-expressing TNF-α have increased 11β-HSD1 activity in the liver (Ignatova 
et al., 2009), providing a mechanism by which inflammatory conditions may 
enhance local glucocorticoid levels.  The combination of decreased 11β-HSD2 
activity with increased levels of glucocorticoids in pro-inflammatory states such as 
atherosclerosis has profound implications for inappropriate MR activation and its 
subsequent pathological consequences.     
 
Effects of eplerenone on plaque composition and inflammation 
Whilst the smaller plaque size in eplerenone treated mice was not associated with a 
larger lumen in the present study, by retarding the progression of atherogenesis 
eplerenone may prolong the stability of the lesion.  However, a smaller plaque does 
not necessarily translate into increased stability.  The only way to determine whether 
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or not eplerenone promotes plaque stability is to investigate its effects on the 
composition of lesions.  The reduction in plaque size with eplerenone treatment was 
accompanied by an alteration in the cellular composition of plaques in DKO mice.   
 
Both smooth muscle cell (SMC) actin and collagen content were significantly 
increased by eplerenone in brachiocephalic plaques.  This implies that MR activation 
concomitantly increases lesion area whilst decreasing the content of particular cells.  
Perhaps activation of MR in the SMCs themselves promotes apoptosis or inhibits 
proliferation and migration.  However, evidence suggests the contrary, and activation 
of MR in human vascular SMCs may promote proliferation by increasing expression 
of the anti-apoptotic cell cycle gene MDM2 (Nakamura et al., 2006).  Smooth 
muscle cell and collagen biology are intimately linked (Rekhter, 1999) and so it 
could be that the increased plaque content of both of these components upon MR 
blockade is a direct result of this relationship.  It is known that SMCs are the major 
cellular source of collagen in plaques (Rekhter, 1999) and that collagen deposition is 
required for SMC migration (Rocnik et al., 1998).  Therefore, does MR activation 
lead to decreased SMC content, resulting in less collagen secretion or does it lead to 
decreased collagen content which, in turn, reduces SMC migration into the plaque?  
It has previously been reported that activation of MR in the heart leads to fibrosis 
characterised by increased collagen deposition (Chai et al., 2006; Young et al., 1994) 
and that this can be reversed with MR blockade (Stas et al., 2007; Suzuki et al., 
2002).  Based on this it might be expected that MR activation in the DKO would 
increase plaque collagen content; perhaps the discrepancy between prediction and 
observation is indicative of differential effects of MR activation in different cell 
types.  The amount of collagen present in a plaque is not only determined by its rate 
of secretion, but also by its degradation.  The matrix metalloproteinases (MMPs) are 
a group of enzymes responsible for degrading extracellular matrix proteins, including 
collagen (Lee et al., 1997), and are up-regulated in human atherosclerotic plaques, 
most notably in the vulnerable shoulder regions (Galis et al., 1995).  The decreased 
collagen content due to MR activation in DKO plaques could, therefore, be a result 
of increased MMP activity.  Indeed, it was reported that blockade of MR with 
eplerenone inhibited MMP activity in the hearts of dogs suffering from 
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experimentally induced heart failure (Suzuki et al., 2002).  Given that macrophages 
are a key source of MMPs (Welgus et al., 1990) and that plaque macrophage content 
was decreased by eplerenone in DKO mice, it could be postulated that MR activation 
promotes macrophage infiltration into DKO plaques, where these cells then secrete 
MMPs causing increased collagen degradation.  
 
Plaque macrophages not only secrete matrix degrading enzymes, but they are also 
involved in a host of pro-inflammatory processes that propagate atheroma 
development and progression (Lucas et al., 2001).  The finding that eplerenone 
treatment was associated with reduced macrophage infiltration into DKO plaques is 
suggestive of a role for MR activation in the generation of a pro-inflammatory 
environment.  In support of this, administration of aldosterone to rats induced the 
formation of coronary inflammatory lesions characterized by macrophage 
infiltration, an effect that was reversed by MR antagonism (Rocha et al., 2002b).  
Also, other studies have demonstrated effects of MR activation on macrophage 
oxidative stress in mice (Keidar et al., 2003) and on macrophage recruitment during 
peritoneal fibrosis in rats (Nishimura et al., 2008).  However, the present study is the 
first to describe a role for vascular 11β-HSD2 in protection against MR-mediated 
enhancement of macrophage infiltration into murine atherosclerotic plaques.  
Increased macrophage content in DKO plaques could be due to MR activation in a 
number of cells.   Macrophages express MR (Barish et al., 2005) and it was recently 
reported that deletion of MR specifically from murine macrophages decreased 
mineralocorticoid-induced cardiac fibrosis and demonstrated an important role for 
macrophage MR signalling in cardiovascular pathologies associated with 
mineralocorticoid excess (Rickard et al., 2009b).  However, this study also reported 
that macrophage recruitment was not affected by loss of MR suggesting that 
activation of MR in DKO macrophages may not be the mechanism of increased 
infiltration into plaques.  Having said this, whilst macrophage recruitment to the 
heart was not affected by loss of MR (Rickard et al., 2009a), perhaps macrophage 
MR activation plays a role in macrophage recruitment to the vascular wall under 
certain conditions.  It could be that activation of MR in macrophages increases their 
circulating levels or activation status and if this were combined with increased 
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adhesion molecule and cytokine expression, as is found in atherosclerosis, then the 
situation could be envisaged where increased capture and infiltration of macrophages 
occurs at sites of lesion development.   However, 11β-HSD2 is not present in 
macrophages to protect the MR (Gilmour et al., 2006) and so the receptor will 
normally be occupied by glucocorticoids in these cells.  Thus, it seems unlikely that 
the loss of 11β-HSD2 activity in DKO mice would have a substantial effect on 
macrophage MR activation, which points towards MR-mediated mechanisms in 
other cell types as being important in macrophage recruitment to DKO plaques.  The 
endothelium is known to play a vital role in the infiltration of monocytes into the 
intimal space during the early stages of atherogenesis, partially through the 
expression of cellular adhesion molecules.  This particular issue is investigated and 
discussed in the following chapters.   
 
The proportion of plaque lipids was not altered by MR blockade with eplerenone and 
this could be attributable to several reasons.  Firstly, DKO mice are on the 
hypercholesterolemic Apoe
-/-
 background and eplerenone treatment is not expected to 
affect cholesterol levels, as shown in other studies (Keidar et al., 2003; Suzuki et al., 
2006b; Takai et al., 2005).  Therefore, if circulating cholesterol levels are the main 
predictor of plaque lipid content, comparable levels between vehicle and eplerenone 
treated mice would be expected.  Secondly, there is little or no evidence in the 
literature to implicate MR signalling pathways in lipid synthesis/metabolism.  
Having said this, the one MR-mediated factor that was not altered by eplerenone in 
DKO mice was blood pressure (Deuchar et al., 2009).  It is possible that the lack of 
effect on plaque lipids is a consequence of the lack of eplerenone efficacy in 
reduction of blood pressure via renal MR.   
 
Effects of eplerenone on plaque stability 
The overall effect of eplerenone on DKO atherogenesis was a stabilisation of the 
plaque.  Mice in the vehicle group exhibited a vulnerable plaque phenotype with a 
larger lipid + macrophage content compared to SMC + collagen content.  MR 
blockade in the eplerenone group shifted the balance towards a more stable plaque 
with a higher SMC + collagen content and a reduced lipid + macrophage content.  
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Collagen, whilst promoting the growth of the atherosclerotic plaque, is thought to be 
a stabilising material by contributing to the integrity of the fibrous cap (Rekhter, 
1999).  A loss of collagen content in DKO mice is therefore considered to be a 
destabilising action of MR activation.  Given that MR activation would normally be 
expected to increase SMC proliferation and collagen deposition in cardiovascular 
pathologies, and that lipid content was not altered with eplerenone, it seems likely 
that the beneficial effect of MR blockade in DKO mice is due to the reduction in 
macrophage infiltration.  Further, it could be that increased MR-mediated 
macrophage infiltration in DKO mice is the underlying mechanism driving the 
accelerated atherogenesis.  Previous studies have demonstrated that macrophages in 
culture
 
may promote collagen breakdown of human fibrous caps (Shah et al., 1995) 
and that the mechanical strength of human
 
aortic plaques was reduced when 
macrophage density was increased (Lendon et al., 1991).  This, along with the fact 
that SMC and collagen content were decreased, either at the expense of or as a direct 
result of increased macrophage content in vehicle treated DKO plaques, reveals a 
very important role for the macrophage in the vulnerable plaque.  Whilst many 
studies have shown an inhibitory effect of eplerenone on atherogenesis in various 
models, there is little information on plaque stabilisation by eplerenone.  An 
investigation in Apoe
-/-
 mice found that eplerenone treatment reduced the 
susceptibility of LDL to oxidation (Keidar et al., 2003).  LDL oxidation and its 
subsequent uptake by macrophages leads to the formation of foam cells which are 
thought to be detrimental to plaque stability (Ball et al., 1995; Rajagopalan et al., 
1996).  Taken together, this provides indirect evidence for a plaque stabilising effect 
of eplerenone.  However, the present study provides direct evidence that MR 
activation leads to a vulnerable plaque phenotype characterised by vascular 
inflammation and that this can be reversed by treatment with eplerenone.  Eplerenone 
also showed a trend to decrease the incidence of buried fibrous caps in DKO plaques 
with only one in five of the mice in the eplerenone group showing the presence of 
buried caps, compared to three out of four mice in the vehicle group.  It has been 
suggested that buried fibrous caps are indicative of previous plaque ruptures, indeed 
one study found a significant positive correlation between acute plaque rupture and 
the development of buried fibrous caps (Johnson et al., 2005).  It is thought that 
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plaques grow through continuous cycles of plaque rupture and healing (Heistad, 
2003) and so it could be that stabilisation of plaques by MR blockade along with the 
associated decrease in buried fibrous caps contributes towards the reduced plaque 
size in eplerenone treated animals.         
 
One final point to consider is that eplerenone treatment was started in DKO mice at 2 
months of age and by this stage inappropriate MR activation will be well established, 
along with some of its phenotypic manifestations.  Detrimental alterations in 
cardiovascular physiology and perhaps anatomy will begin in utero and so some of 
the effects of MR activation may be too advanced by two months of age for 
eplerenone to have a beneficial impact.  Thus, in order to determine more fully the 
range of effects of MR activation on atherogenesis, a direct comparison needs to be 
made between DKO and Apoe
-/-
 control mice, this is dealt with in the next chapter 
 
Conclusions 
Inappropriate activation of MR is causal in the DKO atherosclerotic phenotype.  
Blockade of MR with eplerenone not only reduces the brachiocephalic 
atherosclerotic burden, but it also promotes plaque stability by altering the cellular 
composition of lesions.  Eplerenone also reduces macrophage infiltration into 
plaques indicating an inhibitory effect on vascular inflammation in the DKO mouse.  
The mechanisms behind the cardio-protective effects of eplerenone are largely 
unknown and so the knowledge in this area is enhanced by the results of this study.  
The present study also signifies a vital function of 11β-HSD2 in preventing, or at 
least slowing, the development of vulnerable atherosclerotic plaques.  The fact that 
eplerenone reduced atherogenesis without altering blood pressure is suggestive of a 










































It was determined in the previous chapter that activation of MR in DKO mice is 
responsible for the accelerated atherosclerosis and a vulnerable plaque phenotype 
characterised by inflammation.  However, to more fully characterise the mechanisms 
involved in this phenotype, a direct comparison of the atheroma in DKO and Apoe
-/-
 
brachiocephalic arteries is required.  This will not only aid in determining the effects 
of 11β-HSD2 inactivation on atherogenesis but, by comparing the results with those 
in eplerenone treated DKO mice, it will also help to distinguish between the 
consequences of renal and non-renal MR activation.   
 
Preliminary findings showed that compared to Apoe
-/-
 mice, DKO mice have 
accelerated atherogenesis due to over-activation of MR (Deuchar et al., 2009).  The 
studies in the previous chapter advanced the understanding of how MR activation 
accelerates atherosclerosis by showing effects on the cellular composition and 
inflammatory environment of the plaque.  However, what remains unclear from these 
studies are the mechanisms by which 11β-HSD2 activity influences atherogenesis, 
and whether it is via systemic actions on factors such as plasma lipid levels or blood 
pressure, or caused by a local effect on the cells of the vascular wall.  To begin to 
explore the influence of 11β-HSD2 inactivation on the cellular composition and 
stability of atherosclerotic plaques, it was hypothesised that loss of 11β-HSD2-
mediated protection of MR would alter the cellular composition of lesions and 
promote a pro-inflammatory environment in DKO brachiocephalic plaques.  This 
was based on the previous observations (chapter 3) that blockade of MR in DKO 
mice promotes plaque stability by reducing vascular inflammation. With this in 
mind, the specific aims of this chapter were: 
 
(i) To identify the differences in cellular composition between Apoe-/- and 
DKO plaques that may account for the accelerated atherogenesis. 
(ii) To determine the effects of loss of 11β-HSD2 activity on plaque stability 





4.2.1 Experimental mice 






 DKO mice were 
maintained on standard chow diet with water ad libitum.  At 3 or 6 months of age, 5-
8 male and female (due to lack of sufficient males) mice per group were culled by 
asphyxiation with CO2. 
4.2.2 Assessment of atherosclerosis 
Atherosclerosis was investigated in Apoe
-/-
 and DKO mice at two different time 
points, chosen based on preliminary studies in 3 and 6 month old DKO mice, to 
represent early and established lesions respectively.  For detailed methods on the 
characterisation of atherosclerosis see section 2.3.  Histological and 
immunohistochemical techniques were performed according to the methods detailed 
in section 2.3.2.  The section with the largest plaque was chosen to represent each 
artery when calculating the mean parameters in a group.        
4.2.3 Cholesterol Measurement 
A commercial kit was used to measure cholesterol levels in plasma samples from 
Apoe
-/-
 and DKO mice at 6 months of age (see section 2.3.4). 
4.2.4 Statistical analysis    
Data are mean ± sem and were analysed by two-way ANOVA or unpaired Students 












4.3.1 Effect of 11β-HSD2 inactivation on atherosclerotic burden and 
vascular remodelling in Apoe-/- mice 
In order to confirm the findings of previous studies in DKO mice (Deuchar et al., 
2009), plaque size was compared in brachiocephalic arteries from Apoe
-/-
 and DKO 
mice at 3 and 6 months of age.  These time points were chosen to represent early (3 
months) and established (6 months) atherosclerosis in DKO mice.  Haematoxylin 
stained sections (previously subjected to ‘test-run’ immunohistochemistry for CD31 
staining, not employed itself in this thesis) revealed plaques in DKO mice at 3 
months whilst Apoe
-/-
 mice were completely lesion free at this age (Figure 4.1a).  By 
6 months, some Apoe
-/-
 mice had developed plaques while DKO mice at this age 
showed much larger plaques (Figure 4.1a).  Quantitative analysis of the sections with 
the largest plaques from each vessel confirmed that plaque size was significantly 
increased in DKO mice at both 3 and 6 months compared to age-matched Apoe
-/- 
controls (Figure 4.1b).  This analysis also showed that 3 month DKO plaques are 
comparable in size to those in 6 month Apoe
-/-
 mice (Figure 4.1b). 
Vascular remodelling was investigated in Apoe
-/-
 and DKO brachiocephalic arterial 
sections to determine whether or not the accelerated atherogenesis in DKO mice was 
associated with alterations in other vascular parameters.  The results are shown in 
Table 4.1 and indicate that DKO brachiocephalic arteries are expansively remodelled 
with an increased area inside the EEL at 3 and 6 months and an increased area inside 
the IEL at 6 months, compared to age-matched Apoe
-/-
 mice.  There is also significant 
medial proliferation in DKO mice at 3 and 6 months compared to Apoe
-/-
 controls.  
Despite an increase in plaque area in DKO mice, the luminal area was maintained 
due to the outward remodelling in DKO mice compared to Apoe
-/-
 mice.  
Interestingly, 3 month DKO mice and 6 month Apoe
-/-
 mice are comparable in all 
parameters except medial area, which is significantly increased in the DKOs.  These 
results suggest that whilst loss of 11β-HSD2 activity in DKO mice leads to 
accelerated atherogenesis, it does not affect the luminal patency of brachiocephalic 
arteries due to compensatory outwards remodelling of the vessel.   
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Figure 4.1 Atherosclerotic burden is increased in DKO brachiocephalic 
arteries 
Sections of brachiocephalic arteries from Apoe
-/-
 and DKO animals were stained with 
haematoxylin (A).  Atherosclerotic plaques developed in DKO but not Apoe
-/-
 mice at 3 
months of age and by 6 months Apoe
-/-
 mice showed plaques that appeared smaller in size, 
compared to age-matched DKO mice.  Representative images from Apoe
-/-
 (n= 6-7) and 
DKO (n= 7-8) animals, captured at x10 magnification.   Scale bar = 250 µm.  The area of 
atherosclerotic plaque was quantified using Photoshop CS3 Extended software (B).  DKO 
plaques were larger than Apoe
-/-
 plaques at both 3 and 6 months of age and plaque sizes 
were comparable between 3 month DKO and 6 month Apoe
-/-
 mice. Data are mean ± sem, 
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Table 4.1 Morphometric analysis of brachiocephalic arteries reveals 
maintenance of lumen in DKO mice 
Sections of brachiocephalic arteries from Apoe
-/-
 and DKO mice at 3 and 6 months of age 
were subjected to morphometric analysis using Photoshop CS3 Extended software.  DKO 
mice showed an increase in the area inside the external elastic lamina (EEL) at 3 and 6 
months and an increase in the internal elastic lamina (IEL) at 6 months only compared to 
Apoe
-/-
 mice.  DKO mice showed increased medial area at 3 and 6 months compared to 
Apoe
-/-
 mice.  Whilst plaque size was increased in DKO mice at 3 and 6 months, the luminal 
area remained comparable with that in Apoe
-/-
 mice at both ages.  There was also a trend 
towards an increase in buried fibrous cap incidence in DKO mice compared to Apoe
-/-
 
controls.  Data are mean ± sem, n = 5-8 per group.  Data were analysed by two-way ANOVA 




4.3.2 Total plasma cholesterol levels in Apoe-/- vs. DKO mice 
To determine whether or not the accelerated atherogenesis in DKO mice could be 
accounted for by increased cholesterol levels, over and above the levels conferred by 
Apoe knockout, total plasma cholesterol levels were measured in Apoe
-/-
 and DKO 
mice at 6 months of age.  As expected, it was found that there was no significant 
difference in total plasma cholesterol levels between Apoe
-/-
 and DKO mice (Figure 
4.2) and so this is not a factor in the DKO atherosclerotic phenotype. 
 
4.3.3 Influence of 11β-HSD2 inactivation on the cellular composition of 
brachiocephalic plaques in Apoe-/- mice 
Given the detrimental effect of loss of 11β-HSD2 activity on atherogenesis in DKO 
brachiocephalic arteries, and the benefits observed with MR blockade in the 
eplerenone study, it was of interest to investigate whether or not this phenotype was 
associated with alterations in the cellular composition of plaques.  Thus, 
brachiocephalic sections from Apoe
-/-
 and DKO animals at 3 and 6 months of age 
were subjected to histological staining and immunohistochemistry using cell-specific 
antibodies.   
4.3.3.1 Smooth Muscle Cells 
Smooth muscle cells (SMC) are generally considered to be a stabilising factor in 
plaques and the previous chapter showed an increase in the content of these cells 
following MR blockade, suggesting that 11β-HSD2 inactivation diminishes the SMC 
content of plaques in Apoe
-/-
 mice.  In order to determine if this was in fact the case, 
immunohistochemical staining with anti-smooth muscle α-actin antibody was 
performed.  Quantitative analysis of 5-7 vessels per group established that there was 
no significant difference in plaque SMC content between Apoe
-/-
 and DKO mice at 3 








Figure 4.2 Total plasma cholesterol levels were comparable in Apoe-/- and 
DKO mice 
Total plasma cholesterol levels were measured in Apoe
-/-
 and DKO mice at 6 months of age 
using a commercial kit.  Cholesterol levels were found to be comparable between DKO and 
Apoe
-/-












































Figure 4.3 Smooth muscle cell content is not altered in brachiocephalic 
plaques from DKO mice 
Representative images of atherosclerotic plaques from Apoe
-/-
 and DKO animals stained with 
specific antibody against smooth muscle α-actin show similar abundance of staining for 
SMCs (A).  Captured at x10 magnification, scale bar = 250 µm.  The area of smooth muscle 
actin staining was quantified using Photoshop CS3 Extended software and expressed as a 
% of total plaque area (B).  There was no difference in the SMC content of plaques between 
Apoe
-/-
 and DKO mice at either 3 or 6 months of age, Apoe
-/-
 mice at 3 months lack plaques.  















































The finding that collagen content was increased by eplerenone treatment in DKO 
plaques indicates that lack of 11β-HSD2 activity results in a vulnerable collagen-
poor plaque.  Collagen content was assessed by staining Apoe
-/-
 and DKO 
brachiocephalic sections with Picrosirius red.  Plaques from DKO animals at 3 and 6 
months show less abundant collagen staining compared to plaques in 6 month old 
Apoe
-/-
 mice (Figure 4.4a).  Quantification of Picrosirius red staining in 5-6 vessels 
per group confirmed that collagen content was significantly decreased at both 3 and 6 





As a measure of plaque instability (Davies, 1996; Shiomi et al., 2008), lipid content 
was investigated by measuring the lipid holes left behind during histological 
processing in UST stained brachiocephalic sections.  Measurement of hole size 
suggested that lipid content was greater in plaques of 3 and 6 month DKO than in 6 
month Apoe
-/-
 mice (Figure 4.5a).  Indeed, an enhancing effect of 11β-HSD2 
inactivation on plaque lipid content was verified by quantitative analysis (Figure 
4.5b). 
4.3.3.4 Macrophages 
Inflammatory cell infiltration was assessed in brachiocephalic plaques from DKO 
and Apoe
-/-
 animals by staining for the macrophage specific marker, mac-2. 
Microscopic examination and quantitative image analysis revealed that loss of 11β-
HSD2 activity in Apoe
-/-
 mice increased the area of mac-2 positive staining at both 3 









Figure 4.4 Collagen content is reduced in DKO plaques 
Atherosclerotic plaques from Apoe
-/-
 and DKO animals were stained using Picrosirius red 
stain for collagen (A).  Plaques from 6 month old Apoe
-/-
 mice show more intense and 
abundant staining for collagen than plaques from DKO mice at either 3 or 6 months of age.  
Representative images from Apoe
-/-
 and DKO mice, captured at x10 magnification.   Scale 
bar = 250 µm.  The area of collagen staining was quantified using Photoshop CS3 Extended 
software and expressed as a % of total plaque area (B).  Collagen content was reduced in 
brachiocephalic plaques from 3 and 6 month DKO mice compared to those from Apoe
-/-
 mice 




















































Figure 4.5 Lipid content is increased in DKO plaques 
Atherosclerotic plaques from Apoe
-/-
 and DKO animals stained with UST to reveal lipid holes 
left behind by histological processing (A).  DKO mice at 3 and 6 months of age show larger 
areas of lipid holes in their plaques than Apoe
-/-
 mice at 6 months of age.  Representative 
images from Apoe
-/-
 and DKO mice, captured at x10 magnification.   Scale bar = 250 µm.  
The area of lipid was quantified using Photoshop CS3 Extended software and expressed as 
a % of total plaque area (B).  Lipid content was increased in brachiocephalic plaques from 3 
and 6 month DKO mice compared to those from Apoe
-/-
 mice at 6 months of age.  Data are 













































Figure 4.6  Macrophage content is increased in DKO plaques 
Sections of brachiocephalic arteries from DKO and Apoe
-/-
 mice were stained with antibody 
against Mac-2 (A).  Plaque macrophage abundance appeared greater in 3 and 6 month old 
DKO mice compared to that in 6 month old Apoe
-/-
 mice.  Representative images from Apoe
-/-
 
and DKO mice, captured at x10 magnification.   Scale bar = 250 µm.  The area of 
macrophage staining was quantified using Photoshop CS3 Extended software and 
expressed as a % of total plaque area (B).  Macrophage content was increased in 
brachiocephalic plaques from 3 and 6 month DKO mice compared to those from Apoe
-/-
 mice 

















































4.3.4 Influence of 11β-HSD2 inactivation on overall plaque stability in 
Apoe-/- mice 
In the previous chapter it was shown that MR blockade stabilised DKO plaques by 
increasing the ratio of stabilising (SMC + collagen) to degrading (lipids + 
macrophages) forces.  To determine whether or not loss of 11β-HSD2 in DKO mice 
promotes plaque vulnerability, a stacked bar graph was created ( 
 
Figure 4.7) to enable a direct comparison of plaque composition between Apoe
-/-
 and 
DKO mice.  The graph suggests that lack of 11β-HSD2 alters the composition of 
plaques, favouring a more vulnerable phenotype.  At 6 months of age, Apoe
-/-
 mice 
show stable plaques consisting of 62% stabilising components, largely collagen, and 
only 14% destabilising components, almost equal parts lipids and macrophages.  
Despite having similar plaque sizes to the 6 month Apoe
-/-
 mice, 3 month old DKO 
mice show more vulnerable plaques with only 22% stabilising components, mainly 
collagen, and 39% destabilising components, almost equal lipids and macrophages.  
By 6 months of age, plaques in DKO mice have gained stability with equal 
stabilising (39%) and destabilising (39%) components, but are still more vulnerable 
than those in age-matched Apoe
-/-
 counterparts.  The stabilising component of 6 
month DKO plaques is mostly collagen whilst the destabilising component is mostly 


















Figure 4.7 Effect of 11β-HSD2 inactivation on the stability of plaques 
The contribution that stabilising and destabilising components make to the overall plaque 
gives an indication of plaque stability.  11β-HSD2 inactivation promotes plaque instability by 
altering plaque composition such that the ratio of stabilising (SMC and collagen) to 
degrading (lipid and macrophages) forces is reduced in DKO mice compared to Apoe
-/-


































The studies detailed in this chapter have demonstrated that loss of 11β-HSD2 activity 
on the Apoe
-/-
 background accelerates the progression of atherosclerosis and vascular 
remodelling in DKO mice.  Plaque composition was altered in DKO mice, revealing 
an important function for 11β-HSD2 in protection against the formation of 
vulnerable plaques.  Lack of 11β-HSD2 activity promotes vascular inflammation in 
DKO mice as shown by enhanced macrophage infiltration into brachiocephalic 
plaques during the early stages of atherogenesis.  
 
Effects of 11β-HSD2 inactivation on atherogenesis and vascular remodelling 
The results of the present study confirm those of the preliminary studies showing 
significantly increased atherosclerotic plaques in 3 and 6 month old DKO mice 
compared to age-matched Apoe
-/-
 mice (Deuchar et al., 2009).  On a normal chow 
diet, Apoe
-/-
 mice did not develop plaques until after 3 months of age and this is 
consistent with a study demonstrating the time course of lesion development in the 
aortic sinus of chow fed Apoe
-/-
 mice which reported that composite plaques were not 
evident until 5 – 7 months of age (Reddick et al., 1994).  In addition, brachiocephalic 
plaques were only observed in chow fed Apoe
-/-
 mice at around 6 months of age in 
another study (von Holt et al., 2009).  By contrast, chow fed DKO mice presented 
with full atherosclerotic plaques at 3 months, suggesting very early pro-atherogenic 
consequences of 11β-HSD2 inactivation.  At 6 months of age plaques from DKO 
mice were significantly larger than plaques from age-matched Apoe
-/-
 mice and 
whilst all DKO animals studied had plaques at this age; the same was not true of the 
Apoe
-/-
 animals.  It is note-worthy that 3 month old DKO mice had brachiocephalic 
plaques of comparable size to those in 6 month old Apoe
-/-
 mice.  This not only 
highlights the accelerated nature of atherogenesis in DKO mice, but it also allows for 
comparisons of atherosclerosis between DKO and Apoe
-/-
 plaques that are size-




In the drug study (chapter 3), eplerenone treatment of DKO mice normalised plaque 
size to the dimensions observed in 6 month Apoe
-/-
 mice, implying that MR 
activation is causal in the accelerated atherosclerotic phenotype.  However, it should 
be noted that the plaques in vehicle treated mice in the drug study were smaller than 
those in 6 month old DKO mice, possibly because the vehicle mice were studied at 5 
months of age.  This suggests that caution should be employed when comparing the 
results of the present chapter with those of chapter 3.  Nonetheless, it is clear that 
inappropriate activation of MR due to loss of protection by 11β-HSD2 plays a major 
role in accelerating the atherogenic process in DKO mice.  The benefits of MR 
antagonists in atherosclerosis are well established (Strawn, 2005) and it has been 
reported that inhibition of 11β-HSD1-mediated local glucocorticoid regeneration 
reduces atherogenesis in Apoe
-/-
 mice (Hermanowski-Vosatka et al., 2005).  These 
studies provide an indirect link between inappropriate activation of MR by 
glucocorticoids and the pathogenesis of atherosclerosis.  However, there are no 
published data as yet describing a specific role for 11β-HSD2-mediated protection of 
MR in atherosclerosis.  Therefore, the present investigations provide novel evidence 
that compromised 11β-HSD2 activity, in the setting of hypercholesterolemia, 
promotes atherogenesis via MR-mediated mechanisms.   
 
The atherosclerosis in DKO mice was associated with compensatory outwards 
remodelling of the vascular wall such that luminal patency was preserved in the face 
of increased lesion size.  Brachiocephalic arteries from DKO mice at 3 months of age 
were comparable to those from Apoe
-/-
 mice at 6 months of age in all parameters 
except the medial area.  A significant increase in medial area was observed in DKO 
arteries at 3 and 6 months of age compared to both age- and plaque size-matched 
Apoe
-/-
 arteries, suggesting that 11β-HSD2 inactivation, and not purely atherogenesis, 
promotes proliferation and/or hypertrophy of medial cells.  The results from chapter 
3 show that eplerenone treatment of DKO mice had no effect on the medial area.  
Taken together, these results suggest that loss of 11β-HSD2 activity leads to medial 
proliferation via MR-independent mechanisms.  However, the dose of eplerenone 
used did not alter blood pressure in DKO mice (Deuchar et al., 2009) and so the 
increased medial area observed upon 11β-HSD2 deficiency may be secondary to 
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hypertension (Deuchar et al., 2009) as a result of renal MR activation.  Alternatively, 
the eplerenone treatment may not have commenced early enough or continued long 
enough to inhibit or reverse some of the consequences of inappropriate vascular MR 
activation in DKO mice.  This idea is supported by the fact that aldosterone caused 
hypertrophy of rat aortic smooth muscle cells (Fan et al., 2008) and proliferation of 
human vascular smooth muscle cells (Nakamura et al., 2006), effects that were 
reversed by eplerenone.  This implies a role for activation of SMC MR in the DKO 
phenotype.  However, the differential effects of renal and extra-renal MR activation 
on DKO vascular pathology cannot be fully dissected by the present studies. 
 
DKO mice have total plasma cholesterol levels that are comparable to those found in 
Apoe
-/-
 mice and so the accelerated atherogenesis in DKO mice is not simply a result 
of high plasma cholesterol levels.  Yet, differences in lipid profiles between Apoe
-/-
 
and DKO mice cannot be ruled out and may impact upon atherogenesis.  Indeed, it is 
well known that certain lipid profiles (e.g. high LDL cholesterol, high triglycerides, 
and low HDL cholesterol) are associated with coronary heart disease in humans 
(Kreisberg, 2002).  In addition to this, there is evidence to suggest that 
glucocorticoids affect lipid profiles with one study showing that glucocorticoid 
treatment of patients with congenital adrenal hyperplasia was associated with 
increased triglyceride levels (Botero et al., 2000).  Also, the atherogenic lipid profile 
found in patients with rheumatoid arthritis is thought to be partially due to the 
exogenous glucocorticoid therapy employed to treat the disease (White et al., 2006).  
Thus, increased intracellular glucocorticoid levels in DKO mice may act to 
detrimentally alter lipid profiles.  This is most likely to occur through activation of 
glucocorticoid receptors (GR) and is in agreement with a study in 11β-HSD1 
knockout mice which have improved lipid profiles (Morton et al., 2001).  However, 
since there is no conversion of corticosterone into 11-dehydrocorticosterone in DKO 
mice, there is no substrate available for 11β-HSD1 in DKO animals, rendering them 
essentially 11β-HSD1 knockouts.  In this case it might be suggested that lipid 
profiles would be improved in DKO animals.  Without actually comparing full lipid 
profiles in DKO and Apoe
-/-
 mice, however, we can only speculate as to how this 






Effects of 11β-HSD2 inactivation on plaque composition and inflammation 
As might be expected from the results of the eplerenone study (chapter 3), the 
increase in plaque size in DKO mice was accompanied by an alteration in the cellular 
composition of plaques.  Plaque smooth muscle cell (SMC) content was not different 
between Apoe
-/-
 mice at 6 months and either plaque size- (3 months) or age- (6 
months) matched DKO mice.  This was surprising given that MR blockade 
significantly increased the SMC content of plaques in DKO mice in the drug study.  
Since loss of 11β-HSD2 activity was not sufficient to affect SMC content but 
blockade of MR increased it, it could be that blockade of MR in cells that do not 
express 11β-HSD2 is responsible for the beneficial result.  In this case, it is predicted 
that treatment of Apoe
-/-
 mice with eplerenone will produce the same effects on 
plaque SMC content.  Alternatively, illicit activation of MR in DKO mice may have 
no effect on SMC content, but blockade of MR in the DKO may result in increased 
activation of GR by glucocorticoids, via which glucocorticoids could enhance 
proliferation and/or migration of SMCs.  In support of this, it was reported that 
treatment of rat aortic smooth muscle cells with short bursts of glucocorticoid 
increased proliferation (Kawai et al., 1998).  Plaques from DKO mice demonstrated 
decreased collagen content at both 3 and 6 months compared to plaques from 6 
month old Apoe
-/-
 mice.  Since blockade of MR with eplerenone significantly 
increased collagen content in DKO mice, it is likely that the reduction in collagen 
content in DKO mice when compared to Apoe
-/-
 mice occurs as a result of loss of 
11β-HSD2-mediated protection of MR from glucocorticoids.  It has previously been 
shown that glucocorticoid treatment of rat chondrocytes inhibited collagen mRNA 
expression  (Miyazaki et al., 2000) and collagen synthesis was reduced in chick 
embryos by glucocorticoid treatment (Oikarinen et al., 1988).  However, both of 
these studies employed dexamethasone and so the effects were most likely GR-
mediated (Ramsahoye et al., 1995).  Activation of MR is associated with increased 
collagen synthesis in the heart (Chai et al., 2006; Young et al., 1994), clearly 
contrasting with the observations of the present study in which MR activation is 
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associated with decreased plaque collagen content.  Perhaps activation of MR 
promotes collagen synthesis whilst activation of GR, which is also protected by 11β-
HSD2, results in reduced synthesis or increased degradation.  Also, it is likely that 
activation of MR produces different effects in different cells and tissues, which could 
be dependent upon other local factors such as inflammatory status or redox state.  
Although the mechanism of decreased plaque collagen content in DKO mice cannot 
be determined from the present study, or predicted from other studies, it is evident 
that 11β-HSD2 activity is key in protecting against the formation of a vulnerable 
collagen-poor plaque. 
 
Plaque SMC content was unaltered and collagen content was decreased in DKO 
mice, so what is responsible for the increased plaque size?  It was found that 
macrophage staining was increased in plaques from DKO mice at 3 and 6 months of 
age compared to plaques from 6 month old Apoe
-/-
 mice.  This suggests that despite 
comparable plaque sizes between 3 month DKO and 6 month Apoe
-/-
 mice, there is 
an enhanced inflammatory environment in the vasculature of DKO mice.  
Eplerenone treatment of DKO mice significantly reduced macrophage infiltration 
into plaques (chapter 3) suggesting an MR-mediated mechanism.  That inactivation 
of 11β-HSD2 is pro-inflammatory is supported by a study in rats which demonstrated 
that pharmacological inhibition of 11β-HSD2 mimicked the effects of DOC on 
coronary artery inflammation, reversible in both cases by eplerenone (Young et al., 
2003a).  This study in combination with the present studies indicates that loss of 11β-
HSD2 activity allows endogenous glucocorticoids to activate MR, consequently 
promoting a pro-inflammatory vascular environment.  However, this proposal is 
complicated by the fact that glucocorticoids are anti-inflammatory (Newton, 2000) 
and that glucocorticoid treatment decreased macrophage accumulation in a rabbit 
model of atherogenesis (Asai et al., 1993).  Again, the glucocorticoid employed in 
this study was dexamethasone and so will activate GR, thus, the result of this study is 
not surprising given that the anti-inflammatory properties of glucocorticoids are 
attributed to activation of GR.   Based on the results of the present study, it might 
then be suggested that the conflict between the anti-inflammatory and pro-
atherogenic properties of glucocorticoids may simply reflect differential receptor 
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activation, i.e. GR versus MR.  This in turn will depend on 11β-HSD2 status.  
However, this explanation may be a bit simplistic, especially since glucocorticoid 
activation of GR is associated with insulin resistance (Andrews et al., 1999; Wang, 
2005), which is thought to be a major linking factor between the metabolic syndrome 
and CVD.  Thus, increased activation of GR may exacerbate atherosclerosis in DKO 
mice through promotion of insulin resistance.   
   
Compared to plaques in 6 month old Apoe
-/-
 mice, plaques in both 3 and 6 month old 
DKO mice showed significantly increased lipid levels, as assessed by measuring the 
area of lipid holes left behind by histological processing.  Lipid content was not 
altered by MR blockade in the eplerenone study (chapter 3) and so it appears that 
lipid accumulation in plaques from DKO mice is not a result of inappropriate MR 
activation.  Having said this, as mentioned earlier it might be that the length of 
eplerenone treatment was insufficient to fully reverse some of the consequences of 
MR activation.  On the other hand, the accumulation of lipids may be associated with 
the hypertension in DKO mice (Deuchar et al., 2009) which was not normalised by 
eplerenone.  Whilst there are few data linking hypertension and plaque lipid content, 
it is well established that hypertension precipitates endothelial dysfunction (De 
Meyer et al., 1997), which in turn allows the entry of lipids into the vascular wall 
(Rafflenbeul, 1994).  Thus, hypertension may indeed increase plaque lipid content 
through promotion of endothelial cell dysfunction.  The main sources of plaque lipids 
are blood lipids and lipids released by necrotic macrophage foam cells (Falk et al., 
1995), but the relative contribution of each to total plaque lipid is a controversial 
issue.  Given that total plasma cholesterol levels were unaltered but plaque 
macrophage content was increased in DKO mice, it is tempting to speculate that the 
increased lipid content is due to deposition by macrophages.   
 
Alternative theories 
It is clear from the results of both chapter 3 and the present chapter that illicit 
activation of MR plays a major role in the atherosclerotic phenotype of the DKO 
mouse.  However, there may be other consequences of 11β-HSD2 inactivation that 
contribute towards atherogenesis.  Loss of 11β-HSD2 may not only lead to over-
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activation of MR but also GR, leading to increased negative feedback control of the 
hypothalamic-pituitary-adrenal (HPA) axis (De Kloet, 1991).  This has the effect of 
inhibiting the release of cortisol/corticosterone from the adrenal glands thereby 
reducing the levels of circulating glucocorticoids.  Whilst the findings of the present 
thesis might indicate that decreased local glucocorticoid levels are beneficial during 
atherogenesis, it is well known that high circulating glucocorticoid levels are 
important during inflammation and that glucocorticoid deficiency is associated with 
pathological overshoot of inflammatory responses (Sapolsky et al., 2000).  Thus, 
suppression of circulating glucocorticoid levels may enhance inflammation which 
could drive the atherogenic process.  Renal MR plays an important role in 
maintaining normal electrolyte balance through actions on the epithelial sodium 
channel (ENaC) in the distal tubules (White, 1994).  Over-activation of renal MR 
results in increased sodium re-absorption and potassium excretion (Scheinman et al., 
1999).  Indeed, young 11β-HSD2 knockout mice have low urinary sodium levels and 
are hypokalemic, a phenotype that results from illicit activation of MR by 
endogenous glucocorticoids (Kotelevtsev et al., 1999).  It has been reported that 
sodium can promote endothelial cell dysfunction (Oberleithner et al., 2007) and so 
the situation could be envisaged where  sodium retention in the vasculature of the 
DKO mouse initiates endothelial dysfunction sufficient to be pro-atherogenic.  
Sudden death occurs in DKO (Deuchar et al., 2009) and 11β-HSD2 single knockout 
(Kotelevtsev et al., 1999) mice and this is likely a consequence of sudden cardiac 
death due to the hypokalaemia.  However, hypokalaemia also causes haemodynamic 
changes (Galvez et al., 1977) and it is possible that consequent alterations in shear 
stress could predispose certain vascular beds to atherogenesis.   
 
In the normal physiological state MR is occupied by glucocorticoids, even in 
mineralocorticoid target tissues, but is not activated (Funder et al., 1996).  When 
11β-HSD2 is inhibited, glucocorticoids can then activate MR and it has been 
suggested that this change in activation state may be due to alterations in cellular 
redox state (Funder, 2005b).  When 11β-HSD2 is active, for each molecule of 
corticosterone that is converted into 11-dehydrocorticosterone one molecule of NAD 
is converted into NADH (Funder, 2005b).  Thus, when 11β-HSD2 is inactive there 
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will be a rise in the NAD/NADH ratio which could have an effect on the intracellular 
redox environment.  Not only will this change in redox state allow glucocorticoids to 
activate MR, but it may also contribute to dysfunction of cells of the vasculature, 
particularly endothelial cells (Cai et al., 2000), thereby accelerating the initiation of 
atherogenesis.  In addition to this, tissue damage, during inflammation for example, 
leads to the production of ROS and a subsequent change in intracellular redox state 
(Funder, 2005b).  This in combination with the proposal that intracellular redox 
changes allow for glucocorticoid activation of MR provides a possible mechanism by 
which MR may be illicitly activated by glucocorticoids during pathological 
conditions even when 11β-HSD2 is functional.   
 
Effects of 11β-HSD2 inactivation on plaque stability 
The overall effect of loss of 11β-HSD2 activity on atherogenesis was a 
destabilisation of the plaque.  Apoe
-/-
 mice at 6 months of age exhibited a stable 
plaque phenotype with a larger SMC + collagen content compared to lipid + 
macrophage content.  Despite having similar plaque sizes to the 6 month Apoe
-/-
 
mice, 3 month old DKO mice had more vulnerable plaques with a low SMC + 
collagen component and a high lipid + macrophage content.  By 6 months of age, 
plaques in DKO mice had gained stability with equal contents of SMC + collagen 
and lipid + macrophages, but were still more vulnerable than those in age-matched 
Apoe
-/-
 counterparts.  Eplerenone increased the ratio of stabilising/destabilising 
components in plaques from DKO mice in the drug study (chapter 3), suggesting that 
illicit activation of MR is key in the formation of a vulnerable plaque during 
compromised 11β-HSD2 activity.  The decrease in collagen content in DKO plaques 
could be due to increased MMP activity which, in turn, may be a result of enhanced 
macrophage infiltration into plaques.  Evidence to support the idea that macrophages 
are destabilising components comes from a study in humans that reported 
significantly more macrophages
 
in lesions that underwent rupture than in those that 
were responsible for stable angina pectoris, and did not rupture (Moreno et al., 
1994).  DKO mice also demonstrated an increase in plaque lipid content compared to 
Apoe
-/-
 mice and that this correlates with plaque instability is substantiated by post-
mortem studies in human atherosclerotic arteries which
 





with plaque disruption than in the segments with an intact
 
surface 
(Gertz et al., 1990).  The observation that plaques in DKO mice stabilised between 3 
and 6 months of age was quite surprising given that the atherogenesis and 
inflammation were clearly still ongoing in these later stages.  However, this result 
does reinforce the concept that early pro-inflammatory events accelerate the 
atherogenic process in DKO mice.  It would be of interest to investigate the 
atherosclerosis in older DKO mice to determine whether plaques continue to stabilise 
or whether they go through cycles of vulnerability.  In line with this, more DKO 
mice at 6 months of age had buried fibrous caps within their plaques than DKO mice 
at 3 months of age, showing that this rupture/healing growth cycle continues.  Also, a 
greater percentage of DKO mice at 3 months of age had buried fibrous caps than did 
Apoe
-/-
 mice at 6 months of age, despite comparable plaque sizes between these two 
groups.  Again, this highlights the increased vulnerability of plaques upon 11β-HSD2 
inactivation and shows that this occurs during early stages of plaque development.   
 
Conclusions 
Loss of 11β-HSD2 activity accelerates atherogenesis in hyperlipidemic mice and 
promotes a vulnerable plaque phenotype through alteration of plaque composition 
and enhanced vascular inflammation.  The DKO mouse provides a useful test-bed for 
the development of new anti-atherosclerotic drugs and the assessment of already 
existing drugs such as statins.  Indeed the so called ‘pleiotropic’ effects of statins on 
atherosclerosis could be studied in the DKO mouse to determine whether or not these 
benefits are associated with plaque stabilisation.  The results of this chapter 
combined with those of the previous chapter suggest that illicit activation of extra-
renal MR is largely causative in the DKO atherosclerotic phenotype.  This idea is 
further explored in the next chapter which aims to dissect possible vascular 
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This thesis has so far demonstrated that 11β-HSD2 inactivation enhances 
macrophage infiltration into brachiocephalic plaques on the Apoe
-/-
 background, and 
that this is at least partially an MR mediated mechanism was shown by reversal with 
eplerenone.  This phenotype could result from activation of MR in a number of cells 
and so to begin to isolate roles for specific cell types, the potential of the 
endothelium in mediating increased macrophage infiltration was investigated.   
 
The endothelium plays a vital role in the infiltration of monocytes into the intimal 
space during the early stages of atherogenesis, partially through the expression of 
cellular adhesion molecules.  Vascular Cell Adhesion Molecule 1 (VCAM-1) and 
intercellular cellular adhesion molecule 1 (ICAM-1) largely bind monocytes and T-
lymphocytes (Libby et al., 2002) and the finding that lesion development is disrupted 
in both ICAM-1 (Collins et al., 2000) and VCAM-1 deficient mice (Cybulsky et al., 
2001) highlights the important role of these pro-inflammatory molecules in  
atherogenesis.  Given that endothelial cells express both MR and 11β-HSD2 (Caprio 
et al., 2008; Christy et al., 2003), and that MR over-activation causes enhanced 
macrophage infiltration in the DKO mouse, it is reasonable to postulate that adhesion 
molecule expression may be regulated by MR-mediated mechanisms.  In support of 
this, a study in human vascular endothelial cells found that aldosterone mediated 
activation of MR lead to up-regulation of ICAM-1 mRNA and protein (Caprio et al., 
2008).  Also, MR antagonism in mice with heart failure resulted in reduced 
expression of ICAM-1 (Kuster et al., 2005).  However, a direct role for 11β-HSD2 in 
protection against MR-mediated up-regulation of adhesion molecules remains to be 
defined.   
 
The endothelium not only expresses adhesion molecules during atherogenesis, but it 
also releases pro-inflammatory cytokines such as monocyte chemoattractant protein 
1 (MCP-1).  A role for MR in stimulating MCP-1 expression has been shown in the 
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rat heart, where treatment with aldosterone and salt resulted in increased MCP-1 
mRNA, an effect that was reversed by MR blockade with spironolactone (Sun et al., 
2002).  However, there is little data on the effect of MR activation on MCP-1 
expression in cells of the murine vasculature, particularly during atherogenesis.  In 
addition to cytokines, the endothelium can also shed adhesion molecules (Pigott et 
al., 1992), producing soluble forms (sCAM) that circulate in the plasma (Rothlein et 
al., 1991).  It is thought that plasma concentrations of soluble adhesion molecules 
could be useful markers for predicting the presence and severity of cardiovascular 
pathologies.  Indeed, sICAM-1, sVCAM-1 and sE-selectin are elevated during 
inflammatory conditions (Gearing et al., 1993) and in individuals with 
cardiovascular disease (Caulin-Glaser et al., 1998; Haught et al., 1996).  Also, the 
fact that a positive correlation has been reported between the extent of 
atherosclerosis and the plasma concentrations of sICAM-1 (Rohde et al., 1998) and 
sVCAM-1 (Peter et al., 1997) indicates that these markers may be enhanced in DKO 
mice. 
   
To begin to explore the possible cellular mechanisms by which 11β-HSD2 
inactivation leads to enhanced macrophage infiltration into DKO plaques, it was 
hypothesised that the endothelial cell expression of adhesion molecules, and cytokine 
release, would be enhanced in DKO mice compared to Apoe
-/-
 mice.  With this in 
mind, the specific aims of this chapter were: 
 
(i) To compare VCAM-1 and ICAM-1 expression in brachiocephalic arteries 




(ii) To determine whether there is a role for 11β-HSD2 in protection against 








5.2.1 Adhesion molecule expression 
Histological and immunohistochemical techniques were performed according to the 
methods detailed in section 2.3.2.   
5.2.2 Subjective scoring 
In order to allow quantification of vascular endothelial cell staining for adhesion 
molecules, a subjective scoring system was employed.  A representative section, 
chosen from roughly the same portion of each vessel, was quantified per mouse for 
ICAM-1 or VCAM-1 staining.  The system was based on the proportion of the 
circumference of the endothelium that was stained for each adhesion molecule and 
the scores were applied as follows: 0 = staining absent; 1 = < 25% circumference 
stained; 2 = 25-50% circumference stained; 3 = 50-75% circumference stained; and 4 
= > 75% circumference stained.  
5.2.3 Cytokine expression 
ELISA kits for mouse MCP-1 (Invitrogen) and soluble VCAM-1 (sVCAM-1) (R&D 
Systems) were used according to the manufacturer’s instructions in the measurement 
of plasma levels of these pro-inflammatory molecules (see section 2.4.4.2).     
5.2.4 Statistical analysis 
Data are mean ± sem and were analysed by 2-way Anova for sVCAM-1 data and the 
non-parametric Kruskal-Wallis test was employed for the analysis of endothelial cell 
staining.  
 







5.3.1 Effect of 11β-HSD2 inactivation on the endothelial expression of 
ICAM-1 in Apoe-/- mice 
Immunohistochemistry with specific antibodies against ICAM-1 was used to 
investigate the importance of this molecule in the enhanced macrophage content of 
plaques from DKO mice.  It was immediately clear from observing the stained 
sections (Figure 5.1a) that ICAM-1 was constitutively expressed throughout the 
endothelium of both DKO and Apoe
-/-
 mice at 3 and 6 months of age.  Quantitative 
analysis, using the semi-quantitative scoring system detailed in section 5.2.4, 
confirmed that ICAM-1 expression was not different in DKO mice at either 3 or 6 
months of age compared to either age- or plaque size- matched Apoe
-/-
 mice (figure 
5.1b).  
 
5.3.2 Effect of 11β-HSD2 inactivation on the endothelial expression of 
VCAM-1 in Apoe-/- mice  
Immunohistochemistry was performed with specific antibodies against VCAM-1 and 
it was evident from observing the stained sections (Figure 5.2a) that VCAM-1 was 
more abundant on the endothelium of DKO mice at 3 and 6 months of age when 
compared to age-matched Apoe
-/-
 mice.  Quantitative analysis, using the semi-
quantitative scoring system detailed in section 5.2.4, confirmed that VCAM-1 
expression was significantly increased in DKO mice compared to Apoe
-/-
 mice at 
both 3 and 6 months of age (figure 5.2b).  This analysis also demonstrated that 
VCAM-1 expression was significantly increased in DKO mice at 3 months of age 
compared to Apoe
-/-
 mice at 6 months of age, despite similar plaque sizes between 





Figure 5.1  Loss of 11β-HSD2 activity has no effect on endothelial expression 
of ICAM-1 
Sections of brachiocephalic arteries from Apoe
-/-
 and DKO animals were stained with 
antibody against ICAM-1 (A).  DKO and Apoe
-/-
 mice constitutively express ICAM-1 at 3 and 
6 months of age.  Representative images from Apoe
-/-
 and DKO animals, captured at x10 
magnification.   Scale bar = 250 µm.  Circumferential staining was quantified using a semi-
quantitative scoring system (B).  ICAM-1 expression was comparable between DKO and 
Apoe
-/-
 mice at both 3 and 6 months of age. Data are mean ± sem, n= 4-6 per group. 








































Figure 5.2  Loss of 11β-HSD2 activity increases endothelial expression of 
VCAM-1 
Sections of brachiocephalic arteries from Apoe
-/-
 and DKO animals were stained with 
antibody against VCAM-1 (A).  DKO mice appear to have more abundant VCAM-1 staining 
at 3 and 6 months compared to age-matched Apoe
-/-
 mice.  Representative images from 
Apoe
-/-
 and DKO animals, captured at x10 magnification.   Scale bar = 250 µm.  
Circumferential staining was quantified using a semi-quantitative scoring system (B).  At 3 
months of age, DKO mice had increased VCAM-1 expression compared to both age- (3 
months) and plaque size- (6 months) matched Apoe
-/-
 mice.  At 6 months, VCAM-1 
expression remained increased in DKO compared to Apoe
-/-
 mice. Data are mean ± sem, n= 






















5.3.3 Influence of 11β-HSD2 inactivation on levels of sVCAM-1  
Plasma levels of sVCAM-1 are thought to correlate with inflammation (Gearing et 
al., 1993) and atherosclerosis (Peter et al., 1997).  Thus, ELISA for sVCAM-1 was 
performed in plasma samples from Apoe
-/-
 and DKO mice at 3 and 6 months of age. 
There was no difference in the levels of sVCAM-1 present in plasma from Apoe
-/-
 
and DKO mice at either 3 or 6 months of age (Figure 5.3).   
 
5.3.4 Influence of 11β-HSD2 inactivation on MCP-1 levels 
MCP-1 is important in attracting macrophages to sites of atherosclerosis (see chapter 
1) and so to determine whether or not increased levels of MCP-1 may be involved in 
the increased recruitment of macrophages to DKO plaques, plasma MCP-1 levels 
were measured by ELISA.  Unfortunately, MCP-1 levels were below the limit of 
detection for the assay in both Apoe
-/-
 and DKO mice at 3 and 6 months of age (data 






















Figure 5.3  11β-HSD2 inactivation has no effect on sVCAM-1 levels in 
plasma 
Plasma sVCAM-1 levels were measured in Apoe
-/-
 and DKO mice at 3 and 6 months of age 
using a commercial kit.  sVCAM-1 levels were comparable between DKO and Apoe
-/-
 mice at 












































Loss of 11β-HSD2 activity results in increased endothelial cell expression of 
VCAM-1, but not ICAM-1, in brachiocephalic arteries during the early stages of 
atherogenesis in Apoe
-/-
 mice.  This enhanced vascular inflammation may be 
responsible for, or contribute to, the increased recruitment of macrophages to plaques 
from DKO mice and it exposes an important role for 11β-HSD2 in modulating 
inflammatory responses in the vasculature.  
 
Influence of 11β-HSD2 inactivation on vascular expression of adhesion molecules 
The present studies found that ICAM-1 was constitutively expressed on the 
endothelium of Apoe
-/-
 and DKO mice at 3 and 6 months of age.  This contrasts with 
other studies showing up-regulation of ICAM-1 in response to MR activation in the 
rat coronary vasculature (Rocha et al., 2002b), the rat heart (Sun et al., 2002), rat 
aortic tissue (Hirono et al., 2007), and the murine myocardium (Kuster et al., 2005).  
In addition to this, it was recently shown that MR activation in vitro in human 
vascular endothelial cells resulted in increased ICAM-1 expression (Caprio et al., 
2008), providing a direct link between MR activation and ICAM-1 expression 
without the confounding variables that come with in vivo studies.  The reason for the 
discrepancy between the previously reported results and the observations made in the 
present work is unclear although it may be due to a species variance in ICAM-1 
expression.  The majority of studies on the role of MR activation in the 
cardiovascular expression of adhesion molecules have been carried out in rats or in 
human cells in culture; there are very few data on the effect of MR activation on 
ICAM-1 expression in murine vasculature cells.  Thus, ICAM-1 may be 
constitutively expressed in murine blood vessels and not subject to the same 
regulatory mechanisms present in other species.  In support of this, it was reported 
that ICAM-1 was expressed in the aortas of both wild type and Apoe
-/-
 mice and was 
independent of cholesterol levels (Nakashima et al., 1998).  However, RT-PCR 
methodology has been used to show that ICAM-1 mRNA can be up-regulated by 
TNF-α in murine cerebral blood vessels (Rudin et al., 1997).  Perhaps the methods 
used to investigate ICAM-1 expression in the current studies were not sensitive 
enough to detect alterations from the high baseline levels of expression.  
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Alternatively, whilst mRNA levels may be altered, protein levels may be unchanged.  
Another possible source of variance is the vascular bed used; most of the studies that 
show regulation of ICAM-1 expression by MR-mediated mechanisms are performed 
in either the coronary vasculature, the aorta, or human umbilical vein endothelial 
cells (HUVECs) in culture.  There are no reports on the effects of MR activation on 
ICAM-1 expression in the brachiocephalic artery.  It is well established that large 
and small vessels differ in their ability to express adhesion molecules (Carlos et al., 
1994) and so it might be that the endothelial cells of the murine brachiocephalic 
artery constitutively express ICAM-1 and do not up-regulate this particular molecule 
in response to pro-inflammatory stimuli.        
 
Another possibility is that ICAM-1 expression was investigated too late in DKO 
mice.  Comparing expression at an earlier age (1 or 2 months) may have revealed 
differences between DKO and Apoe
-/-
 mice.  Alternatively, the difference between 
the results of the present study and those reported in the literature may reflect 
differential ligand effects on MR-mediated regulation of ICAM-1.  The studies by 
Rocha et al., Sun et al., Hirono et al., and Caprio et al. detailed above all employed 
aldosterone as the MR ligand whereas it is more likely that the ligand for MR in the 
present study will be corticosterone.  Perhaps unlike aldosterone, glucocorticoid 
activation of MR has no effect on the transcriptional activity of the ICAM-1 gene.  
The increased local glucocorticoids in the DKO mouse will not only activate MR, 
but they may also activate GR.  Given that activation of GR has been shown to 
suppress cytokine-induced ICAM-1 expression in HUVECs (Cronstein et al., 1992) 
and in a human monocytic cell line (van de Stolpe et al., 1994), it might be proposed 
that activation of GR in DKO mice counters any stimulatory effects of MR activation 
on ICAM-1 expression.  Brachiocephalic sections from the DKO mice that received 
eplerenone treatment (chapter 3) were stained for ICAM-1 (data not shown) and, in 
line with the results of the present chapter ICAM-1 remained constitutive throughout 
the endothelium.  Taken together, these results suggest that ICAM-1 expression is 




It has been suggested that VCAM-1 is more important in the pathogenesis of 
atherosclerosis than ICAM-1 (Cybulsky et al., 2001), particularly in the initiation of 
atherosclerosis.  The present study found significant up-regulation of VCAM-1 on 
the endothelium of brachiocephalic arteries from DKO mice at 3 and 6 months of age 
compared to Apoe
-/-
 mice.  The increased VCAM-1 expression at 3 months of age 
may be partially responsible for the accelerated development of atherosclerosis in 
DKO mice and is consistent with the hypothesis that DKO mice have enhanced 
vascular inflammation during the early stages of disease.  Importantly, despite 
similar plaque sizes, 3 month old DKO mice had significantly increased VCAM-1 
expression and macrophage infiltration (chapter 4) compared to 6 month old Apoe
-/-
 
mice.  This provides an indirect link between endothelial VCAM-1 expression and 
macrophage infiltration into plaques.  Indeed, the vital role that VCAM-1 plays in 
monocyte emigration in vivo was demonstrated in a study that showed blockade of 
emigration into the peritoneum of rabbits upon treatment with neutralising antibody 
against VCAM-1 (Winn et al., 1993).  In addition to this, it has been reported that 
not only is VCAM-1 required for the firm attachment of rolling monocytes to sites of 
atherosclerosis (Ramos et al., 1999), but that VCAM-1 expression precedes sub-
endothelial monocyte accumulation in a model of vein graft atherosclerosis (Hanyu 
et al., 2001).  Furthermore, there is evidence to suggest that intimal macrophage 
recruitment in humans is dependent upon the expression level of adhesion molecules, 
particularly VCAM-1 (Duplàa et al., 1996).  However, whilst it is likely that the 
increased macrophage content in DKO mice is due to the increased endothelial 
expression of VCAM-1, the present study does not prove that this is the case.  In 
order to determine a direct relationship between VCAM-1 expression and 
macrophage infiltration in DKO mice, the effects of VCAM-1 ablation, via gene 
disruption or neutralising antibodies, on macrophage content of plaques would need 
to be investigated.   
 
The main stimulus for investigating VCAM-1 expression in DKO mice was to 
determine whether it might underlie the enhanced macrophage infiltration into 
plaques, particularly during the early stages of atherogenesis.  However, increased 
macrophage recruitment may not be the only consequence of VCAM-1 up-
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regulation.  It has been reported that VCAM-1 signalling in endothelial cells is 
important not only in leukocyte migration (Matheny et al., 2000) but also in the 
production of MMPs via ROS generation (Deem et al., 2004).  It is thought that this 
endothelial production of MMPs aids in leukocyte migration across endothelial cells 
(Deem et al., 2004).  In the setting of atherosclerosis, increased MMP production 
may also be implicated in promoting a vulnerable plaque phenotype through collagen 
degradation.  Thus, in the case of the DKO mouse, it is possible that MR-mediated 
up-regulation of VCAM-1 leads to increased macrophage infiltration and production 
of MMPs in endothelial cells which, in turn, promotes the breakdown of plaque 
integrity and the consequent formation of the macrophage-rich/collagen-poor 
vulnerable plaques observed in DKO mice.   
 
That VCAM-1 expression was increased in DKO mice compared to Apoe
-/-
 mice 
implicates 11β-HSD2 in protection against endothelial expression of pro-
inflammatory molecules.  It also suggests that illicit MR activation in endothelial 
cells plays a key role in promoting vascular inflammation and the initiation of 
atherogenesis in hyperlipidaemic mice.  In line with the present results, it was 
recently reported that aldosterone significantly increased VCAM-1 mRNA in 
HUVECs (Hashikabe et al., 2006) and that MR blockade in aldosterone-treated rats 
reduced aortic expression of VCAM-1 mRNA (Hirono et al., 2007).  Taken all 
together, the evidence suggests that illicit activation of MR in vascular endothelial 
cells promotes up-regulation of VCAM-1.  Also, the fact that 11β-HSD2 is protective 
against this implies that endogenous glucocorticoids are the MR ligands responsible.  
However, there are no data concerning glucocorticoid-mediated MR activation and 
VCAM-1 expression in the literature.   
 
The question now arises as to how activation of MR can lead to increased expression 
of VCAM-1 in the brachiocephalic artery.  There are no known mineralocorticoid 
response elements (MRE) in the VCAM-1 gene promoter (Caprio et al., 2008; Neish 
et al., 1992) so the mechanism, which has not been investigated, must involve 
intermediate steps.  It is well established that cytokines are the major regulators of 
adhesion molecule expression (Carlos et al., 1994) and so it is possible that 
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activation of MR leads to increased secretion of cytokines from endothelial cells.  
Both interleukin 4 (IL-4) (Masinovsky et al., 1990) and tumor necrosis factor α 
(TNF-α) (Osborn et al., 1989) induce endothelial VCAM-1 expression and it has 
previously been reported that activation of MR increases expression of TNF-α in 
human mononuclear cells (Miura et al., 2006) and in plasma of rats with 
experimentally induced heart failure (Kang et al., 2006).  Thus, perhaps the MR-
mediated up-regulation of VCAM-1 in DKO mice is via increased production of 
TNF-α and/or other cytokines.  It would be beneficial to subject plasma samples 
from young DKO and Apoe
-/-
 mice to a cytokine array assay to discover whether or 
not any particular cytokines are differentially regulated between the two genotypes.  
In addition to cytokines, it is known that endothelial nitric oxide (NO) has an 
inhibitory role in VCAM-1 gene expression (De Caterina et al., 1995).  Therefore, it 
might be that activation of MR inhibits endothelial NO production which, in turn, 
results in increased VCAM-1 expression.  In support of this, it was shown that both 
aldosterone and glucocorticoid activation of MR in rats led to decreased endothelial 
nitric oxide synthase (eNOS) mRNA expression in the vascular wall (Wilson et al., 
2009).  It was also previously demonstrated that NO production was decreased by 
aldosterone in rat vascular smooth muscle cells in vitro (Ikeda et al., 1995).  A 
further possibility is that MR activation leads to up-regulation of VCAM-1 
expression via its effects on oxidative stress, which have been repeatedly 
demonstrated both in vivo (Keidar et al., 2003; Keidar et al., 2004; Nishiyama et al., 
2004) and in vitro (Calo et al., 2004; Mazak et al., 2004).  Indeed, it was reported 
that IL-4-induced VCAM-1 expression in HUVECs (Lee et al., 2001) and AngII-
induced VCAM-1 expression in rat aortic endothelial cells (Pueyo et al., 2000) was 
mediated by increased oxidative stress.  These studies, in combination with the 
present data, provide the link between MR activation, oxidative stress, and VCAM-1 
expression in endothelial cells.  A final factor to consider in the MR-mediated 
expression of VCAM-1 is the involvement of transcription factors, which are also 
intimately involved with the other intracellular mechanisms described above.  This 





Influence of 11β-HSD2 inactivation on vascular production of MCP-1 and sVCAM-1 
The endothelium, along with macrophages and SMCs, releases pro-inflammatory 
cytokines that attract macrophages to the developing atherosclerosis, the best 
characterised of which is monocyte chemoattractant protein 1 (MCP-1) (Libby et al., 
1995).  MR activation in humans was associated with increased levels of MCP-1 in 
the urine of diabetic patients (Takebayashi et al., 2006) and in rats, with increased 
MCP-1 mRNA in the heart (Sun et al., 2002).  Aldosterone has also been shown to 
increase MCP-1 mRNA expression in the kidneys of wild type mice (Ma et al., 
2006).  However, there are few data on the effect of MR activation on MCP-1 
expression in cells of the murine vasculature.  In the present study, MCP-1 levels in 
plasma of DKO and Apoe
-/-
 mice were measured by ELISA but unfortunately were 
below the limit of detection for the assay.   It is believed that MCP-1 plays a vital 
role in the recruitment of macrophages to sites of atherogenesis (Gu et al., 1998; 
Harrington, 2000) and MCP-1 is detectable in Apoe
-/-
 mice (Dol et al., 2001), so the 
failure to detect MCP-1 in the present study was surprising.  Perhaps the assay used 
was unsuitably optimised for detecting MCP-1 in plasma samples or perhaps MCP-1 
protein degrades rapidly once the blood sample has been taken.  It could be that 
MCP-1 levels in the plasma peak early on, prior to the onset of atherosclerosis and so 
maybe this assay should be performed at a younger age.  On the other hand, MCP-1 
just may not be an important mediator of macrophage recruitment in the current 
model.  Activation of GR has been shown to inhibit MCP-1 production in vascular 
smooth muscle cells (Dhawan et al., 2007), in endothelial cells (Shyy et al., 1995)  
and in vivo in rats (Lopez et al., 2008).  Therefore, it could be that activation of GR 
is sufficient to counteract any stimulatory effects of MR activation on MCP-1 
production in the DKO mouse.  However, if this were the case then MCP-1 would 
still have been detectable in Apoe
-/-
 mice.  No conclusion could be drawn from the 
present results about the role of MCP-1 in the increased recruitment of macrophages 
to plaques from DKO mice.    
 
The lack of difference in levels of sVCAM-1 in plasma from Apoe
-/-
 and DKO mice 
at either 3 or 6 months of age was quite surprising given that endothelial cell surface 
expression of VCAM-1 was up-regulated in DKO mice and plasma levels of 
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sVCAM-1 are thought to correlate with cell surface expression (Garton et al., 2003), 
inflammation (Gearing et al., 1993) and atherosclerosis (Peter et al., 1997).  There 
are several possible explanations for this result.  First of all, and in line with several 
other studies (Blann et al., 1994; Frijns et al., 1997; Morisaki et al., 1997), sVCAM-
1 levels may not correlate all that well with the presence of cardiovascular disease.  
There are conflicting data in the literature about which particular soluble adhesion 
molecules are increased in various pathologies.  These discrepancies could be a result 
of different methods of detection or natural variances between different groups of 
patients.  It could be that, as suggested for MCP-1, the time-points chosen were not 
optimal for detecting differences in sVCAM-1 levels.  Alternatively, the loss of 11β-
HSD2 activity may be insufficient to raise plasma levels of soluble adhesion 
molecules above that already afforded by the Apoe
-/-
 state.  However, since sVCAM-
1 levels are a reflection of cell surface VCAM-1 levels (Garton et al., 2003), it seems 
more likely that the increased VCAM-1 in DKO mice is not being shed properly.  At 
3 months of age, sVCAM-1 levels were comparable between Apoe
-/-
 and DKO mice 
whilst cell surface VCAM-1 was virtually absent from Apoe
-/-
 mice.  This suggests 
that Apoe
-/-
 mice are able to shed VCAM-1, perhaps as a regulatory mechanism to 
prevent macrophage accumulation.  Indeed, it has been reported that sVCAM-1 at 
pathophysiological levels significantly inhibited monocyte adhesion to endothelial 
cells in culture (Abe et al., 1998) , implicating elevated sVCAM-1 levels in 
protection against monocyte adherence.  In contrast, a dysregulation in the 
mechanisms responsible for sVCAM-1 shedding may partially explain the increased 
cell surface VCAM-1 levels and enhanced macrophage accumulation in DKO mice.  
Perhaps constant MR activation in DKO mice results in continual VCAM-1 
expression such that shedding cannot occur fast enough to have a significant impact.  
Nonetheless, sVCAM-1 levels are not a good marker of disease severity in the DKO 
model. 
 
Clinical relevance of findings 
Based on the present findings it might be proposed that illicit activation of MR, 
perhaps due to inflammatory down-regulation of 11β-HSD2 (Suzuki et al., 2005), 
promotes endothelial up-regulation of VCAM-1 and subsequent monocyte 
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infiltration into the vascular wall with the consequence of accelerating atherogenesis.  
Thus, the benefits of MR blockade may arise from inhibition of the initial pro-
inflammatory consequences of MR activation, i.e. VCAM-1 expression.  Clearly, it 
would be useful to repeat the eplerenone study in DKO mice in order to obtain frozen 
vessels to perform VCAM-1 staining.  This would help elucidate the role that 
VCAM-1 plays in the MR-mediated phenotype of the DKO mouse.   
 
Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), 
suffer from accelerated forms of atherosclerosis.  It is thought that this may be due to 
the exogenous glucocorticoid therapy employed to treat the disorder (Nashel, 1986), 
which certainly corresponds well with the present thesis, but given the inflammatory 
nature of both of these conditions it is tempting to speculate that there may be other 
linking factors.  It is known that patients with RA are insulin resistant, irrespective of 
therapy (Gonzalez-Gay et al., 2005) and insulin resistance is associated with 
inflammation (Svenson et al., 1988).  In line with this, the presence of foam cells in 
the blood vessels of the connective tissue was reported in patients with RA (Winyard 
et al., 1993), implying that cellular adhesion molecules may be up-regulated.  Indeed, 
endothelial expression of E-selectin, VCAM-1, and ICAM-1 is known to be 
increased in RA (Bevilacqua et al., 1994; Koch et al., 1991).  This, in combination 
with the present studies, suggests the hypothesis that in rheumatoid arthritis, 
compromised 11β-HSD2 activity by the pro-inflammatory environment in 
combination with exogenous glucocorticoid therapy may overwhelm the MR leading 
to up-regulation of adhesion molecules and accelerated atherogenesis.  This predicts 
that eplerenone treatment would be beneficial in patients with RA and it has in fact 
been recently reported that spironolactone treatment improved endothelial 
dysfunction and inflammatory disease activity in RA patients (Syngle et al., 2009).  
This supports a role for inappropriate MR activation in RA and suggests that 11β-
HSD2 could be a major link between rheumatoid arthritis and atherosclerosis. 
 
Conclusions 
Inactivation of 11β-HSD2 selectively up-regulates endothelial cell expression of 
VCAM-1, providing a mechanism by which enhanced macrophage recruitment may 
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occur in DKO mice.  This implicates MR activation in endothelial cells as a major 
contributing factor to the early pro-inflammatory changes that accelerate 
atherogenesis in DKO mice.  Endothelial cell specific knockout of 11β-HSD2 on the 
Apoe
-/-
 background would aid in defining a more specific role for endothelial MR 
activation in the DKO atherosclerotic phenotype.  Whilst this is not within the scope 
of the present thesis, the experiments detailed in the next chapter were designed to 
determine whether or not MR activation specifically in endothelial cells accounts for 
































6 Chapter 6: The role of the endothelial cell in MR-

























It was shown in the previous chapter that 11β-HSD2 inactivation results in up-
regulation of VCAM-1 on the endothelial cell surface of DKO brachiocephalic 
arteries.  However, these studies did not determine whether or not this was due to 
illicit MR activation, or another effect of loss of 11β-HSD2 activity.  It was also not 
established whether this increase in VCAM-1 was a direct result of MR activation in 
endothelial cells or an indirect result of MR activation in other cells types.  Given 
that blood pressure is increased in DKO mice (Deuchar et al., 2009) the possibility 
that VCAM-1 expression was affected by hypertension cannot be ruled out.  The 
literature is deficient in studies investigating the role of MR activation, and 11β-
HSD2-mediated protection of MR, in VCAM-1 expression specifically in endothelial 
cells.  Given the early endothelial expression of VCAM-1 in DKO mice and the 
importance of endothelial cell dysfunction in the initial stages of atherogenesis, 
investigations into endothelial MR-mediated effects on VCAM-1 are clearly 
warranted.        
 
In order to overcome some of the difficulties associated with in vivo experiments, an 
in vitro cell culture model was employed.  This allows the assessment of the role of 
endothelial cell MR activation without the confounding variables present in the 
mouse; such as the presence of other cell types, haemodynamic and humoral factors, 
and the influence of disease progression.  Mouse Aortic Endothelial Cells (MAECs) 
were obtained from the lab of Dr Saito at Tsurumi University in Japan (Nishiyama et 
al., 2007).  These immortalised cells were isolated from the aortas of p53-deficient 
mice and the group initially cultured the MAECs for over 100 passages to ensure 
they retained endothelial cell (EC) properties, such as cobblestone morphology, 
active uptake of acetylated low-density lipoprotein, and expression of EC markers 
(Nishiyama et al., 2007).  As well as this, tumour necrosis factor α (TNF-α) 
treatment promoted lymphocyte adhesion to MAECs (Nishiyama et al., 2007), 
lending these cells to the study of inflammatory responses and atherosclerosis. 
 
A further advantage of cell culture is that the study of intracellular mechanisms is 
straightforward and less time-consuming than it is in vivo.  As mentioned in the 
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previous chapter, there are no known mineralocorticoid response elements (MRE) in 
the promoter of the VCAM-1 gene and so other intracellular pathways must be 
involved.  The transcription factor NF-κB is involved in a whole host of 
inflammatory responses (Ghosh et al., 2002; Hayden et al., 2008; Vallabhapurapu et 
al., 2009) and is activated in atherosclerosis (Brand et al., 1996; de Winther et al., 
2005; Gareus et al., 2008).  It is also known that endothelial cell NF-κB plays a 
major role in many pro-atherogenic processes (Collins et al., 2001; Gareus et al., 
2008).  In addition to this, NF-κB, is a known regulator of VCAM-1 (Binion et al., 
2009; Neish et al., 1992), and rats over-expressing human renin and angiotensin II 
have increased NF-kB activity which is inhibited by MR antagonism (Fiebeler et al., 
2001).  NF-κB activity in rats with heart failure was also shown to be inhibited by 
MR antagonism (Kobayashi et al., 2006).  Taken together, these studies provide a 
link between MR activation, NF-κB, and VCAM-1 expression and it is likely, but to 
date unconfirmed, that this pathway is operational in endothelial cells.   
 
It was hypothesised that VCAM-1, but not ICAM-1 or MCP-1, would be up-
regulated in MAECs in response to activation of MR by both mineralocorticoid and 
glucocorticoid and that 11β-HSD2 plays a protective role.  This pathway likely 
involves activation of NF-κB.  Thus, the aims of this chapter were: 
 
(i) To determine the effects of MR activation in endothelial cells on the 
expression of VCAM-1, ICAM-1, and MCP-1. 
(ii) To elucidate the intracellular pathways involved in MR-mediated up-










6.2.1 Treatment of MAECs 
The following hormones and drugs were employed at the indicated concentrations: 
TNF-α (10ng/mL), Aldosterone (1nM), Corticosterone (1nM), Spironolactone 
(1µM), and glycyrrhetinic acid (1µM).  In all studies, MAECs were first pre-treated 
with the inhibitor drugs (spironolactone or glycyrrhetinic acid) for 2 hours prior to 
the addition of the hormone treatments to ensure maximal inhibition at the time of 
treatment.  For justification of the use of these treatments, see section 2.4.2. 
6.2.2 Adhesion molecule expression 
For details of immunocytochemistry staining protocols and image analysis, see 
section 2.4.3. 
6.2.3 Cytokine expression 
A mouse MCP-1 sandwich ELISA kit (Invitrogen) was used according to the 
manufacturer’s instructions.  For full methodological description, see section 2.4.4.   
6.2.4 Electromobility shift assay (EMSA) 
6.2.4.1 Nuclear protein extractions 
Nuclear proteins were extracted using a modified version of the protocol described 
by Dignam et al (Dignam JD, 1983).  See chapter 2.4.5 for full description.   
6.2.4.2 NF-κB band shift assay 
The activity of NF-κB in nuclear protein extracts was determined by EMSA using 
NF-κB IRDye 700-labelled DNA oligonucleotides.  Binding reactions containing 
crude nuclear extract (10µg), binding buffer and labelled oligonucleotide were 
separated by electrophoresis at 20mA in pre-run 6% polyacrylamide gels for around 
2 hours.  Specific NF-κB binding was shown using an antibody to supershift the 
band.  The Odyssey infrared imaging system was use to analyse the gel.  For full 
methodological details, see section 2.4.5.  
6.2.5 Statistical analysis 




6.3.1 The role of endothelial MR activation on VCAM-1 expression 
VCAM-1 was shown to be increased on the brachiocephalic endothelium of DKO 
mice compared to Apoe
-/-
 mice in the previous chapter.  In an attempt to determine a 
direct role for endothelial cell MR activation in this phenotype, 
immunocytochemistry was performed on treated MAECs with specific antibody 
against VCAM-1 (Figure 6.1a).  The number of VCAM-1-positive cells per field at 
x40 magnification was counted in four randomly selected fields per treatment and the 
mean of five separate experiments was used to construct the graph (Figure 6.1b).  
Images of stained MAECs show that, compared to untreated cells, aldosterone 
treatment dramatically increased VCAM-1 expression in MAECs (Figure 6.1a) with 
the number of cells positively stained for VCAM-1 increased >7-fold (Figure 6.1b), 
comparable to the 13-fold increase observed with TNF-α (Figure 6.1b), included as a 
positive control (Wajant et al., 2003).  Spironolactone pre-treatment blocked the 
effect of aldosterone (Figure 6.1a & b), suggesting an MR-mediated mechanism.  
Corticosterone alone had no effect on VCAM-1 expression (Figure 6.1a & b).  
However, inhibition of 11β-HSD2 by pre-treatment with glycyrrhetinic acid, an 11β-
HSD2 inhibitor (Bujalska et al., 1997) which had no effect on VCAM-1 expression 
on its own (Figure 6.1b), allowed corticosterone to induce a >9-fold increase in the 
number of VCAM-1-stained MAECs (Figure 6.1b), demonstrating functional 
expression of 11β-HSD2 in MAECs.  Consistent with MR involvement, VCAM-1 
up-regulation by corticosterone in the presence of glycyrrhetinic acid was reversed 











Figure 6.1 VCAM-1 is induced following MR activation in MAECs 
MAECs were treated for 24h with 10ng/mL TNF-α, 1nM aldosterone, or 1nM corticosterone, 
with or without pre-treatment with 1µM spironolactone or 1µM glycyrrhetinic acid for 2h, as 
indicated.  (A) brown staining shows VCAM-1 immunoreactivity.  Images captured at x40 
magnification.  Scale bar = 62.5 µm.  VCAM-1 immunopositive cells were counted in 4 
randomly selected fields (x40 magnification) per treatment in 5 separate experiments.  
Aldosterone increased VCAM-1 expression, an effect that was reversible by MR blockade 
with spironolactone.  When 11β-HSD2 was inhibited with glycyrrhetinic acid, corticosterone 
was able to increase VCAM-1 expression, an effect that was reversible by spironolactone 
pre-treatment.  Data are means +/- sem of 5 experiments.  Data were analysed by one-way 
ANOVA and *** p<0.0001.  Un = untreated, A = aldosterone, S = spironolactone, C = 
corticosterone, GA = glycyrrhetinic acid.   
Un TNF A





6.3.2  The role of endothelial MR activation on ICAM-1 expression 
The results of the previous chapter suggest that ICAM-1 expression is not an MR-
mediated mechanism as it was constitutively expressed throughout the endothelium 
in Apoe
-/-
 and DKO mice.  However, much of the literature contrasts with this finding 
and so it was decided to determine whether or not MR activation in endothelial cells 
had an effect on the level of ICAM-1 expression.  Thus, immunocytochemistry was 
performed on treated MAECs with a specific antibody to ICAM-1 (Figure 6.2a) and 
the intensity of staining was measured by replacing the DAB in the last step of the 
staining protocol with the soluble substrate OPD.  This allowed colorimetric 
measurement of staining intensity and the absorbance at 490nm was used to 
construct the graph (Figure 6.2b).  It was evident from observation of images of 
ICAM-1 stained MAECs (obtained using the same procedure as was used for 
VCAM-1 staining) that these cells constitutively expressed ICAM-1, even in the 
untreated state (Figure 6.2a).  It appeared as though some of the treatments might 
have increased the staining intensity (Figure 6.2a), however, quantification in the 
plate reader demonstrated no significant effect of any of the treatments on ICAM-1 
expression level, including TNF-α (Figure 6.2b).  
6.3.3 The influence of MR activation on MCP-1 secretion in MAECs     
In the previous chapter, plasma MCP-1 levels were below the limit of detection for 
the ELISA kit used and so no conclusion could be drawn about the role of MR 
activation in MCP-1 production.  MAECs were used to determine whether MCP-1 is 
truly not up-regulated by MR activation, which is in contrast to the literature, or 
whether the kit used was just not suitable for detection of MCP-1 in plasma samples.  
MAECs were treated for 16h and any MCP-1 protein that was secreted into the cell 
culture medium was analysed by ELISA.  It was found that the only treatment to 
significantly increase MCP-1 secretion from MAECs was the positive control, TNF-
α (Figure 6.3).  None of the treatments that activate MR pathways had an effect on 








Figure 6.2 ICAM-1 is not regulated by MR-mediated mechanisms in MAECs 
MAECs were treated for 24h with 10ng/mL TNF-α, 1nM aldosterone, or 1nM corticosterone, 
with or without pre-treatment with 1µM spironolactone or 1µM glycyrrhetinic acid for 2h, as 
indicated.  (A) brown staining shows ICAM-1 immunoreactivity.  Images captured at x10 
magnification.  Scale bar = 250 µm.  ICAM-1 expression intensity was measured 
colorimetrically (B).  ICAM-1 expression levels were unaffected by any of the treatments 
employed, including the positive control, TNF-α.  Data are means +/- sem.  Data were 
analysed by one-way ANOVA and p=ns.  Un = untreated, A = aldosterone, S = 









Figure 6.3  MCP-1 secretion is not affected by MR activation in MAECs 
MAECs were treated for 16h as indicated prior to measurement of MCP-1 levels in cell 
supernatants.   TNF-α, included as a positive control, increased MCP-1 secretion from 
MAECs whilst activation of MR had no effect on MCP-1 secretion from MAECs.  ELISA was 
performed in quadruplicate for each treatment.  Data are means +/- sem.  Data were 
analysed by one-way ANOVA: *** = p<0.0001.  Un = untreated, A = aldosterone, S = 










6.3.4 Involvement of NF-κB in MR-mediated mechanisms 
To determine whether the pro-inflammatory effect of MR activation in MAECs 
involved NF-κB pathways, activation of NF-κB was investigated by electromobility 
shift assay (EMSA).  MAECs were treated with the MR-activating hormones shown 
to be effective in increasing VCAM-1 expression for 2h before extraction of nuclear 
proteins and subsequent gel shift assay analysis of NF-κB activation.  If NF-κB has 
been activated by any of the treatments the protein will be present in the nuclear 
extracts and it will bind to the IR-labelled NF-κB oligo, causing a shift on the gel due 
to increased size compared to the oligo alone.  To ensure that the oligo is specifically 
binding to NF-κB, an antibody against NF-κB is added to some of the samples which 
will disrupt the protein-oligo complex thereby causing a supershift on the gel.  It can 
be seen from the gel (Figure 6.4) that NF-κB was activated in the positive control 
sample (TNF-α) as shown by the presence of a darker band compared to the 
untreated sample.  The specificity of binding was shown by disruption of the band in 
the second TNF-α lane, marked with a + to indicate the presence of antibody.  Thus, 
the assay is optimised to detect specific activation of NF-κB in MAECs.  The next 
two control lanes, representing spironolactone and glycyrrhetinic acid, showed bands 
of comparable intensity to those in the untreated samples.  NF-κB was activated by 
aldosterone and the band was disrupted in the presence of antibody.  Co-
administration of the MR blocker spironolactone reversed this affect of aldosterone 
on NF-κB activation.  Corticosterone alone had no effect on NF-κB activity, however 
pre-treatment with the 11β-HSD2 inhibitor glycyrrhetinic acid allowed 
corticosterone to minimally activate NF-κB in MAECs.  This band was not disrupted 












Figure 6.4 Activation of MR in MAECs activates the NF-κB pathway 
NF-κB activity was investigated in MAEC nuclear extracts by EMSA.  Compared to untreated 
samples (U), TNF-α (T) and aldosterone (A) activated NF-κB, the specificity of protein-DNA 
binding in these samples was shown by disruption of the bands in the presence of an NF-κB 
antibody (Ab) (+ lanes).  This affect of aldosterone was reversed by co-administration of 
spironolactone (SA), demonstrating an MR-mediated mechanism.  Spironolactone alone had 
no effect on NF-κB (S).  Corticosterone (C) was unable to activate NF-κB whilst pre-
treatment with glycyrrhetinic acid (GA+C), which had no effect on its own (GA), enabled 
corticosterone to minimally activate NF-κB.  There was no binding in the no protein (NP) 
control sample.       
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Activation of MR specifically increased VCAM-1, and not ICAM-1 or MCP-1, 
expression in MAECs, suggesting that the increased expression of VCAM-1 in DKO 
mice could be due to illicit activation of MR directly in endothelial cells.  The 
protective role of endothelial 11β-HSD2 was demonstrated by the finding that 
glucocorticoids mimicked the pro-inflammatory actions of mineralocorticoids when 
11β-HSD2 activity was compromised.   
 
Pathways of VCAM-1 up-regulation in endothelial cells 
In order to determine the possible cellular and molecular mechanisms responsible for 
the increased endothelial VCAM-1 observed in DKO mice in the previous chapter, 
activation of MR-mediated pathways was investigated in vitro in MAECs.  The 
findings of the present chapter revealed that activation of MR in endothelial cells 
does indeed lead to increased expression of VCAM-1.  Significantly, 11β-HSD2 
prevents glucocorticoids from illicitly activating pro-inflammatory pathways in 
MAECs.  It was shown that under conditions of compromised 11β-HSD2 activity, 
glucocorticoids became MR agonists and were able to promote the same intracellular 
events as mineralocorticoids.  In line with this, it has been reported that 
glucocorticoids can activate MREs in human coronary and aortic endothelial cells 
when 11β-HSD2 enzyme is inhibited (Caprio et al., 2008).  Also, the beneficial 
effects of MR blockade in salt-sensitive rats with heart failure were attributed to 
inhibition of glucocorticoid-mediated activation of MR in light of the low 
aldosterone levels found in these animals (Nagata et al., 2006).  However, the present 
study provides novel direct evidence that activation of MR by glucocorticoids in 
endothelial cells is pro-inflammatory and, therefore, likely pro-atherogenic.  It also 
supports the concept that extra-renal MR activation is important in the DKO 
phenotype, as implied by the results of the eplerenone study (chapter 3), and that 
VCAM-1 up-regulation is not simply a result of hypertension in DKO mice.   
 
Glucocorticoids have been reported to antagonise the actions of mineralocorticoids at 
the MR in rats (Kenyon et al., 1984) and in the toad bladder (Brem et al., 1991) and 
it was more recently reported that low concentrations of cortisol blocked aldosterone-
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induced MR activation in the presence, but not in the absence, of 11βHSD2 in 
HEK293 cells (Odermatt et al., 2001).  Thus, in MAECs, the lack of effect of 
glucocorticoids administered alone on VCAM-1 may have been a result of 
antagonism of the MR.  Then, when 11β-HSD2 is inhibited, glucocorticoids might 
become agonists and mimic the effects of aldosterone at the MR.  It would be useful 
to pre-treat MAECs with glucocorticoid before co-administering aldosterone to 
establish whether or not glucocorticoids do antagonise the actions of aldosterone at 
the MR with respect to VCAM-1 expression.  Perhaps this idea may explain the 
finding that physiological levels of aldosterone were able to up-regulate VCAM-1 on 
MAECs.  Given that vascular endothelial cells might normally be exposed to these 
levels of aldosterone in vivo it might not be expected that aldosterone would be pro-
inflammatory under normal physiological conditions.  However, unlike in the cell 
culture experiments, vascular endothelial cells in vivo will also be exposed to 
glucocorticoids, which may normally prevent aldosterone activation of MR.  This 
suggests that whilst excess glucocorticoids, and/or 11β-HSD2 inactivation, are 
detrimental to the vasculature, normal physiological levels may be required to protect 
against the pathological actions of aldosterone.   How and why glucocorticoids can 
switch from antagonism to agonism of MR remains to be investigated.  On the other 
hand, 1nM is considered to be in the ‘high’ physiological range of aldosterone, as it 
has been shown to circulate at around 0.2nM in mice (Spyroglou, 2008).  Therefore, 
it could be that small fluctuations of aldosterone within the physiological range are 
sufficient to compete with glucocorticoids in vivo and over-activate the MR, 
producing pathophysiological effects.  This could be a relevant mechanism in the 
cardiovascular pathologies associated with conditions of mineralocorticoid excess, 
such as Conn’s syndrome (Conn, 1955).     
 
The ultimate result of VCAM-1 up-regulation on endothelial cells is increased 
adherence and infiltration of monocytes into the intimal space.  It would therefore be 
interesting to perform monocyte adhesion and transmigration experiments on treated 
MAECs to determine whether or not MR activation, with the associated increase in 
VCAM-1, can enhance monocyte attachment to the endothelium and subsequent 
migration.  The fact that macrophage content of DKO plaques was significantly 
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increased compared to Apoe
-/-
 plaques suggests that this is in fact the case.  Indeed, it 
was recently demonstrated that MR activation by aldosterone in human coronary and 
aortic endothelial cells led to increased adherence of monocytes (Caprio et al., 2008).  
However, this was shown to be through up-regulation of ICAM-1, not VCAM-1, and 
the ability of glucocorticoids to affect adherence was not studied.  Nonetheless, this 
study does verify that activation of MR in endothelial cells promotes monocyte 
adhesion through up-regulation of adhesion molecules.   
VCAM-1 up-regulation in response to both mineralocorticoid- and glucocorticoid-
mediated activation of MR in endothelial cells likely involves a common intracellular 
pathway.  As previously mentioned, there are no known mineralocorticoid response 
elements (MRE) in the VCAM-1 gene promoter (Caprio et al., 2008; Neish et al., 
1992) and so it could be that MR activation promotes activity of other transcription 
factors which, in turn, regulate VCAM-1 gene transcription.  NF-κB, a known 
regulator of VCAM-1 (de Martin et al., 2000; Neish et al., 1992), was a prime 
candidate for this role since it has been reported that MR activity is associated with 
activation of this transcription factor (Fiebeler et al., 2001; Kobayashi et al., 2006).  
To determine whether or not NF-κB might be the link between MR activation and 
VCAM-1 expression in endothelial cells, activation of NF-κB was assessed in treated 
MAECs by EMSA.  It was found that MR activation by aldosterone caused 
activation of NF-κB.  In line with this, it was previously reported that mice treated 
with aldosterone had increased NF-κB activity in the heart (Johar et al., 2006).  Also, 
aldosterone treatment of diabetic rats led to an increase in renal NF-κB activation 
which was reversed by spironolactone, demonstrating the involvement of MR (Cha 
et al., 2005).  In addition to this, it was recently reported that MR activation by 
aldosterone in mouse VSMCs resulted in activation of NF-κB (Lemarie et al., 2009).  
This suggests that this pathway is active in the vasculature and, therefore, could 
contribute to the pathogenesis of atherosclerosis in DKO mice.  Indeed, it is tempting 
to speculate that MR-mediated up-regulation of VCAM-1 in MAECs involves NF-
κB pathways.  However, a previous study reported that aldosterone treatment of 
HUVECs caused up-regulation of mRNA for VCAM-1 without activation of NF-κB 
(Hashikabe et al., 2006).  Perhaps this reflects differences in methodologies or in 
species, or it could be that other signalling pathways are important in MR-mediated 
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VCAM-1 expression in endothelial cells.  For example, it has been demonstrated that 
aldosterone induces not only NF-κB, but also active protein 1 (AP-1) activity in 
hepatic cells in culture (Li et al., 2007).  In the present study, corticosterone alone 
had no effect on NF-κB activation in MAECs, which mirrors the VCAM-1 data.  
Pre-treatment with the 11β-HSD2 inhibitor glycyrrhetinic acid allowed 
corticosterone to minimally activate NF-κB, suggesting an MR-dependent 
mechanism.  However, the band for corticosterone-induced NF-κB on the gel (see 
figure 6.4) was very pale and the presence of NF-κB antibody did not disrupt the 
band.  Thus, it might be concluded that corticosterone in the presence of 
glycyrrhetinic acid did not specifically activate NF-κB.  However, given that the 
intensity of the band was not convincingly increased compared to untreated control 
samples, no solid conclusions can be drawn.  Perhaps glucocorticoid-mediated up-
regulation of VCAM-1 in MAECs was due to activation of alternative pathways.  
Indeed, it has been shown that the VCAM-1 promoter in HUVECs contains a 
potential AP-1 binding site (Iademarco et al., 1992).  This, in combination with the 
afore mentioned study demonstrating aldosterone-mediated activation of AP-1 in 
hepatic cells (Li et al., 2007) suggests a potential role for this pathway in MR-
mediated VCAM-1 expression in MAECs.  The most reliable way to investigate the 
importance of NF-κB activation in MR-mediated VCAM-1 expression would be to 
repeat the VCAM-1 staining experiments in MAECs (see section 6.3.1) in the 
presence of an NF-κB inhibitor.        
 
 ICAM-1 and MCP-1 expression in endothelial cells 
Whilst MR-mediated activation of NF-κB was likely involved in VCAM-1 up-
regulation on MAECs, this pathway does not appear to affect ICAM-1 or MCP-1 
expression.  This was surprising given that both ICAM-1 (Roy et al., 2001) and 
MCP-1 (Landry et al., 1997; Pindolia et al., 1996) are also known to be regulated by 
NF-κB.  Perhaps the particular set of co-activator and co-repressor proteins recruited 
upon MR activation in MAECs preferentially directs NF-κB activity towards the 
VCAM-1 promoter.  It was reported that inhibition of NF-κB by pyrrolidine 
dithiocarbamate (PDTC) in HUVECs repressed TNF-α-induced VCAM-1, but not 
ICAM-1, mRNA expression (Marui et al., 1993).  As mentioned above, other 
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transcription factors may be involved in VCAM-1 expression and so it could be that 
MR activation in MAECs leads to an interaction between the specific transcription 
factors that are required to promote VCAM-1 expression, but not ICAM-1 or MCP-
1.  Alternatively, the methods of detection employed may not have been sensitive 
enough to expose an effect of MR activation on expression in MAECs.   
 
The fact that the positive control, TNF-α, significantly enhanced MCP-1 secretion 
from MAECs suggests that the protocol was suitably optimised for detecting changes 
in MCP-1 production.  Time points ranging from 2-24h of treatment were initially 
studied and activation of MR pathways had no effect on MCP-1 levels at any time 
point studied.  Also, the results are in agreement with those obtained from plasma 
samples (chapter 5) where MCP-1 levels were equally undetectable in DKO and 
Apoe
-/-
 mice.  This contrasts with previous studies where MR activation in humans 
was associated with increased levels of MCP-1 in the urine of diabetic patients 
(Takebayashi et al., 2006) and in rats with increased MCP-1 mRNA in the heart (Sun 
et al., 2002).  Aldosterone has also been shown to increase MCP-1 mRNA 
expression in the kidneys of wild type mice (Ma et al., 2006).  However, there is 
little data on the effect of MR activation on MCP-1 expression in cells of the murine 
vasculature.  Our data demonstrate that MR activation in mouse endothelial cells has 
no effect on MCP-1 secretion and MCP-1, therefore, is unlikely to play a significant 
role in the initial recruitment of macrophages to DKO plaques.   
 
The lack of effect of MR activation on ICAM-1 expression in MAECs mirrors the 
constitutive endothelial expression observed in Apoe
-/-
 and DKO mice in the previous 
chapter.  However, TNF-α, a known mediator of ICAM-1 expression (Rothlein et al., 
1988), failed to up-regulate ICAM-1 in MAECs, suggesting that the methods used 
were not sensitive enough to detect changes in ICAM-1.  The basal expression levels 
were high on untreated MAECs and so perhaps they could not be increased further 
by stimuli.  If ICAM-1 was maximally expressed on MAECs under normal 
conditions then it might be suggested that some factor present in the cell culture 
medium was responsible for this.  Culture medium, particularly that supplemented 
with serum, contains growth factors and other components that can affect cell 
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physiology.  Importantly, it has recently been reported that one of the components of 
the endothelial basal medium used in the present study, epidermal growth factor, 
increases ICAM-1 expression in bronchial epithelial cells (Liu et al., 2008).  Thus, it 
could be that in order to detect changes in ICAM-1 expression on MAECs, the 
culture medium needs to be altered.  Indeed, the study in which MR activation was 
shown to increase ICAM-1 levels in human endothelial cells (Caprio et al., 2008) 
employed medium that had been charcoal-stripped to remove factors that may 
interfere with expression levels.  Given the high constitutive expression of ICAM-1 
observed both in vitro and in vivo, it is difficult to draw any definite conclusions 
about the role of MR activation in ICAM-1 expression. 
 
Conclusions 
Inactivation of 11β-HSD2 in endothelial cells allows glucocorticoids to illicitly 
activate the MR, promoting up-regulation of VCAM-1 possibly through NF-κB 
activation.  This confirms that the pro-atherosclerotic effects of 11β-HSD2 
inactivation are not purely due to inappropriate activation of renal MR with 
associated hypertension but that extra-renal, and specifically endothelial, MR 
activation likely plays a significant role.  Given the protective effect of MR blockade 
on aldosterone- and glucocorticoid- mediated up-regulation of VCAM-1 in MAECs, 
the benefits of eplerenone treatment both in DKO mice and in humans may be 
partially due to inhibition of pro-inflammatory molecule expression in the 







































The work described in this thesis used a transgenic mouse model to assess the role of 
inappropriate MR activation, and the protective role of 11β-HSD2, in atherogenesis. 
The potential of MR antagonist administration for the inhibition of atherosclerosis 
has been demonstrated in several animal models and the cardio-protective effects of 
MR blockade in humans were greater than expected for the moderate decrease in 
blood pressure observed.  However, the roles of MR signalling during atherosclerosis 
are largely unknown.  Furthermore, whilst glucocorticoids and mineralocorticoids 
can influence certain aspects of vascular structure and function, the role of 
endogenous steroid hormones and 11β-HSD2 in modulating atherogenic processes 
has not been investigated.  Therefore, the overall objective of the present studies was 
to advance understanding of how MR activation influences atherogenesis and to 
determine a protective role for 11β-HSD2 in vascular pathology. 
7.1 The DKO mouse as a model of atherosclerosis 




 DKO mouse and therefore 
it is very important to discuss the suitability of this model in the study of 
atherosclerosis.  The Apoe
-/-
 mouse has been extensively used to investigate 
numerous aspects of atherosclerotic disease (Meir et al., 2004) and has proved to be 
a very convenient and reliable model for these purposes.  This model has also been 
used as a test bed for studying the effects of a variety of endogenous and exogenous 
agents on atherosclerosis.  For example, the effects of dietary components (Guo et 
al., 2002; Kaplan et al., 2001; Stocker et al., 2004) , anti-oxidant therapy (Nakata et 
al., 2002; Pratico et al., 1998), steroid hormones (Bourassa et al., 1996; Elhage et al., 
1997), lipid-lowering drugs (Chiwata et al., 2001; Kusunoki et al., 2001), and 
immunomodulatory agents (Daugherty et al., 1997; Inoue et al., 2002; Paul et al., 
2004) on atherogenesis have been investigated in the Apoe
-/-
 mouse.  In recent years, 
other genes that may affect atherosclerosis have been studied through the generation 
of DKO mice or Apoe
-/-
 mice over-expressing a transgene.  Each of these methods 
has advantages and disadvantages.  Over-expressing a transgene can be particularly 
useful in studying the function of proteins that are not normally expressed in the 
mouse, however this technique is limited by the fact that integration into the mouse 
genome occurs randomly and the copy number of the transgene cannot be controlled.  
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This results in different expression levels between mice and the accidental insertion 
of the transgene into an endogenous mouse gene sequence can produce a non-
specific phenotype (Marschang et al., 2003).  The use of gene targeting to knockout 
genes of interest overcomes some of the problems of transgene over-expression and 
crossing these mice with Apoe
-/-
 mice enables the effects of the gene of interest on 
atherosclerosis to be investigated.  Indeed, a variety of mice in which genes involved 
in lipid metabolism (Suzuki et al., 1997; Willner et al., 2003), inflammation 
(Caligiuri et al., 2003; Dong et al., 2000), and haemostasis (Xiao et al., 1997; Xiao et 
al., 1998) have been knocked out and crossed with Apoe
-/-
 mice to generate DKO 





 DKO mouse offers several advantages over other DKO models 
of atherosclerosis.  In the current model, both mutations are on a pure C57Bl/6 
background, which is in contrast to other models in which mice from mixed 
backgrounds were used (Willner et al., 2003; Xiao et al., 1997; Xiao et al., 1998).  It 
is known that mutations may manifest differentially on different genetic backgrounds 
and so by maintaining genetic uniformity through in-breeding, inter-individual 
variances in phenotype are minimized.  Importantly, the current model also has the 
advantage that advanced lesions develop rapidly on a normal chow diet, removing 
the need to expose the mice to abnormally high levels of cholesterol, which may 
itself affect lesion properties (Jawien et al., 2004).  The observation that DKO mice 
have buried fibrous caps in their plaques is indicative of previous plaque ruptures and 
instability.  Whilst there is evidence to suggest that plaque rupture may occur in 
Apoe
-/-
 mice fed a high-fat high-cholesterol diet (Johnson et al., 2005; Johnson et al., 
2001), there is no widely accepted model of murine plaque rupture to date.  Thus, the 
DKO mouse may prove to be a more clinically significant model of human 
atherosclerosis.  This is supported by the finding that DKO mice also suffer from an 
as yet undetermined form of cardiac sudden death, which whilst thought not to be 
due to plaque rupture, might be a result of cardiac ischaemia induced by coronary 
atherosclerosis (Deuchar et al., 2009a).                      
 
With relevance to the themes of the present thesis, investigations into roles of the 
renin-angiotensin-aldosterone system (RAAS) in atherosclerosis and the cardio-
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protective mechanisms of MR antagonists using Apoe
-/-
 mice have revealed 
important insights into the pathological consequences of dysregulation of this 
system.  However, many of these studies employ supra-physiological concentrations 
of aldosterone and so do not reflect the consequences of endogenous steroid hormone 
action.  Also, the majority of the investigations into MR activation in CVD focus on 
aldosterone and neglect to mention glucocorticoids.  Furthermore, a role for 11β-
HSD2 in protection against MR-mediated pro-atherogenic events remains to be 
determined.  The DKO mouse counters these problems by allowing the effects of 
endogenous steroid hormones inappropriately activating the MR in the absence of 
11β-HSD2 to be studied.  Thus, the DKO mouse is an ideal model for investigating 
the roles of illicit MR activation during atherogenesis.    
7.2 The role of MR activation in atherosclerosis 
Treatment of DKO mice with eplerenone allowed an assessment of the contribution 
of illicit MR activation to the accelerated atherogenesis observed in these mice.  It 
was shown that MR activation was responsible, at least partially, for the accelerated 
nature of atherogenesis, the promotion of an unstable plaque phenotype, and an 
enhanced vascular inflammatory environment.  A comparison between DKO and 
Apoe
-/-
 mice supported the results of the eplerenone study, demonstrating that loss of 
11β-HSD2 activity accelerates the formation of unstable plaques and promotes a pro-
inflammatory vascular environment.  Taken together, these results suggest that 11β-
HSD2 plays a vital role in protecting against MR-mediated pro-atherogenic changes 
in the vasculature.  However, these studies did not determine whether it was 
aldosterone or glucocorticoids that were activating the MR in DKO mice.  The much 
greater circulating concentrations of glucocorticoids compared to aldosterone makes 
it tempting to assign this action to glucocorticoids.  Indeed, 11β-HSD2
-/-
 mice have 
decreased circulating levels of aldosterone (Kotelevtsev et al., 1999) and so, 
presuming that loss of ApoE has no effect on mineralocorticoid levels, DKO mice are 
expected to also have low aldosterone levels.  Thus, the demonstration that MR 
blockade was anti-atherosclerotic in DKO mice, with low aldosterone levels, lends 
support to the notion that glucocorticoid activation of MR precipitates vascular 
155 
 
disease in this model.  One method of resolving this would be to adrenalectomise the 
DKO mice and exogenously replace either aldosterone or glucocorticoids. 
In recent years it has become increasingly apparent that activation of MR in non-
epithelial, non-classical aldosterone target tissues is very important in various 
cardiovascular pathologies.  The work in the present thesis supports this idea and 
extends the knowledge in this area by providing mechanistic information about MR 
activation in the vasculature.  Whilst renal MR activation with associated 
hypertension is likely to play a role in the atherosclerotic phenotype of the DKO 
mouse, it is clear that activation of MR directly in cells of the vasculature is also key 
to the pathology.  It is well established that hypertension is a major risk factor for 
atherosclerosis and may well contribute towards endothelial dysfunction during the 
initial stages of atherogenesis in DKO mice.  That this is possible is supported by the 
fact that patients with Cushing’s disease (Setola et al., 2007) and 11β-HSD2
-/-
 mice 
(Christy et al., 2003) both have hypertension and endothelial dysfunction.  Further, it 
was concluded that glucocorticoids did not promote the endothelial dysfunction in 
11β-HSD2
-/-
 mice through direct actions on the vascular wall (Christy et al., 2003), 
but rather through indirect effects, likely hypertension.  Thus, hypertension cannot be 
ruled out as an important mediator of atherosclerosis in DKO mice.  However, the 
finding that blockade of MR without a reduction in blood pressure in DKO mice had 
a significant inhibitory effect on atherogenesis suggests that hypertension is not the 
only, and probably not the main, factor involved.  It has been noted throughout this 
thesis that the vast majority of studies showing cardio-protective benefits of MR 
blockade find that this is independent of blood pressure lowering.   Endothelial cells 
are not only intimately involved in the pathogenesis of atherosclerosis but they also 
express the necessary receptors and enzymes to be glucocorticoid/mineralocorticoid 
responsive.  The finding that VCAM-1 was significantly up-regulated on 
brachiocephalic endothelial cells in DKO mice compared to Apoe
-/-
 mice further 
supported a role for endothelial cell MR activation in atherosclerosis.  The need for 
frozen instead of paraffin embedded sections in the VCAM-1 staining procedure 
prevented the expression of VCAM-1 being studied in mice treated with eplerenone.  
However, whilst this could have shown whether or not the increase in VCAM-1 was 
MR-mediated, it would not have proven that this phenotype was a direct result of 
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MR activation in the endothelial cells themselves.  This issue was addressed in cell 
culture using a mouse aortic endothelial cell (MAEC) immortalised secondary cell 
line.  The results of these experiments were very important in that they demonstrated 
a causative role for endothelial MR activation in up-regulation of VCAM-1.  A novel 
role for endothelial 11β-HSD2 in protection against glucocorticoid-mediated 
expression of VCAM-1 through the MR was also revealed.  This in combination with 
the in vivo data for VCAM-1 provides one of the non-renal mechanisms by which 
illicit MR activation may promote atherogenesis. 
In an attempt to further distinguish between the consequences of renal and extra-
renal MR activation, the kidney-rescue DKO mouse was generated (KRDKO).  A 
wild-type mouse expressing human 11β-HSD2 under the control of the aquaporin 2 
(AQP2) promoter was crossed with a DKO mouse in order to obtain DKO mice that 
have been ‘rescued’ for 11β-HSD2 in the AQP-2 expressing collecting duct cells of 
the kidney.  It was expected that these mice should have normalised blood pressure 
and electrolyte balance and therefore any atheroma still present over and above that 
afforded by the Apoe
-/-
 state would be due to activation of extra-renal MR.  These 
mice were not ready in sufficient numbers until very recently and so could not be 
included in the present thesis.  However, some preliminary experiments have been 
recently been performed and suggest that blood pressure is significantly reduced 
compared to DKO mice but is still significantly greater than that in Apoe
-/-
 mice.  
Thus the rescue is likely not complete and requires further characterisation.       
7.3 Mechanisms of accelerated atherogenesis in DKO mice 
Based on the results of the present studies along with those reported in the literature, 
a schematic diagram illustrating the possible mechanisms involved in MR-mediated 
atherogenesis in DKO mice has been composed (Figure 7.1).  The early increased 
expression of VCAM-1 in DKO brachiocephalic arteries (chapter 5), and the finding 
that glucocorticoids illicitly activate endothelial cell MR in the absence of 11β-HSD2 
activity to cause up-regulation of VCAM-1 (chapter 6); led to the hypothesis that 
VCAM-1 may be the initiating event in atherogenesis in DKO mice.  In order to 
more fully investigate this possibility, it would be constructive to study VCAM-1 
expression at a younger age in DKO mice (1-2 months).  This would show whether 
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or not VCAM-1 up-regulation precedes the development of atherosclerotic lesions.  
In support of this, it was previously shown that VCAM-1 expression preceded sub-
endothelial monocyte accumulation in a model of vein graft atherosclerosis (Hanyu 
et al., 2001).  As well as direct effects on VCAM-1 expression, MR activation may 
also indirectly increase VCAM-1 through inhibition of NO synthesis in the 
endothelium (Wilson et al., 2009).   
In the current proposal, this initial increase in endothelial VCAM-1 would then lead 
to enhanced capture of macrophages, thereby contributing to the increased 
infiltration of macrophages observed in plaques from DKO mice (chapter 4).  That 
this was an MR-mediated mechanism was demonstrated by reversal with eplerenone 
treatment (chapter 3).  In addition to this, it has been reported that VCAM-1 
expression is also associated with the production of MMPs via ROS generation 
(Deem et al., 2004).  It is thought that this endothelial production of MMPs aids in 
leukocyte migration across endothelial cells (Deem et al., 2004), providing a further 
mechanism by which VCAM-1 may increase macrophage recruitment to plaques.  In 
turn, these MMPs in union with MMPs that are likely to be secreted by the increased 
numbers of macrophages, could promote the breakdown of collagen within the 
plaque.  In order to determine if this might be an important mechanism in the 
significantly decreased collagen content found in plaques from DKO mice (chapter 
4), it would be beneficial to perform zymography experiments on plaque 
homogenates from Apoe
-/-
 and DKO mice to assess MMP activity.   
The current hypothesis then proposes that the MR-mediated reduction in plaque 
collagen content in DKO mice (chapter 3) could alter SMC content, shown to be 
increased by MR blockade (chapter 3), through a concomitant decrease in migration 
of SMCs into the intimal space (Rocnik et al., 1998).  SMC content may also be 
directly affected by macrophages through release of pro-apoptotic factors which have 
been shown to deplete plaque-derived SMCs in culture (Boyle et al., 2001b).  
Finally, the macrophage may also be partially responsible for the increased plaque 
lipid content observed in DKO mice (chapter 4).  The main sources of plaque lipids 
are blood lipids and lipids released by necrotic macrophage foam cells (Falk et al., 
1995), but the relative contribution of each to total plaque lipid is a controversial  
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Figure 7.1 Mechanisms of atherogenesis in DKO mice 
Schematic representation of atherogenesis in DKO mice.  MR-mediated up-regulation of 
VCAM-1 in endothelial cells, either directly or indirectly through reduced NO synthesis, may 
precipitate a host of pro-inflammatory and pro-atherogenic events responsible for the 
accelerated atherosclerotic phenotype.  VCAM-1 may aid enhanced capture of macrophages 
resulting in the increased plaque macrophage content observed in DKO mice.  Macrophages 
may then lead to increased collagen breakdown through release of MMPs, enhanced SMC 
apoptosis through release of pro-apoptotic factors, and increased lipid deposition via the 
formation and necrosis of lipid-laden foam-cells.  The proposed mechanism involves a 
complex interplay of cellular and molecular events with the macrophage being central to 
pathology.  M = macrophages, SMC = smooth muscle cells, L = lipids, and collagen is 













































issue.  Given that total plasma cholesterol levels were unaltered (chapter 4) but 
plaque macrophage content was increased in DKO mice, it is tempting to speculate 
that the increased lipid content is due to deposition by macrophages.   
In summary, the results of this thesis have enabled the development of a reasonable 
theory of the mechanisms by which illicit MR activation, specifically in endothelial 
cells, may accelerate the atherosclerotic process in Apoe
-/-
 mice.  This combined with 
the evidence in the literature suggests a variety of inter-dependent mechanisms 
through which atherogenesis may occur in DKO mice.  Whilst it is more than likely 
that a complex interplay of mechanisms are involved, it is tempting to speculate that 
a very early increase in endothelial VCAM-1 expression may be the initiating MR-
mediated factor.     
7.4 Potential clinical significance of results 
Studies assessing the actions of illicit MR activation on atherosclerosis have 
implications for the clinical use of both steroids and MR antagonists in humans for 
the treatment of various diseases.  The present findings further the knowledge on 
how eplerenone produces cardioprotective benefits in patients with heart failure by 
providing possible mechanisms of action in the vasculature.  It could be suggested 
that illicit activation of MR, perhaps due to inflammatory down-regulation of 11β-
HSD2 (Suzuki et al., 2005) during chronic disease, promotes endothelial up-
regulation of VCAM-1 and subsequent monocyte infiltration into the vascular wall 
with the consequence of accelerating atherogenesis.  Continuing MR activation may 
then result in the formation of macrophage and lipid rich plaques that lack structural 
integrity due to diminished collagen content, thereby increasing the likelihood of 
plaque rupture and the associated clinical sequalae.  Thus, MR blockade in patients 
might be expected to halt the progression of atherosclerosis and favour the formation 
of more stable plaques.  This, in turn, would decrease the frequency and/or severity 
of clinical endpoints.  The results of this thesis also support previous evidence for the 
positive relationship between exogenous glucocorticoid therapy and cardiovascular 
risk in humans.  Whilst in the present studies endogenous glucocorticoids had 
unrestricted access to the MR, which is not the case in patients treated with 
exogenous glucocorticoids, it has previously been reported that high concentrations 
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of glucocorticoids can overwhelm 11β-HSD2 and subsequently illicitly activate the 
MR (Odermatt et al., 2001).  Whether these increased levels of glucocorticoids in 
humans undergoing therapy promote CVD through saturation of 11β-HSD2, and 
activation of MR, in renal or extra-renal tissues remains to be determined.  Perhaps 
there is a case for employing local treatment with glucocorticoids in the future rather 
than subjecting the whole systemic circulation to abnormally high levels of these 
steroids.   
The observed detrimental actions of glucocorticoids on the vasculature in the present 
study point towards the use of 11β-HSD1 inhibitors in atherosclerosis.  In line with 
this, 11β-HSD1 inhibition has been shown to delay the progression of atherosclerosis 
in mice (Hermanowski-Vosatka et al. 2005).  Recent evidence suggests that 
increased tissue 11β-HSD1 activity is associated with symptoms of the metabolic 
syndrome (Walker, 2006a).  Thus, intracellular glucocorticoids may contribute to this 
condition, and inhibitors of 11β-HSD1 have become an important novel therapeutic 
target for the treatment of its underlying cardiovascular risk factors (hypertension, 
insulin resistance, dyslipidemia and atherosclerosis).  However, whilst this appears to 
be an attractive target, other aspects relating to the systemic inhibition of tissue 
11β-HSD1 activity need to be considered.  A reduction in inflammatory cell 
glucocorticoid levels may have pro-inflammatory effects and delay the resolution of 
inflammatory responses (Gilmour et al. 2006).  This has important implications in 
the development of chronic inflammatory conditions, including atherosclerosis.  
Also, enhancement of angiogenesis via 11β-HSD1 inhibition (Small et al., 2005) 
would be detrimental in some pathological conditions, such as cancer or diabetic 
retinopathy.  Therefore a balance between the ‘positive’ and ‘potentially adverse’ 
affects of 11β-HSD1 inhibition needs to be established if these agents are to be 
successfully used in the clinic.  
Blockade of MR with currently available antagonists has clear benefits in 
cardiovascular pathologies, however, the use of these drugs is limited in patients due 
to inactivation of renal MR and associated hyperkalemia (Pitt et al., 1999).  
Systematic investigations into the effects of MR activation in specific cells of the 
cardiovascular system are required to aid in the development of tissue and/or cell 
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specific antagonists.  Knowing the exact detrimental mechanisms caused by MR 
activation in individual cells will be important in determining which cells to target 
for treating various aspects of disease.  For example, the results of the present thesis 
implicate endothelial cell MR activation in the pathogenesis of the DKO phenotype 
and therefore suggest that an endothelial cell specific MR antagonist may be 
efficacious in the treatment of atherosclerosis.  A recent study showing a protective 
effect of macrophage-specific MR knockout against hypertension in the DOC/salt 
mouse model (Rickard et al., 2009a) is suggestive that targeting macrophage MR 
with a cell-specific antagonist would be beneficial in hypertensive disorders.  This 
promising evidence should lead to the development of cell-specific MR antagonists 
in the future.  
7.5 Future directions 
As well as highlighting important aspects regarding the effects of adrenal steroids 
and MR activation on the pathogenesis of atherosclerosis, the work described in this 
thesis has also provided a basis for further experiments.  The introduction of the 
DKO mouse as a model of MR activation in atherosclerosis will allow the study of 
many other potential factors and pathways in atherogenesis. In addition, there are 
several prospective studies that could extend the work described here. 
7.5.1 The DKO mouse as a ‘test-bed’ 
The DKO mouse has clear potential as a test-bed for anti-atherosclerotic agents, and 
not only those associated with MR/11β-HSD pathways but also agents that act on 
other pathways.  Given the hypertensive phenotype of the DKO mouse it could be a 
good model for testing new and existing anti-hypertensive drugs.  As well as testing 
their ability to lower blood pressure, the impact of these drugs upon atherosclerosis 
could also be investigated.  It was recently reported that in addition to their 
cholesterol lowering abilities, statins also reduced systolic blood pressure in 
hypertensive hypercholesterolaemic patients (Chopra et al., 2007).  The DKO mouse 
would be ideal for investigating the mechanisms involved in both the anti-
atherosclerotic and anti-hypertensive actions of statins.  One of the main advantages 
of the DKO mouse over the Apoe
-/-
 mouse is that they develop complex lesions early 
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in life without the need for high-fat feeding.  The present studies have shown that 
plaque stability can easily be measured in DKO mice through comparisons of plaque 
composition, lending the DKO mouse to investigations of the plaque-stabilising 
effects of statins (Libby et al., 2003) and other drugs.  The DKO mouse may also 
prove useful for testing anti-inflammatory agents targeted towards atherosclerosis 
due to the enhanced inflammatory nature of the atherosclerosis in this model.  
Recent advances in non-invasive imaging techniques have allowed atherosclerosis to 
be assessed in live mice (Fayad et al., 1998).  These techniques are becoming 
increasingly sensitive and it is now possible to differentiate between different plaque 
components (Itskovich et al., 2003).  Given that DKO mice develop large complex 
plaques on a chow diet, they would be particularly useful in the development of 
techniques that allow a detailed examination of plaque composition through non-
invasive imaging.  The fact that the composition of plaques in DKO mice can be 
quite dramatically altered with drug treatment further supports the idea that this 
model would be particularly useful in developing this type of technology.      
7.5.2 MR vs. GR 
The pro-atherogenic actions of mineralocorticoids/glucocorticoids in the DKO 
mouse have been attributed to MR activation which, given the loss of 11β-HSD2-
mediated protection of MR, is a sound hypothesis.  In addition to this, the results of 
the drug study and the cell culture work provide direct evidence that MR activation is 
causative in the DKO phenotype.  However, 11β-HSD2 also limits glucocorticoid 
access to the GR (Paterson et al., 2005) and so effects of GR activation of 
atherogenesis cannot be completely ruled out.  It is thought that 11β-HSD2 mediated 
protection of GR is particularly important during pre-natal development where 11β-
HSD2 in
 
the placenta may protect against the effects
 
of abundant maternal 
glucocorticoids (Seckl, 2001).  Foetal exposure to glucocorticoids is associated with 
increased cardiovascular risk factors (hypertension, hyperglycaemia, and 
hyperinsulinaemia) and disease in adult life (Seckl, 2001).  Thus, it might be 
suggested that increased glucocorticoid access to GR during pre-natal development 
would play an important role in the DKO atherosclerotic phenotype later in life.  In 
order to try and minimise the in utero effects of glucocorticoids in DKO mice, 
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females that were heterozygous, and not complete knockout, for 11β-HSD2 were 
used for breeding.  However, it was recently demonstrated that 11β-HSD2
-/-
 mice 
born to either 11β-HSD2 homozygous or heterozygous null mothers exhibited 
features of excess foetal glucocorticoid exposure (Holmes et al., 2006).  Therefore, 
DKO mice born to 11β-HSD2 heterozygous mothers will likely still suffer from the 
effects of enhanced GR activation in pre-natal life.   
Whilst GR activation may be important in ‘programming’ DKO mice in utero to 
increase their susceptibility to cardiovascular disease, MR activation is most likely 
responsible for the accelerated atherosclerotic disease.  Indeed, previous studies 
suggest that activation of GR would be anti-atherosclerotic (Asai et al., 1993; Tauchi 
et al., 2001).  To investigate this further, a pharmacological approach to confirm the 
role of GR in atherosclerosis in the DKO mouse could be employed.  The GR 
antagonist RU38486 could be administered to pregnant females such that the effects 
of pre-natal glucocorticoid exposure on atherosclerosis in the offspring could be 
investigated.  RU38486 could also be administered to DKO mice in the same way 
that eplerenone was in this thesis to study the effects of GR activation on 
atherogenesis later in life.   
7.5.3 Mechanisms of unstable plaque formation 
If cell-specific drugs are to be developed for the treatment of atherosclerosis, it will 
be important to determine the cellular and molecular mechanisms by which MR 
activation accelerates the formation of vulnerable plaques in this model.  Since it is 
very likely that MR antagonists act by inhibiting the early inflammation in DKO 
mice, experiments to investigate this hypothesis are an important next step.  Treating 
DKO mice with a neutralising antibody against VCAM-1 would aid in determining 
the contribution that increased endothelial VCAM-1 expression makes to the 
formation of macrophage-rich plaques.  As well as this, the macrophages themselves 
may be phenotypically different in DKO mice.  It is known that macrophages can be 
polarized by the microenvironment to mount specific functions and they can be 
broadly classified into two main groups; classically activated and alternatively 
activated (Martinez et al., 2008).  It was recently shown that knockout of MR in 
macrophages reduced the inflammatory response in hearts of DOCA/salt-treated 
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mice (Rickard et al., 2009a), suggesting a specific role for macrophage MR 
activation in the inflammatory response to injury.  Obtaining primary cultures of 
macrophages from DKO mice may be informative in determining their specific 
phenotype.  If it were found that macrophages in DKO mice were polarised towards 
the classically activated ‘inflammatory’ phenotype (Mosser et al., 2008) it might be 
worth considering the development of a macrophage-specific MR blocker.  Only a 
small proportion of the possible inflammatory mechanisms involved in atherogenesis 
were studied in this thesis and so it would be worth more fully characterising the 
inflammatory response elicited by MR activation in DKO mice.  This could be 
investigated using a cytokine array to determine which molecules are differentially 
regulated between DKO and Apoe
-/-
 mice.   
As previously mentioned, the role of MMPs in degrading collagen in DKO plaques 
should be investigated to dissect the mechanisms by which MR activation reduces 
plaque collagen content and thus integrity.  It would also be important to determine 
the cellular source of MMPs in plaques, this could be done using confocal 
microscopy to co-localise MMP-specific immunostaining with cell-specific markers 
(e.g. Mac-2, SMA, and CD31).  Whilst it would be challenging to determine the 
contributions of plasma and macrophage lipids to the increased plaque lipid content 
observed in DKO mice, it would be possible to investigate each separately.  Cultured 
macrophages from DKO and Apoe
-/-
 mice could be compared in their abilities to 
differentiate into lipid-laden foam-cells.  Also, primary cultures of endothelial cells 
from Apoe
-/-
 and DKO mice could be tested for their potential to oxidise and take-up 
LDL particles.        
7.5.4 Renal vs. extra-renal MR activation 
Whilst blood pressure was not fully normalised in the KRDKO mouse, it would still 
be worth investigating the atherosclerosis in these animals.  First of all, the extent of 
the renal 11β-HSD2 rescue would need to be established by performing radioactive 
enzyme activity assays on kidneys from KRDKO, DKO and Apoe
-/-
 mice.  It would 
also be useful to perform immunohistochemistry on kidneys from KRDKO mice to 
investigate the expression pattern of the human transgene.  It has previously been 
reported that a physical association between the MR and 11β-HSD2 is required for 
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normal function of the receptor (Odermatt et al., 2001).  Therefore, co-localisation 
studies using antibodies against murine MR and human 11β-HSD2 could be 
performed to determine whether or not this interaction occurs in KRDKO mice.  In 
line with the blood pressure results, plasma potassium levels were also not 
normalised in KRDKO mice, further supporting the idea that the rescue is not 
complete.  However, if it were found that the atherosclerotic burden, plaque 
composition, and VCAM-1 expression was not altered in KRDKO mice compared to 
DKO mice then it could reasonably be postulated that renal hypertension is not the 
determining factor in the DKO phenotype.  It might be more informative to generate 
vascular cell-specific 11β-HSD2 KO mice on the Apoe
-/-
 background to distinguish 
between renal and non-renal MR-mediated effects.  Given the results of this thesis, 
the obvious target for a cell-specific 11β-HSD2 KO would be the endothelial cell.     
7.6 Conclusions 
In conclusion, these studies have provided valuable insight into the effects of MR 
activation on atherosclerosis. The role of endogenous glucocorticoids and their 
metabolism by 11β-HSD2 during atherogenesis was investigated for the first time.  
The importance of continued research into the mechanisms of eplerenone action is 
highlighted by the results of this thesis.  One of the most important observations of 
these studies is the detrimental consequences of compromised 11β-HSD2 activity on 
atherosclerotic disease.  Investigations of the regulation of 11β-HSD2 activity, 
particularly by inflammatory factors, during different pathological conditions might 
aid in determining the potential efficacy of MR blockade in certain diseases.  Until 
very recently, the detrimental actions of MR activation were attributed to 
mineralocorticoid activity, this thesis demonstrates a potential role for 
glucocorticoid-mediated activation of MR in pathophysiological conditions.  Perhaps 
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